PMID,Multiple Answer,time_usage
18715920,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. Instead, it focuses on laboratory-generated recombinant enzymes and mutations in integrase proteins from different HIV subtypes.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: To delineate the effect of resistance mutations on viral susceptibility to integrase inhibitors, in vitro resistance selections with raltegravir and with MK-2048, an integrase inhibitor with a second-generation-like resistance profile, were performed.

Rationale: The paper mentions to delineate the effect of resistations mutations on viral susceptibility to integrase inhibitors.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on in vitro experiments and does not mention depositing sequences in GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on in vitro experiments and does not mention depositing sequences in GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: Not reported

Rationale: The paper mentioned in vitro reistance selection, and all sequences were generated using site-directed mutation technology, which means the sequence were not from clinical samples.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: Not reported

Rationale: The sequenced samples were obtained in vitro, meaning they were not derived from patient isolates from any specific country.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: Not reported

Rationale: The paper does not provide any information about the years from which sequenced samples were obtained. It focuses on in vitro experiments and does not mention specific years for sample collection.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No

Rationale: The paper mentioned in vitro reistance selection, and all sequences were generated using site-directed mutation technology, which means the sequence were not cloned from clinical samples.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: Site-directed mutants (SDMs) of IN coding sequences were constructed in the pUC19-5′HXB2D vector (XbaI–SalI fragment of pHXB2D), containing the HIV-1 clone HXB2D IN coding sequence, by using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and high-performance liquid chromatography-purified primers (Genset Oligos, La Jolla, CA). Plasmid sequences were confirmed by dideoxyribose sequencing.

Rationale: The paper focuses on the integrase gene (IN) of HIV-1, and mentioned that SDM of IN were confiredm by sequencing.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: Plasmid sequences were confirmed by dideoxyribose sequencing.

Rationale: The paper mentions the use of dideoxyribose sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Not reported

Rationale: The paper mentioned in vitro reistance selection, and all sequences were generated using site-directed mutation technology, which means the sequence were not from clinical samples.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No

Rationale: The paper mentioned in vitro reistance selection, and all sequences were generated using site-directed mutation technology, which means the sequence were not from clinical samples.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: Not reported

Rationale: The paper mentions the in vitro resistance selection study, which means no sequence were from HIV infected individuals

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: Not reported

Rationale: The paper mentions the in vitro resistance selection study, which means no sequence were from HIV infected individuals

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: Not reported

Rationale: The paper mentions the in vitro resistance selection study, which means no sequence were from HIV infected individuals

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: Not reported

Rationale: The paper mentions the in vitro resistance selection study, which means no sequence were from HIV infected individuals

Answer: Not reported
""""""",79
19104010,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper describes the resistance profiles and phenotypic analyses of viral isolates and drug-resistant molecular clones, with the mention of calculating EC50.

Rationale: The paper includes in vitro drug susceptibility data, specifically examining the susceptibility of HIV-1 to various drugs using short-term resistance assays.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on the resistance profiles and phenotypic analyses without mentioning specific accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on the resistance profiles and phenotypic analyses without mentioning specific accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information on the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the integrase (IN) gene of HIV-1, discussing various polymorphisms and resistance-associated mutations within this gene.

Rationale: The paper focuses on the integrase (IN) gene of HIV-1, as it discusses mutations and resistance related to integrase strand transfer inhibitors (INSTIs).

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not provide any information on the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not provide any information on the treatment history of the individuals from whom the sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not provide any information on whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide any information on the treatment history of the individuals from whom the sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information on the drug classes received by the individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information on the specific drugs received by the individuals in the study before sample sequencing.

Answer: Not reported
""""""",68
21115794,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on in vitro studies and does not mention depositing sequences in GenBank.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""The in vitro antiviral profile and mechanism of action of GSK1265744 were established through integrase enzyme assays, resistance passage experiments, and cellular assays with site-directed molecular (SDM) HIV clones resistant to other classes of anti-HIV-1 agents and earlier INSTIs.""

Rationale: The paper provides in vitro drug susceptibility data, through integrase enzyme assays, resistance passage experiments, and cellular assays with site-directed molecular (SDM) HIV clone

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on the resistance profiles and phenotypic analyses without mentioning specific accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on the resistance profiles and phenotypic analyses without mentioning specific accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: Not reported

Rationale: The paper does not mention the sequencing of clinical specimens. Instead, it focuses on in vitro studies using laboratory strains and site-directed molecular (SDM) HIV clones.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: Not reported

Rationale: The paper does not mention the specific countries from which the sequenced samples were obtained. It focuses on laboratory-based studies and does not mention the geographical information about the samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: Not reported

Rationale: The paper does not provide any information about the years from which the sequenced samples were obtained. There is no mention of specific years in the provided content.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: Not reported

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""The viral cDNA (2.5 μl of a 40-μl reaction mixture) was amplified through 35 cycles of PCR using the primers RT18 (5′-GGAAACCAAAAATGATAGGGGGAATTGGAGG-3′) and RT4361 (5′-GCTGACATTTATCACAGCTGGCTAC-3′) to generate a 1,985-bp viral-DNA fragment containing the entire RT portion of the *pol* gene (spanning nucleotide 200 of protease to nucleotide 105 of integrase).""

Rationale: The paper mentions sequencing the entire RT portion of the pol gene, spanning nucleotide 200 of protease to nucleotide 105 of integrase. This indicates that the RT, integrase, and protease genes were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: Not reported

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Not reported

Rationale: The paper does not mention the sequencing of clinical specimens. Instead, it focuses on in vitro studies using laboratory strains and site-directed molecular (SDM) HIV clones.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: Not reported

Rationale: The paper does not mention the sequencing of clinical specimens. Instead, it focuses on in vitro studies using laboratory strains and site-directed molecular (SDM) HIV clones.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: Not reported

Rationale: The paper does not mention that the patients from whom the sequences were obtained were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: Not reported

Rationale: The paper does not mention the sequencing of clinical specimens. Instead, it focuses on in vitro studies using laboratory strains and site-directed molecular (SDM) HIV clones.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: Not reported

Rationale: The paper does not mention the sequencing of clinical specimens. Instead, it focuses on in vitro studies using laboratory strains and site-directed molecular (SDM) HIV clones.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: Not reported

Rationale: The paper does not mention the sequencing of clinical specimens. Instead, it focuses on in vitro studies using laboratory strains and site-directed molecular (SDM) HIV clones.

Answer: Not reported
""""""",88
23749954,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention obtaining HIV sequences from patient samples. It focuses on cell culture drug selections and the use of various drugs to select for resistance mutations in HIV-1.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper reports on the selection of resistance mutations in HIV-1 under various drug pressures, including tenofovir, didanosine, stavudine, apricitabine, and abacavir.

Rationale: The paper describes the results of cell culture drug selections, which involve exposing HIV-1 to various drugs and selecting for resistance mutations.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not mention obtaining samples from individuals for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention cloning samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the reverse transcriptase (RT) gene of HIV-1.

Rationale: The paper discusses the selection of resistance mutations in the RT gene under various drug pressures.

Answer: RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not mention the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention obtaining sequences from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention the patients being in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention obtaining sequences from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",58
24227862,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Rationale: The paper does not provide any information about the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper includes in vitro drug susceptibility data, specifically examining the susceptibility of HIV-1 to dolutegravir (DTG) and raltegravir (RAL) using short-term resistance assays with TZM-bl cells.

Rationale: The paper includes in vitro drug susceptibility data, specifically examining the susceptibility of HIV-1 to dolutegravir (DTG) and raltegravir (RAL) using short-term resistance assays with TZM-bl cells.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide any information about the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide any information about the years from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about the sequencing method used, nor does it mention whether samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the integrase (IN) gene of HIV-1, particularly examining mutations and their effects on drug resistance and enzyme activity.

Rationale: The paper focuses on the integrase (IN) gene of HIV-1, particularly examining mutations and their effects on drug resistance and enzyme activity.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples sequenced.

Rationale: The paper does not provide any information about the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide any information about sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information about the patients being part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention sequences obtained from individuals who had previously received ARV drugs.

Rationale: The paper does not provide any information about sequences obtained from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",91
25637519,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention in vitro drug susceptibility data or phenotypic data. It mentions clinical isolates and sequencing of plasma samples.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. There is no mention of accession numbers in the provided content.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. There is no mention of accession numbers in the provided content.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide information on the HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify the type of clinical specimens sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: Not reported
""""""",60
26246578,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""HIV susceptibilities to DTG, RAL, and EVG were measured through the determination of the 50% inhibitory concentration (IC50) (Table 2). HIV susceptibilities to INSTIs were measured through infection of 30,000 TZM-bl cells using 200,000 reverse transcriptase (RT) units per well of each virus in the presence of 1:4 serial dilutions of drugs.""

Rationale: The paper includes data on HIV-1 susceptibility to DTG, RAL, and EVG in tissue culture, as well as the determination of the 50% inhibitory concentration (IC50) for these drugs.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide information on the HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify the type of clinical specimens that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not provide information on the treatment history of the individuals from whom sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not provide information on whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide information on the treatment history of the individuals from whom sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",64
26311878,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions the in vitro resistance selection study, which means no sequence were from HIV infected individuals.

Rationale: The paper does not provide any information on the years from which sequenced samples were obtained. It focuses on laboratory-based studies and does not mention the timeline of sample collection.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide any information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide any information on the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the integrase (IN) gene of HIV-1, particularly examining mutations and their effects on drug resistance and enzyme activity.

Rationale: The paper mentions that the study is about integrase transfer activity and susceptiblity, no sequences samples were from individuals.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not specify the type of clinical specimens that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper mentions that the study is about tissue culture selection, samples were not from HIV infected individuals.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not provide any information on the treatment history of the individuals.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information on the drug classes received by the individuals in the study.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information on the specific drugs received by the individuals in the study.

Answer: Not reported
""""""",62
26559830,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention that HIV sequences were obtained from patient samples. It focuses on the in vitro activity of dolutegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not mention specific patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility data. It focuses on the in vitro activity of dolutegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not provide specific data on drug susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. The focus is on the in vitro activity of dolutegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not mention specific accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. The focus is on the in vitro activity of dolutegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not mention specific accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not mention that samples were obtained from individuals for HIV sequencing. The focus is on the in vitro activity of dolutegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not provide information on patient samples.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not specify the countries from which the sequenced samples were obtained. It mentions that HIV-2 is a significant public health problem in West Africa and has been reported in other countries with socioeconomic ties to the region, but it does not provide specific details about the origin of the samples used in the study.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information about the years from which the sequenced samples were obtained. The focus is on the in vitro activity of dolutegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not mention specific time frames for sample collection.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention that samples were cloned prior to sequencing. 

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not mention which HIV genes were sequenced. The focus is on the in vitro activity of dolutegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not provide information on specific genes.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify the method used for sequencing the HIV isolates. It discusses the in vitro activity of dolutegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not provide details about sequencing methods.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not mention what clinical specimens were sequences, although PBMC was mentioned it's in the introduction part.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper mentioned the individuals were INSTI naïve, but not mentioned the treatment history.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients from whom the HIV isolates were obtained were part of a clinical trial.  the study focuses on the in vitro activity of dolutegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not provide details about clinical trials involving the patients.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper is about in vitro activity of dolutegravir, although the paper mentioned sample from INSTI-naïve individuals, the treatment history is not reported.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper is about in vitro activity of dolutegravir, although the paper mentioned sample from INSTI-naïve individuals, the treatment history is not reported.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper is about in vitro activity of dolutegravir, although the paper mentioned sample from INSTI-naïve individuals, the treatment history is not reported.

Answer: Not reported
""""""",84
27009474,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper describes the creation of infectious molecular clones to assess the effect of the novel mutation Q148N on INSTI susceptibility, and it mentions that the sequence of the clinical clone has been submitted to the GenBank under the accession number KU761565.

Rationale: The paper reports HIV sequences from patient samples, as evidenced by the creation of infectious molecular clones and the submission of the clinical clone sequence to GenBank.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper describes phenotypic susceptibility testing using the PhenoSense assay (Monogram) to assess the effect of the novel mutation Q148N on INSTI susceptibility.

Rationale: The paper reports in vitro drug susceptibility data, as evidenced by the phenotypic susceptibility testing using the PhenoSense assay.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that the sequence of the clinical clone has been submitted to the GenBank under the accession number KU761565.

Rationale: The sequence of the clinical clone was made publicly available through submission to GenBank.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper mentions that the sequence of the clinical clone has been submitted to the GenBank under the accession number KU761565.

Rationale: The GenBank accession number for the sequenced HIV isolate is KU761565.

Answer: KU761565
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper describes a single patient case throughout the study.

Rationale: The focus of the paper is on one individual, indicating that only one person had samples obtained for sequencing.

Answer: 1
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention any specific countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information about the country or countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the patient underwent HIV-1 seroconversion in August 2014.

Rationale: The sequenced samples were obtained in 2014.

Answer: 2014
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper describes the creation of infectious molecular clones to assess the effect of the novel mutation Q148N on INSTI susceptibility.

Rationale: The paper mentions the creation of infectious molecular clones, which indicates that samples were cloned prior to sequencing.

Answer: Yes
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the integrase gene of HIV-1, discussing various polymorphisms and resistance-associated mutations within this gene.

Rationale: The paper focuses on the sequencing of the HIV-1 integrase gene.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the sequencing method used.

Rationale: The paper does not provide information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper describes the creation of infectious molecular clones to assess the effect of the novel mutation Q148N on INSTI susceptibility.

Rationale: The paper mentions the creation of infectious molecular clones, which indicates that the samples sequenced were molecular clones.

Answer: Molecular clones
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper describes a patient who experienced virological failure while on a treatment regimen with tenofovir/emtricitabine/elvitegravir/cobicistat.

Rationale: The paper reports sequences obtained from an individual who experienced virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patient was part of a clinical trial.

Rationale: The paper does not provide information about the patient being part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper describes a patient who had previously received antiretroviral drugs, including tenofovir/emtricitabine/elvitegravir/cobicistat.

Rationale: The paper reports HIV sequences from an individual who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patient had previously received antiretroviral drugs, including tenofovir/emtricitabine/elvitegravir/cobicistat, which are INSTIs.

Rationale: The paper reports that the patient had previously received INSTIs.

Answer: INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patient had previously received antiretroviral drugs, including tenofovir/emtricitabine/elvitegravir/cobicistat.

Rationale: The paper reports that the patient had previously received tenofovir/emtricitabine/elvitegravir/cobicistat.

Answer: Tenofovir/emtricitabine/elvitegravir/cobicistat
""""""",81
27124362,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention obtaining HIV sequences from patient samples. It focuses on in vitro resistance selection studies using HIV-1 subtype A, B, and C viruses in cell culture systems.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions the fold change of DOR-resistant isolates, it also mentions the mutant viruses in the clinical trial were tested for susceptibility to DOR, which indicates in vitro susceptibliity data were reported.

Rationale: The paper mentions the fold change of DOR-resistant isolates, it also mentions the mutant viruses in the clinical trial were tested for susceptibility to DOR, which indicates in vitro susceptibliity data were reported.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention whether the sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not mention any specific GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not report on any individuals from whom samples were obtained for sequencing, as it does not involve patient-derived sequences.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention any countries from which sequenced samples were obtained, as it does not report on patient-derived sequences.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the years from which sequenced samples were obtained, as it does not report on patient-derived sequences.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention whether samples were cloned prior to sequencing, as it does not report on patient-derived sequences.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not report on the sequencing of specific HIV genes, as it focuses on the integrase mutations and their effects rather than on sequencing data.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify any sequencing method, as it does not report on patient-derived sequences or sequencing data.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not report on any clinical specimens being sequenced, as it focuses on laboratory-generated viral mutants.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention any sequences obtained from individuals with virological failure, as it does not report on patient-derived sequences.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention any patients or clinical trials, as it focuses on laboratory-generated viral mutants.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention any sequences from individuals who had previously received ARV drugs, as it does not report on patient-derived sequences.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not report on any individuals or drug classes received prior to sequencing, as it does not involve patient-derived sequences.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention any specific drugs received by individuals, as it does not report on patient-derived sequences.

Answer: Not reported
""""""",69
28559249,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on the in vitro activity of dolutegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not mention specific accession numbers.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2. HIV-2 group A, HIV-2 group B, and HIV-1 isolates from INSTI-naïve individuals were comparably sensitive to dolutegravir in the single-cycle assay

Rationale: The paper reports in vitro drug susceptibility data for dolutegravir in both HIV-1 and HIV-2 strains. The study employs single-cycle assays to compare the sensitivity of wild-type and INSTI-resistant strains of HIV-1 and HIV-2 to dolutegravir, demonstrating comparable EC50 values across different strains.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. The focus is on the in vitro activity of dolutegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not mention specific accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. The focus is on the in vitro activity of dolutegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not mention specific accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not mention the number of individuals from whom samples were obtained for HIV sequencing. The focus is on the in vitro activity of dolutegravir and the resistance profiles of various HIV-1 and HIV-2 strains.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not specify the countries from which the sequenced samples were obtained. It mentions that HIV-2 is a significant public health problem in West Africa and has been reported in other countries with socioeconomic ties to the region, but it does not provide specific details about the origin of the samples used in the study.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific years during which the samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not mention what clinical specimens were sequences, although PBMC was mentioned it's in the introduction part.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention whether the individuals had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the specific drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",74
29373677,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the case of a patient treated with dolutegravir monotherapy and the emergence of N155H, K156N, K211R, and E212T mutations in the integrase (IN) gene.

Rationale: The paper mentions that the patient was treated with dolutegravir monotherapy and that genotypic analysis of integrase was performed on DNA from PBMCs and plasma RNA, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper discusses the in vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2, and the effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.

Rationale: The paper mentions various in vitro experiments, including single-cycle assays and cell-free reactions, to assess the susceptibility of HIV-1 and HIV-2 strains to dolutegravir and other integrase strand transfer inhibitors (INSTIs).

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any information on the public availability of the sequences.

Rationale: The paper does not mention the submission of sequences to GenBank or any other public database.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention the submission of sequences to GenBank or any other public database.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper discusses the case of a single patient treated with dolutegravir monotherapy.

Rationale: The paper focuses on a single patient and does not mention any other individuals.

Answer: 1
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide any information on the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention the geographical origin of the patient or the samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the patient was treated with dolutegravir monotherapy in 2014.

Rationale: The paper does not provide a specific time frame for the collection of the samples, but mentions the year 2014 as part of the patient's treatment history.

Answer: 2014
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information on the sequencing methods used or whether cloning was involved.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the integrase (IN) gene of HIV-1.

Rationale: The paper discusses various mutations and resistance-associated substitutions within the IN gene.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the sequencing method used.

Rationale: The paper does not provide any information on the sequencing methods used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that DNA from PBMCs and plasma RNA were used for genotypic analysis of integrase.

Rationale: The paper specifies that DNA from PBMCs and plasma RNA were used for sequencing.

Answer: DNA from PBMCs and plasma RNA
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper discusses the case of a patient who experienced virological failure on dolutegravir monotherapy.

Rationale: The paper mentions that the patient experienced virological failure on dolutegravir monotherapy.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patient was part of a clinical trial.

Rationale: The paper does not provide any information on clinical trials involving the patient.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper discusses the case of a patient who had previously received antiretroviral treatment, including raltegravir and dolutegravir.

Rationale: The paper mentions that the patient had received antiretroviral treatment, including raltegravir and dolutegravir, before the emergence of resistance mutations.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patient had received antiretroviral treatment, including raltegravir and dolutegravir, which are integrase strand transfer inhibitors (INSTIs).

Rationale: The paper specifies that the patient had received INSTIs before the emergence of resistance mutations.

Answer: INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patient had received raltegravir and dolutegravir before the emergence of resistance mutations.

Rationale: The paper specifies that the patient had received raltegravir and dolutegravir before the emergence of resistance mutations.

Answer: Raltegravir (RAL), Dolutegravir (DTG)
""""""",84
30053052,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that viral RNA was extracted using the QIAmp viral RNA extraction kit (Qiagen, Hilden, Germany) from 140 μL of plasma. The *gag-pol* fragment (HXB2: 0702-5798) was cloned into pNL43 plasmid following digestion with BssHII and SalI (New England Biolabs, USA) and ligation using T4 DNA ligase (New England Biolabs), as described by us previously.

Rationale: The paper mentions that viral RNA was extracted from plasma samples and used for cloning and sequencing, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions that DSA was performed by determining the extent to which EFdA, nevirapine, efavirenz, etravirine, rilpivirine and tenofovir alafenamide inhibited the replication of the reference virus (NL43) and the 24 treatment-naive patient-derived chimeric viruses (HIV-1B, 6; HIV-1C, 14; HIV-1A-like, 4).

Rationale: The paper reports in vitro drug susceptibility data using a phenotypic assay to measure the inhibition of viral replication by various drugs.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention the submission of sequences to GenBank or provide any accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention the submission of sequences to GenBank or provide any accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that stored plasma samples from patients who were either therapy naive (n = 42) or had a virological treatment failure (n = 9) were randomly selected from the HIV cohort at Karolinska University Hospital, Stockholm, Sweden.

Rationale: The paper mentions that samples were obtained from 42 therapy-naive patients and 9 patients with virological treatment failure.

Answer: 51
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from patients at Karolinska University Hospital, Stockholm, Sweden.

Rationale: The paper specifies that the samples were obtained from Sweden.

Answer: Sweden
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific years during which the sequenced samples were obtained.

Rationale: The paper does not mention the time period for sample collection.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper mentions that the *gag-pol* fragment (HXB2: 0702-5798) was cloned into pNL43 plasmid following digestion with BssHII and SalI (New England Biolabs, USA) and ligation using T4 DNA ligase (New England Biolabs), as described by us previously.

Rationale: The paper mentions that the *gag-pol* fragment was cloned into a plasmid, indicating that samples were cloned prior to sequencing.

Answer: Yes
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the *gag-pol* fragment (HXB2: 0702-5798) was cloned into pNL43 plasmid following digestion with BssHII and SalI (New England Biolabs, USA) and ligation using T4 DNA ligase (New England Biolabs), as described by us previously.

Rationale: The paper mentions that the *gag-pol* fragment was sequenced, which includes the gag and pol genes.

Answer: gag, pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that DSA was performed by determining the extent to which EFdA, nevirapine, efavirenz, etravirine, rilpivirine and tenofovir alafenamide inhibited the replication of the reference virus (NL43) and the 24 treatment-naive patient-derived chimeric viruses (HIV-1B, 6; HIV-1C, 14; HIV-1A-like, 4).

Rationale: The paper does not specifically mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that viral RNA was extracted using the QIAmp viral RNA extraction kit (Qiagen, Hilden, Germany) from 140 μL of plasma.

Rationale: The paper mentions that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that stored plasma samples from patients who were either therapy naive (n = 42) or had a virological treatment failure (n = 9) were randomly selected from the HIV cohort at Karolinska University Hospital, Stockholm, Sweden.

Rationale: The paper mentions that samples were obtained from 9 patients with virological treatment failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that stored plasma samples from patients who were either therapy naive (n = 42) or had a virological treatment failure (n = 9) were randomly selected from the HIV cohort at Karolinska University Hospital, Stockholm, Sweden.

Rationale: The paper mentions that samples were obtained from 9 patients with virological treatment failure, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not mention the treatment history of the patients.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not mention the treatment history of the patients.

Answer: Not reported
""""""",105
30803972,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention that HIV sequences were obtained from patient samples. It focuses on the in vitro activity of bictegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not provide details about the origin of the samples used in the study.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: Yes, the paper reports in vitro drug susceptibility data for bictegravir against HIV-1 and HIV-2 isolates and integrase inhibitor-resistant HIV-2 mutants.

Rationale: The paper describes the use of a single-cycle assay to measure the activity of bictegravir against HIV-1 and HIV-2 isolates, including integrase inhibitor-resistant mutants.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any information about the public availability of the sequences used in the study.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not mention the number of individuals from whom samples were obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not specify the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information about the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the integrase gene of HIV-1 and HIV-2.

Rationale: The paper examines the effects of various integrase mutations on the susceptibility to bictegravir.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not mention what clinical specimens were sequences.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention that the patients from whom the HIV isolates were obtained were part of a clinical trial or had virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention that the individuals had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the specific drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",64
31988104,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper focuses on antiviral activity of tenofovir alafenamide (TAF) against HIV-1 clinical isolates, but it does not mention the treatment history of the patients.

Rationale: The paper does not explicitly state that the HIV sequences were obtained from patient samples, but it does mention the use of clinical isolates.

Answer: Not reported
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions the study is about selection of in vitro resistance to both TAF and the parent compound, which means the samples were not from HIV infected individuals.

Rationale: The paper does not report in vitro drug susceptibility data from patient samples.

Answer: Not reported
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention that the sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 42 samples with TFV genotypic and phenotypic data were selected for the study.

Rationale: The paper does not explicitly state the number of individuals, but it mentions the number of samples.

Answer: 42
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide any information about the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention any geographical locations.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide any information about the years from which the sequenced samples were obtained.

Rationale: The paper does not mention any specific years.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not specify the method used for sequencing.

Rationale: The paper does not mention cloning.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that a 1463 bp DNA fragment from the RT gene was amplified and cloned into the pXXLAI proviral DNA vector.

Rationale: The paper specifically mentions the RT gene.

Answer: RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the method used for sequencing.

Rationale: The paper does not mention the sequencing method.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not specify the type of clinical specimens sequenced.

Rationale: The paper does not mention the type of samples.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper focuses on antiviral activity of tenofovir alafenamide (TAF) against HIV-1 clinical isolates, but it does not mention the treatment history of the patients.

Rationale: The paper does not explicitly state that the sequences were obtained from individuals with virological failure.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper focuses on antiviral activity of tenofovir alafenamide (TAF) against HIV-1 clinical isolates, but it does not mention the treatment history of the patients.

Rationale: The paper does not explicitly state that the sequences were from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide information on the drug classes received by the individuals in the study.

Rationale: The paper does not mention the drug classes.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide information on the drugs received by the individuals in the study.

Rationale: The paper does not mention the drugs.

Answer: Not reported
""""""",75
32601157,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper includes in vitro drug susceptibility data, specifically examining the susceptibility of HIV-1 to dolutegravir (DTG) and raltegravir (RAL) using short-term resistance assays with TZM-bl cells.

Rationale: The paper includes in vitro drug susceptibility data by detailing the effectiveness of TMC278 against various HIV-1 isolates and mutations. It mentions specific effective concentrations (EC50 values) of TMC278 against wild-type and resistant strains of HIV-1, which are typically measured in vitro.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention whether any sequences were made publicly available. It primarily discusses the efficacy of the drugs without providing details on data availability.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on in vitro studies and does not mention depositing sequences in GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the number of individuals from whom samples were obtained for sequencing, as it does not report on sequencing data.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention the specific countries from which the sequenced samples were obtained. It focuses on the resistance profiles and phenotypic analyses without providing geographical information about the samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained. It focuses on the resistance profiles and phenotypic analyses without mentioning the time frame of sample collection.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention whether samples were cloned prior to sequencing, as it does not provide any details on sequencing processes.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not mention any specific HIV genes that were sequenced. It discusses the antiviral activities of the drugs against various mutants but does not provide details on gene sequencing.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify any sequencing methods used, as it does not report on sequencing data or methodologies.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify any clinical specimens that were sequenced. It focuses on the antiviral efficacy of the drugs rather than on clinical sample data.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention any sequences obtained from individuals with virological failure. It primarily discusses the efficacy of the drugs against resistant mutants.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention any clinical trials involving patients. It discusses laboratory studies on drug efficacy without reference to clinical trial data.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide any information regarding whether the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention any specific drugs received by individuals prior to sample sequencing. It focuses on the efficacy of the drugs in vitro rather than on patient treatment history.

Answer: Not reported
""""""",78
33855437,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that viruses were amplified from treatment-naive persons harbouring WT variants, including 5326, 14637, 14969, 6343 and 4742 (GenBank accession numbers MW484893, MW484894, MW484895, DQ380549 and AF492618, respectively). Viruses were also amplified from patients bearing common NRTI and NNRTI RAMs, including 4242, 5555, 5652, 5686 and 5697 (GenBank Accession numbers OQ336290–4).

Rationale: The paper mentions that viruses were amplified from treatment-naive patients, drug-treated persons, and lab isolates, which means some sequences were from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper describes the results of phenotypic drug susceptibility assays that assess the resistance conferred by acquired NNRTI RAMs (Resistance-Associated Mutations) after serial passaging of viruses in escalating concentrations of doravirine and other drugs over 24 weeks.

Rationale: The paper reports in vitro drug susceptibility data using a cell-based assay to assess the resistance conferred by acquired NNRTI RAMs.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper lists several GenBank accession numbers for the sequenced HIV isolates, both from treatment-naive and treated persons.

Rationale: The paper provides specific GenBank accession numbers for the sequences used in the study.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper lists several GenBank accession numbers for the sequenced HIV isolates, both from treatment-naive and treated persons.

Rationale: The paper provides specific GenBank accession numbers for the sequences used in the study.

Answer: MW484893, MW484894, MW484895, DQ380549, AF492618, OQ336290, OQ336291, OQ336292, OQ336293, OQ336294, MW48492, AF324493
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper lists 5 clinical samples from treatment-naïve persons and 5 clinical samples from patients bearing NRTI and NNRTI RAMS. Two samples 96USSN20 and pNL4.3 recombinant clone (GenBank AF324493) were not clinical samples. So the number of individuals is 10

Rationale: The paper mentions that viruses were amplified from treatment-naive patients, drug-treated persons, and lab isolates, which means some sequences were from individuals who had previously received ARV drugs.

Answer: 10
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not specify the countries from which the sequenced samples were obtained. It mentions that clinical samples were obtained through the Fonds de Recherche du Québec Santé-Réseau SIDA, but no specific countries are listed.

Rationale: The paper does not provide information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific years for when the sequenced samples were obtained. It mentions the study's timeline and publication dates but does not specify the years of sample collection.

Rationale: The paper does not provide specific information about the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide information about cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the sequencing of the reverse transcriptase (RT) gene, as it discusses mutations and resistance associated with NNRTIs and NRTIs, which target the RT gene.

Rationale: The paper mentions that genotypic analyses were performed by the Sanger method on viral extracts isolated at Weeks 8, 16 and 24 to evaluate the acquisition and accumulation of mutations associated with reduced susceptibility to antiretroviral drugs.

Answer: RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that genotypic analyses were performed by the Sanger method on viral extracts isolated at Weeks 8, 16 and 24 to evaluate the acquisition and accumulation of mutations associated with reduced susceptibility to antiretroviral drugs.

Rationale: The paper mentions that genotypic analyses were performed by the Sanger method on viral extracts.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not specify the exact type of clinical specimens sequenced, it mentions samples were from naïve patients, which means the samples were collected from plasma.

Rationale: The paper does not provide information about the type of samples sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that viruses were amplified from patients bearing common NRTI and NNRTI RAMs, which suggests that some sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper mentions that viruses were amplified from patients bearing common NRTI and NNRTI RAMs.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide information about the patients being part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that viruses were amplified from treatment-naïve patients, drug-treated persons, and lab isolates, which means some sequences were from individuals who had previously received ARV drugs.

Rationale: The paper mentions that viruses were amplified from treatment-naive patients, drug-treated persons, and lab isolates.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that viruses were amplified from treatment-naïve patients, drug-treated persons, and lab isolates, which means some sequences were from individuals who had previously received ARV drugs, the received drugs were not reported.

Rationale: The paper does not provide information about the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that viruses were amplified from treatment-naïve patients, drug-treated persons, and lab isolates, which means some sequences were from individuals who had previously received ARV drugs, the received drugs were not reported.

Rationale: The paper does not provide information about the drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",109
34516245,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. This is an in vitro paper focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not provide any information on in vitro drug susceptibility experiments.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information on the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide any information on the HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not provide any information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not provide any information on the treatment history of the individuals from whom the sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide any information on the treatment history of the individuals from whom the sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information on the drug classes received by the individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information on the specific drugs received by the individuals in the study before sample sequencing.

Answer: Not reported
""""""",61
35730213,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: Among 1228 participants, 1131 completed follow-up.

Rationale: The paper mentions that 1131 participants completed follow-up.

Answer: 1131
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted in Lesotho.

Rationale: The paper mentions that the study was conducted in Lesotho.

Answer: Lesotho
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The study was conducted from February to December 2020.

Rationale: The paper mentions that the study was conducted from February to December 2020.

Answer: 2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not mention any HIV genes being sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention any sequencing method.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not mention any type of samples being sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention any sequences being obtained from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The study was a prospective cohort study.

Rationale: The paper mentions that the study was a prospective cohort study, not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The study included adults changing from tenofovir disoproxil fumarate (TDF)/lamivudine (3TC)/EFV to TDF/3TC/DTG within first-line ART.

Rationale: The paper mentions that participants were changing from one ART regimen to another, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The study included adults changing from tenofovir disoproxil fumarate (TDF)/lamivudine (3TC)/EFV to TDF/3TC/DTG within first-line ART.

Rationale: The paper mentions that participants were changing from one ART regimen to another, indicating that they had previously received NRTI, NNRTI, and INSTI drugs.

Answer: NRTI, NNRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The study included adults changing from tenofovir disoproxil fumarate (TDF)/lamivudine (3TC)/EFV to TDF/3TC/DTG within first-line ART.

Rationale: The paper mentions that participants were changing from one ART regimen to another, indicating that they had previously received TDF, 3TC, and EFV.

Answer: Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)
""""""",68
35913500,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention HIV sequences from patient samples.

Rationale: The paper discusses a demonstration project for long-acting injectable antiretroviral therapy (LAI-ART) for persons with and without detectable human immunodeficiency virus (HIV) viremia in an urban HIV clinic, but it does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the demonstration project for LAI-ART and does not discuss in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not discuss the public availability of sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not discuss HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which sequenced samples were obtained.

Rationale: The paper does not discuss HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years from which sequenced samples were obtained.

Rationale: The paper does not discuss HIV sequencing.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not discuss HIV sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper does not discuss HIV sequencing.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not discuss HIV sequencing.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not discuss HIV sequencing.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not discuss HIV sequencing.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study is a demonstration project, not a clinical trial.

Rationale: The paper discusses the demonstration project for LAI-ART.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Rationale: The paper does not discuss HIV sequencing.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drug classes received by individuals before sample sequencing.

Rationale: The paper does not discuss HIV sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs received by individuals before sample sequencing.

Rationale: The paper does not discuss HIV sequencing.

Answer: Not reported
""""""",64
35945163,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the use of genotypic drug resistance testing by Sanger sequencing to identify emergent resistance mutations in plasma viral load specimens collected after combination antiretroviral therapy initiation in all participants.

Rationale: The paper mentions that HIV sequences were obtained from patient samples for genotypic drug resistance testing.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing.

Rationale: The paper focuses on clinical outcomes and genotypic resistance testing rather than in vitro susceptibility assays.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 35 people living with HIV-1 had data available.

Rationale: The paper specifies that 35 people living with HIV-1 had data available.

Answer: 35
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that included individuals were from ten countries, including 12 from the UK; 11 from the USA; two each from Belgium, Canada, Netherlands, and Switzerland; and one each from Portugal, Italy, South Korea, and Spain.

Rationale: The paper lists the countries where the study was conducted, which implies that the sequenced samples were obtained from these locations.

Answer: UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, Spain
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the compassionate use programme was conducted from February 2016 through July 2020.

Rationale: The paper provides the timeline for the compassionate use programme.

Answer: 2016-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that genotypic resistance testing was performed on the reverse transcriptase and integrase genes.

Rationale: The paper mentions that genotypic resistance testing was performed on the reverse transcriptase and integrase genes.

Answer: RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that genotypic resistance testing was performed by Sanger sequencing.

Rationale: The paper explicitly states that Sanger sequencing was used for genotypic resistance testing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma viral load specimens were used for sequencing.

Rationale: The paper specifies that plasma viral load specimens were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that seven people living with HIV-1 discontinued cabotegravir LA + rilpivirine LA therapy because of incomplete virological response.

Rationale: The paper discusses sequences obtained from individuals who experienced virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the compassionate use programme was not a clinical trial.

Rationale: The paper explicitly states that the compassionate use programme was not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that most people living with HIV-1 had previously failed on oral ART due to psychological conditions or physical challenges.

Rationale: The paper discusses sequences obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that individuals had previously failed on regimens containing abacavir/3TC/efavirenz and tenofovir disoproxil/3TC/DTG.

Rationale: The paper lists specific antiretroviral drugs that were received by the individuals before sample sequencing.

Answer: NRTI, NNRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that individuals had previously failed on regimens containing abacavir/3TC/efavirenz and tenofovir disoproxil/3TC/DTG.

Rationale: The paper lists specific antiretroviral drugs that were received by the individuals before sample sequencing.

Answer: Abacavir (ABC), Lamivudine (3TC), Efavirenz (EFV), Tenofovir disoproxil (TDF), Dolutegravir (DTG)
""""""",83
36415058,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not provide any information regarding in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide specific information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding whether the samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide specific information about the HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify the exact sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify the type of clinical specimens that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not provide specific information about virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not provide any information regarding whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide specific information about the treatment history of the individuals.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide specific information about the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide specific information about the drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",53
36454248,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: HIV-1 *pol* sequences were recovered from 67 (88.2%) of 76 children/adolescents (median age 12 years), carrying 65 subtype B, 1 subtype G and 1 unique recombinant URF_A1B.

Rationale: The paper explicitly states that HIV-1 *pol* sequences were recovered from patient samples, indicating that sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: HIV-1 sequences were submitted to GenBank with the following accession numbers: OM201778 -- OM201846.

Rationale: The paper states that the sequences were deposited in GenBank, indicating that they were made publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: OM201778 -- OM201846

Rationale: The paper provides specific accession numbers for the sequenced HIV isolates, indicating where they can be found in the GenBank database.

Answer: OM201778 -- OM201846
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: Plasma samples from 76 HIV-infected children/adolescents were collected during 2018--19.

Rationale: The paper states that plasma samples were collected from 76 HIV-infected children/adolescents, indicating the number of individuals from whom samples were obtained.

Answer: 76
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted in Panama.

Rationale: The paper explicitly mentions that the study was conducted in Panama, indicating the country of origin for the sequenced samples.

Answer: Panama
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: Plasma samples were collected during 2018--19.

Rationale: The paper specifies the years during which the samples were collected, providing a specific range of years.

Answer: 2018-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the cloning of samples prior to sequencing, indicating that this process was not performed.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: HIV-1 *pol* sequences were recovered from 67 (88.2%) of 76 children/adolescents (median age 12 years), carrying 65 subtype B, 1 subtype G and 1 unique recombinant URF_A1B.

Rationale: The paper mentions that the HIV-1 *pol* gene was sequenced, which includes the protease, reverse transcriptase, and integrase regions.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The extracted RNA was amplified by RT--PCR and nested PCR to obtain the HIV-1 *pol* region, using primers designed by WHO for protease (PR) and reverse transcriptase (RT) amplification and ANRS primers for integrase (IN) amplification.

Rationale: The paper describes the use of RT--PCR and nested PCR for amplification, followed by sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Plasma samples from 76 HIV-infected children/adolescents were collected during 2018--19.

Rationale: The paper specifies that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: All 71 treated children/adolescents had received NRTIs, 45.1% NNRTIs, 95.8% PIs and just 11 (15.5%) patients were INSTI-experienced.

Rationale: The paper discusses the presence of drug resistance mutations in patients with treatment, indicating that sequences were obtained from individuals with virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: Among the 71 treated children/adolescents, 14 (19.7%) had failed more than three different ART regimens at sampling.

Rationale: The paper mentions that among the 71 treated children/adolescents, 14 had failed more than three different ART regimens at sampling, indicating that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: All 71 treated children/adolescents had received NRTIs, 45.1% NNRTIs, 95.8% PIs and just 11 (15.5%) patients were INSTI-experienced.

Rationale: The paper lists specific ARV drugs that were administered to the patients, indicating the drug classes involved.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The two naive children had received zidovudine and lamivudine as prophylaxis before sampling.

Rationale: The paper lists specific antiretroviral drugs that for the case 1 (3TC, NVP, EFV, D4T, AZT, LPV, ABC, ATZ, DTG, TDF) and case 2 (TDF, 3TC, EFV, ABC, ATZ, DTG)

Answer: Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP), Stavudine (D4T), Efavirenz (EFV), Abacavir (ABC), Lopinavir (LPV), Atazanavir (ATZ), Dolutegravir (DTG), Tenofovir (TDF)
""""""",99
36519389,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention that the sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not mention which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",53
36571282,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that ""For this study, we used the RT FASTA viral sequence from 50 naive patients diagnosed during the study period, with a broad representation of HIV subtypes in the cohort harboring V106I and no other NNRTI RAMs.""

Rationale: The paper explicitly states that RT FASTA viral sequences were used from 50 naive patients from cohort harboring V106I, indicating that the sequences were derived from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility data or phenotypic data. It mentions clinical isolates and sequencing of plasma samples.

Rationale: The paper focuses on the analysis of drug resistance mutations and their prevalence in patient samples, but it does not mention conducting in vitro drug susceptibility tests.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that ""For this study, we used the RT FASTA viral sequence from 50 naive patients diagnosed during the study period, with a broad representation of HIV subtypes in the cohort harboring V106I and no other NNRTI RAMs.""

Rationale: The paper states that RT FASTA viral sequences were used from 50 naive patients from cohort harboring V106I.

Answer: 50
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that ""MeditRes HIV is a consortium that includes ART-naive PWH in France, Greece, Italy, Portugal, and Spain who have been newly diagnosed during 2018--2021.""

Rationale: The paper explicitly lists the countries from which the sequenced samples were obtained.

Answer: France, Greece, Italy, Portugal, Spain
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that ""MeditRes HIV is a consortium that includes ART-naive PWH in France, Greece, Italy, Portugal, and Spain who have been newly diagnosed during 2018--2021.""

Rationale: The paper specifies that the samples were obtained from antiretroviral-naive PWH newly diagnosed during the years 2018-2021.

Answer: 2018-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not specify the method used for sequencing, but it does not mention cloning.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that ""Reverse transcriptase and INSTI sequences were provided by participating centers.""

Rationale: The paper explicitly states that reverse transcriptase and INSTI sequences were provided by participating centers.

Answer: RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that ""The integrase region from HIV was sequenced using different protocols at testing sites, including the Sanger sequencing--based assay and next-generation sequencing (NGS)--based assay.""

Rationale: The paper specifies that Sanger sequencing and next-generation sequencing (NGS) were used for sequencing.

Answer: Sanger sequencing, NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that ""Nucleic acids were extracted from plasma or whole blood samples.""

Rationale: The paper mentions that nucleic acids were extracted from plasma or whole blood samples for sequencing.

Answer: Plasma; Whole Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper specifies that the study included antiretroviral-naive PWH, indicating that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes the study as a consortium that includes antiretroviral-naive PWH newly diagnosed in France, Greece, Italy, Portugal, and Spain during the years 2018-2021.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper specifies that the study included antiretroviral-naive PWH, indicating that the sequences were not from individuals who had previously received ARV drugs.

Rationale: The paper explicitly states that the study included antiretroviral-naive PWH.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention that the individuals had previously received ARV drugs.

Rationale: The paper specifies that the study included antiretroviral-naive PWH, indicating that the sequences were not from individuals who had previously received ARV drugs.

Answer: nan
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention that the individuals had previously received ARV drugs.

Rationale: The paper specifies that the study included antiretroviral-naive PWH, indicating that the sequences were not from individuals who had previously received ARV drugs.

Answer: nan
""""""",89
36597160,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention the reporting of HIV sequences from patient samples. However, it discusses the use of genotypic resistance testing and the results of those tests, which implies that HIV sequences were obtained from patient samples.

Rationale: The paper focuses on the clinical outcomes and resistance mutations in patients but does not explicitly mention the reporting of HIV sequences from patient samples. However, the use of genotypic resistance testing implies that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not report in vitro drug susceptibility data. It focuses on clinical outcomes and genotypic resistance testing rather than in vitro susceptibility assays.

Rationale: The paper does not mention any in vitro drug susceptibility testing or results.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not specify the exact number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide specific information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not specify the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the geographical origin of the samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not specify the exact years during which the sequenced samples were obtained.

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that genotypic resistance testing was performed, which typically involves sequencing the reverse transcriptase, protease, and integrase genes.

Rationale: The paper does not specify which HIV genes were sequenced, but genotypic resistance testing typically involves sequencing the reverse transcriptase, protease, and integrase genes.

Answer: RT, PR, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the exact sequencing method used for genotypic resistance testing.

Rationale: The paper does not mention the specific sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not specify which clinical specimens were sequenced.

Rationale: The paper does not provide specific information on the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper discusses cases of individuals who developed treatment-emergent resistance mutations, which means they experienced virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes a case report of a single patient and does not mention any clinical trial involvement.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that sequences were from individuals who had previously received ARV drugs.

Rationale: The paper discusses cases of individuals who had treatment-emergent resistance, which means sequences were from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that individuals had previously failed on regimens containing abacavir/3TC/efavirenz and tenofovir disoproxil/3TC/DTG.

Rationale: The paper lists various antiretroviral drugs from different classes that were received by the individuals before sample sequencing.

Answer: NRTI, NNRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper lists specific antiretroviral drugs that were received by the individuals before sample sequencing, including efavirenz, tenofovir disoproxil fumarate, emtricitabine, lamivudine, nevirapine, and zidovudine.

Rationale: The paper lists specific antiretroviral drugs that were received by the individuals before sample sequencing.

Answer: Efavirenz (EFV), Tenofovir (TFV), Emtricitabine (FTC), Lamivudine (3TC), Nevirapine (NVP), Zidovudine (AZT), Dolutegravir (DTG)
""""""",86
36645792,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 genotyping and phenotyping of plasma samples at baseline and the first sample of the 2 required to meet CVW criteria were conducted by Monogram Biosciences.

Rationale: The paper explicitly states that HIV-1 genotyping and phenotyping of plasma samples were conducted, which indicates that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing.

Rationale: The paper does not report any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 130 participants were randomly assigned to receive lead-in supplementary dolutegravir or placebo.

Rationale: The paper mentions that 130 participants were randomly assigned to receive lead-in supplementary dolutegravir or placebo, and all participants had samples obtained for HIV sequencing.

Answer: 130
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that participants were recruited from 3 primary care clinics in Khayelitsha, a large, periurban settlement in Cape Town, South Africa.

Rationale: The paper explicitly states that the study was conducted in South Africa.

Answer: South Africa
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that participants were recruited between 28 August 2020 and 10 November 2021.

Rationale: The paper explicitly states the years during which the samples were obtained.

Answer: 2020-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV-1 genotyping and phenotyping of plasma samples at baseline and the first sample of the 2 required to meet CVW criteria were conducted by Monogram Biosciences.

Rationale: The paper does not specify which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the sequencing method used.

Rationale: The paper does not specify the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that HIV-1 genotyping and phenotyping of plasma samples at baseline and the first sample of the 2 required to meet CVW criteria were conducted by Monogram Biosciences.

Rationale: The paper explicitly states that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that participants had virologic failure (2 consecutive HIV-1 RNA ≥1000 copies/mL) on first-line TEE.

Rationale: The paper explicitly states that participants had virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was a randomized, double-blind, placebo-controlled, phase 2 trial.

Rationale: The paper explicitly states that the study was a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that participants had virologic failure (2 consecutive HIV-1 RNA ≥1000 copies/mL) on first-line TEE.

Rationale: The paper explicitly states that participants had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants had virologic failure (2 consecutive HIV-1 RNA ≥1000 copies/mL) on first-line TEE.

Rationale: The paper explicitly states that participants had previously received ARV drugs, including TEE.

Answer: NRTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants had virologic failure (2 consecutive HIV-1 RNA ≥1000 copies/mL) on first-line TEE.

Rationale: The paper explicitly states that participants had previously received ARV drugs, including TEE.

Answer: Tenofovir, Emtricitabine, Efavirenz
""""""",80
36659824,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention any HIV sequences from patient samples. It focuses on the efficacy, safety, and feasibility of using BIC/FTC/TAF as a first-line regimen in a same-day initiation strategy.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility data. It focuses on clinical outcomes and genotypic resistance testing rather than in vitro susceptibility assays.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention whether the sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not report any individuals from whom samples were obtained for HIV sequencing, as it does not involve sequencing.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention any specific countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not mention any specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention any specific sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not provide any information about the type of samples that were sequenced, as it does not report any sequencing data.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not report any sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The FAST study was a national, prospective, single-arm study assessing the efficacy, safety and feasibility of BIC/FTC/TAF in a same-day initiation model.

Rationale: The paper clearly states that the study is a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not report any HIV sequences from individuals, regardless of their previous ARV drug history, as it does not involve sequencing.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention any specific drug classes that were received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention any specific drugs that were received by individuals before sample sequencing.

Answer: Not reported
""""""",62
36660819,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the use of HIV-1 sequences from patient samples to evaluate the efficacy and safety of cabotegravir and rilpivirine therapy.

Rationale: The paper mentions the use of HIV-1 sequences from patient samples to evaluate the efficacy and safety of cabotegravir and rilpivirine therapy, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper discusses the in vitro susceptibility of HIV-1 strains to cabotegravir and rilpivirine, including the use of phenotypic and genotypic assays.

Rationale: The paper mentions the use of phenotypic and genotypic assays to evaluate the in vitro susceptibility of HIV-1 strains to cabotegravir and rilpivirine, indicating that in vitro drug susceptibility data are reported.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any information about the public availability of the sequences.

Rationale: The paper does not mention the public availability of the sequences, and no accession numbers are provided.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 1045 participants were included in the study.

Rationale: The paper mentions that 1045 participants were included in the study, but it does not specify how many of these participants had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide any information about the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide any information about the years from which the sequenced samples were obtained.

Rationale: The paper does not mention the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not provide any information about cloning of samples prior to sequencing.

Rationale: The paper does not mention cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper discusses the sequencing of the integrase gene.

Rationale: The paper mentions the sequencing of the integrase gene, but it does not specify whether other HIV genes were also sequenced.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not provide any information about the sequencing method used.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper mentions that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper discusses the sequencing of samples from individuals with virological failure on a treatment regimen.

Rationale: The paper mentions the sequencing of samples from individuals with virological failure on a treatment regimen, indicating that sequences were obtained from these individuals.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper discusses the ATLAS-2M study, which is a clinical trial.

Rationale: The paper mentions the ATLAS-2M study, which is a clinical trial, indicating that the patients were part of a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper discusses the sequencing of samples from individuals who had previously received ARV drugs.

Rationale: The paper mentions the sequencing of samples from individuals who had previously received ARV drugs, indicating that sequences were obtained from these individuals.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper discusses the use of cabotegravir and rilpivirine, which are INSTIs and NNRTIs, respectively.

Rationale: The paper mentions the use of cabotegravir and rilpivirine, which are INSTIs and NNRTIs, respectively, indicating that these drug classes were received by individuals before sample sequencing.

Answer: INSTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper discusses the use of cabotegravir and rilpivirine.

Rationale: The paper mentions the use of cabotegravir and rilpivirine, indicating that these drugs were received by individuals before sample sequencing.

Answer: Cabotegravir (CAB), Rilpivirine (RPV)
""""""",83
36694270,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV genotyping and drug resistance was evaluated using the Stanford v8.7 algorithm, and that the matched CSF and plasma samples of 62 HIV-1 patients were tested.

Rationale: The paper reports HIV sequences from patient samples, as it mentions the use of HIV genotyping and drug resistance evaluation, and the testing of matched CSF and plasma samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data or phenotypic data. It mentions clinical isolates and sequencing of plasma samples.

Rationale: The paper does not report in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information regarding the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that the matched CSF and plasma samples of 62 HIV-1 patients were tested.

Rationale: The paper states that 62 individuals had samples obtained for HIV sequencing.

Answer: 62
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide information regarding the country of origin for the sequenced samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the samples were collected from June 2020 to June 2022.

Rationale: The paper states that the samples were collected from June 2020 to June 2022.

Answer: 2020-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information regarding the cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the nucleotide sequences of HIV-1 protease, reverse transcriptase and integrase were amplified using nested polymerase chain reaction (nest-pcr) method.

Rationale: The paper reports that the protease, reverse transcriptase, and integrase genes were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that the amplified product was sequenced, but it does not specify the sequencing method.

Rationale: The paper does not provide information regarding the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that the matched CSF and plasma samples of 62 HIV-1 patients were tested.

Rationale: The paper states that CSF and plasma samples were sequenced.

Answer: CSF, Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that 8/11 (72.7 %) of patients receiving ARV treatment had HIV-1 resistance mutations in both plasma and CSF.

Rationale: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information regarding the patients being part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that 8/11 (72.7 %) of patients receiving ARV treatment had HIV-1 resistance mutations in both plasma and CSF.

Rationale: The paper reports that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patients received ARV treatment, but it does not specify the drug classes.

Rationale: The paper does not provide information regarding the specific drug classes received by the individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patients received ARV treatment, but it does not specify the drugs.

Rationale: The paper does not provide information regarding the specific drugs received by the individuals before sample sequencing.

Answer: Not reported
""""""",77
36706364,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses a study where participants were switched to a regimen of dolutegravir with a recycled tenofovir and lamivudine NRTI backbone, and their viral loads were monitored over time.

Rationale: The paper does not explicitly mention the reporting of HIV sequences from patient samples. However, it does discuss the monitoring of viral loads and the development of resistance to antiretroviral drugs, which suggests that some form of genetic analysis may have been performed.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper discusses the development of resistance to antiretroviral drugs in patients, but it does not provide any in vitro drug susceptibility data.

Rationale: The paper focuses on the clinical outcomes of patients on a regimen of dolutegravir with a recycled tenofovir and lamivudine NRTI backbone, and does not include any laboratory-based experiments or data on drug susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention the public availability of sequences.

Rationale: The paper does not provide any information on the public availability of sequences, and it does not include any accession numbers or links to publicly available sequence data.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not include any GenBank accession numbers or links to publicly available sequence data.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper discusses a study with 62 participants.

Rationale: The paper mentions that 62 participants were enrolled in the study, but it does not explicitly state that all of them had samples obtained for HIV sequencing.

Answer: 62
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information on the country of origin for the sequenced samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted between August 2019 and July 2020.

Rationale: The paper provides a specific time frame for the study, but it does not explicitly state that the sequenced samples were obtained during this time.

Answer: 2019-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide any information on the cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper does not provide any information on the specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide any information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper discusses the development of resistance to antiretroviral drugs in patients, which suggests that some individuals may have experienced virological failure.

Rationale: The paper focuses on the clinical outcomes of patients on a regimen of dolutegravir with a recycled tenofovir and lamivudine NRTI backbone, and it mentions the development of resistance to antiretroviral drugs.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was a single-arm, prospective, interventional study.

Rationale: The paper explicitly states that the study was a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper discusses the development of resistance to antiretroviral drugs in patients, which suggests that some individuals may have previously received ARV drugs.

Rationale: The paper focuses on the clinical outcomes of patients on a regimen of dolutegravir with a recycled tenofovir and lamivudine NRTI backbone, and it mentions the development of resistance to antiretroviral drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants were on a regimen of dolutegravir with a recycled tenofovir and lamivudine NRTI backbone.

Rationale: The paper explicitly states that participants were on a regimen of dolutegravir with a recycled tenofovir and lamivudine NRTI backbone.

Answer: NRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants were on a regimen of dolutegravir with a recycled tenofovir and lamivudine NRTI backbone.

Rationale: The paper explicitly states that participants were on a regimen of dolutegravir with a recycled tenofovir and lamivudine NRTI backbone.

Answer: Dolutegravir, Tenofovir, Lamivudine
""""""",88
36738248,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the sequencing of HIV from patient samples, specifically mentioning the detection of mutations in the reverse transcriptase and integrase genes through Sanger and deep sequencing methods.

Rationale: The paper mentions the use of patient samples for sequencing, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Rationale: The paper focuses on the presence of drug resistance mutations rather than susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention whether the sequences obtained were made publicly available.

Rationale: The paper does not provide any information regarding the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any specific GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not specify the number of individuals from whom samples were obtained for sequencing.

Rationale: The paper does not provide any information regarding the number of individuals.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not specify any countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information regarding the countries of origin for the samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific years for when the sequenced samples were obtained.

Rationale: The paper does not provide any information regarding the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information regarding whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions the sequencing of the protease, reverse transcriptase, and integrase genes for resistance genotyping.

Rationale: The paper describes the sequencing of the protease, reverse transcriptase, and integrase genes.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions the use of Sanger sequencing for genotypic drug resistance testing and Illumina MiSeq for ultra-deep sequencing.

Rationale: The paper describes the use of Sanger sequencing and Illumina MiSeq for sequencing.

Answer: Sanger sequencing, Illumina sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper specifies that plasma samples were used for sequencing.

Rationale: The paper indicates that plasma samples were the clinical specimens sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not specify whether any sequences were obtained from individuals with virological failure.

Rationale: The paper does not provide any information regarding virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not indicate that the patients were part of a clinical trial.

Rationale: The paper does not provide any information regarding clinical trials.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not provide information regarding whether the individuals had previously received ARV drugs.

Rationale: The paper does not provide any information regarding prior ARV treatment.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any specific drug classes that individuals received prior to sample sequencing.

Rationale: The paper does not provide any information regarding specific drug classes.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide any information regarding specific drugs received by individuals before sample sequencing.

Rationale: The paper does not provide any information regarding specific drugs.

Answer: Not reported
""""""",70
36751650,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Individuals newly diagnosed with HIV in Guangxi from 2016 to 2020, which mainly included MSM and the heterosexual (HES) population, were recruited in this study. Pol sequences were sequenced to analyze PDR and construct a genetic network.""

Rationale: The paper mentions that pol sequences were sequenced from patient samples to analyze PDR and construct a genetic network.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""A total of 1653 samples, including 716 MSM, 827 HES, 50 PWID, and 15 others, were successfully sequenced.""

Rationale: The paper states that a total of 1653 samples were successfully sequenced.

Answer: 1653
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""Individuals newly diagnosed with HIV in Guangxi from 2016 to 2020, which mainly included MSM and the heterosexual (HES) population, were recruited in this study.""

Rationale: The paper specifies that the study was conducted in Guangxi, China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""Individuals newly diagnosed with HIV in Guangxi from 2016 to 2020, which mainly included MSM and the heterosexual (HES) population, were recruited in this study.""

Rationale: The paper mentions that the samples were obtained from 2016 to 2020.

Answer: 2016-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""The target fragment of 1316 bp in the pol gene (HXB2: 2147-3462, encoding the protease and the first 299 residues of reverse transcriptase), which spans the reverse transcriptase and protease-encoding regions, was amplified using nested polymerase chain reaction (PCR).""

Rationale: The paper mentions that the pol gene, specifically the protease and reverse transcriptase regions, was sequenced.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""The PCR products were sent to the company for Sanger sequencing.""

Rationale: The paper mentions that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Plasma was separated within 12 hours of blood collection and stored at -80°C until further use.""

Rationale: The paper mentions that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""No evidence""

Rationale: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""No evidence""

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""No evidence""

Rationale: The paper does not mention any sequences obtained from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",72
36779485,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide information on the years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not provide information on the specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not provide information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not provide information on whether sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not provide information on whether the patients were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not provide information on whether the individuals had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information on the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information on the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",55
36795586,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the effectiveness and safety of dolutegravir (DTG) in children and adolescents living with HIV (CALHIV) in real-world settings in 6 countries in Eastern and Southern Africa.

Rationale: The paper does not explicitly mention HIV sequences from patient samples. However, it discusses the effectiveness and safety of DTG in CALHIV, which implies that HIV sequences may have been analyzed as part of the study.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper discusses the effectiveness and safety of dolutegravir (DTG) in children and adolescents living with HIV (CALHIV) in real-world settings in 6 countries in Eastern and Southern Africa.

Rationale: The paper does not mention in vitro drug susceptibility data. It focuses on the clinical outcomes and effectiveness of DTG in CALHIV.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide any information about making sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper discusses a cohort of 9419 children and adolescents living with HIV (CALHIV) who received dolutegravir (DTG) across 6 countries in Eastern and Southern Africa.

Rationale: The paper mentions that 9419 CALHIV received DTG, but it does not explicitly state that all of these individuals had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper discusses a cohort of children and adolescents living with HIV (CALHIV) who received dolutegravir (DTG) across 6 countries in Eastern and Southern Africa, including Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda.

Rationale: The paper explicitly mentions the countries from which the samples were obtained.

Answer: Botswana, Eswatini, Lesotho, Malawi, Tanzania, Uganda
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper discusses a cohort of children and adolescents living with HIV (CALHIV) who received dolutegravir (DTG) from 2017 to 2020.

Rationale: The paper explicitly mentions the years during which the samples were obtained.

Answer: 2017-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not explicitly mention which HIV genes were sequenced.

Rationale: The paper does not provide any information about the specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper discusses a cohort of children and adolescents living with HIV (CALHIV) who received dolutegravir (DTG) across 6 countries in Eastern and Southern Africa.

Rationale: The paper does not explicitly mention the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper discusses a cohort of children and adolescents living with HIV (CALHIV) who received dolutegravir (DTG) across 6 countries in Eastern and Southern Africa, and mentions that some individuals had virological failure on their treatment regimens.

Rationale: The paper implies that sequences may have been obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper discusses a retrospective cohort study of children and adolescents living with HIV (CALHIV) who received dolutegravir (DTG) across 6 countries in Eastern and Southern Africa.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper discusses a cohort of children and adolescents living with HIV (CALHIV) who received dolutegravir (DTG) across 6 countries in Eastern and Southern Africa, and mentions that some individuals had previously received ARV drugs.

Rationale: The paper implies that sequences may have been obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper discusses a cohort of children and adolescents living with HIV (CALHIV) who received dolutegravir (DTG) across 6 countries in Eastern and Southern Africa, and mentions that some individuals had previously received ARV drugs from various classes.

Rationale: The paper implies that sequences may have been obtained from individuals who had previously received ARV drugs from various classes.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper discusses a cohort of children and adolescents living with HIV (CALHIV) who received dolutegravir (DTG) across 6 countries in Eastern and Southern Africa, and mentions that some individuals had previously received ARV drugs.

Rationale: The paper implies that sequences may have been obtained from individuals who had previously received ARV drugs.

Answer: Not reported
""""""",93
36851704,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Whole blood specimens were collected by venipuncture in EDTA-containing tubes from participants before initiating or reinitiating ART. Plasma was separated within 12 h of collection; all plasma specimens were stored at −80 °C at the National HIV-AIDS Reference Laboratory of Uruguay until the completion of the specimen collection period (October 2019).""

Rationale: The paper mentions that whole blood specimens were collected from participants and plasma was separated and stored for later analysis, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""HIV drug resistance was predicted using the Stanford HIV drug resistance database (HIVdb v 8.9-1) tool [15, 16]. Sequences with a penalty score ≥15 were considered resistant to a given ARV drug.""

Rationale: The paper does not report in vitro drug susceptibility data, but rather uses a computational tool to predict HIV drug resistance based on the sequences obtained.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""The data presented in this study are available on request from the corresponding author.""

Rationale: The paper does not provide a clear statement on whether the sequences were made publicly available, but rather offers to provide the data upon request.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: Not reported

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""From October 2018 to October 2019, 206 adults who initiated or reinitiated ART in Uruguay were enrolled in the survey;""

Rationale: The paper mentions that 206 adults were enrolled in the survey and had samples obtained for HIV sequencing.

Answer: 206
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""The first nationally representative cross-sectional HIV drug resistance (HIVDR) survey was conducted in Uruguay in 2018--2019 among adults diagnosed with HIV and initiating or reinitiating antiretroviral therapy (ART).""

Rationale: The paper clearly states that the samples were obtained from Uruguay.

Answer: Uruguay
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""The first nationally representative cross-sectional HIV drug resistance (HIVDR) survey was conducted in Uruguay in 2018--2019 among adults diagnosed with HIV and initiating or reinitiating antiretroviral therapy (ART).""

Rationale: The paper mentions that the samples were obtained between 2018 and 2019.

Answer: 2018-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: Not reported

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""Protease, reverse transcriptase, and integrase genes of HIV-1 were sequenced.""

Rationale: The paper explicitly mentions that the protease, reverse transcriptase, and integrase genes of HIV-1 were sequenced.

Answer: Protease, reverse transcriptase, integrase
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""Sanger sequencing was performed on a 3730xl Genetic Analyser (ThermoFisher, Waltham, MA, USA).""

Rationale: The paper mentions that Sanger sequencing was used for sequencing the HIV genes.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Whole blood specimens were collected by venipuncture in EDTA-containing tubes from participants before initiating or reinitiating ART. Plasma was separated within 12 h of collection; all plasma specimens were stored at −80 °C at the National HIV-AIDS Reference Laboratory of Uruguay until the completion of the specimen collection period (October 2019).""

Rationale: The paper mentions that whole blood specimens were collected and plasma was separated and stored for later analysis, indicating that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: Not reported

Rationale: The paper does not provide information on whether any sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""The first nationally representative cross-sectional HIV drug resistance (HIVDR) survey was conducted in Uruguay in 2018--2019 among adults diagnosed with HIV and initiating or reinitiating antiretroviral therapy (ART).""

Rationale: The paper describes a cross-sectional survey, not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""The proportion of individuals who reported previous exposure to ARV drugs was 35.6% (95% CI: 34.2--37.0%).""

Rationale: The paper mentions that some individuals had previously received ARV drugs, indicating that sequences were obtained from these individuals.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""NNRTI-based ART regimens were the most frequently prescribed (55.1%, 95% CI: 54--56.1%), followed by dolutegravir (DTG)-based regimens (29.4%, 95% CI: 28.4--30.4%), and PI/r-based regimens (11.7%, 95% CI: 11.0--12.6%).""

Rationale: The paper mentions that individuals received NNRTI-based, DTG-based, and PI/r-based regimens before sample sequencing.

Answer: NNRTI, INSTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""NNRTI-based ART regimens were the most frequently prescribed (55.1%, 95% CI: 54--56.1%), followed by dolutegravir (DTG)-based regimens (29.4%, 95% CI: 28.4--30.4%), and PI/r-based regimens (11.7%, 95% CI: 11.0--12.6%).""

Rationale: The paper mentions that individuals received NNRTI-based, DTG-based, and PI/r-based regimens before sample sequencing.

Answer: Efavirenz (EFV), Nevirapine (NVP), Dolutegravir (DTG), Atazanavir (ATV), Lopinavir (LPV)
""""""",102
36851760,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 RNA was extracted from dried blood spots (DBSs) obtained from 107 HIV-1-infected children aged less than 15 years old in two West African countries, Benin and Mali.

Rationale: The paper explicitly states that the study involved the collection and analysis of HIV sequences from patient samples, specifically from children living with HIV/AIDS in West Africa.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Rationale: The paper focuses on the analysis of HIV sequences and the presence of drug resistance mutations rather than susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: All sequences were submitted to GenBank and registered under accession numbers OQ435656-OQ435729.

Rationale: The paper explicitly states that the sequences were submitted to GenBank and provides the accession numbers.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: OQ435656-OQ435729.

Rationale: The paper explicitly provides the GenBank accession numbers for the sequenced HIV isolates.

Answer: OQ435656-OQ435729
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: 107 HIV-1-infected children aged less than 15 years old in two West African countries, Benin and Mali.

Rationale: The paper explicitly states that the study involved the collection and analysis of HIV sequences from 107 children.

Answer: 107
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: Benin and Mali.

Rationale: The paper explicitly states that the samples were obtained from children living with HIV/AIDS in two West African countries, Benin and Mali.

Answer: Benin, Mali
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific information about the years from which the sequenced samples were obtained.

Rationale: The paper does not mention the specific years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide any information regarding whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that genetic sequencing of HIV integrase was successful in 75 samples.

Rationale: The paper explicitly states that the study involved the sequencing of the HIV integrase gene.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that the Sanger sequencing method was used.

Rationale: The paper explicitly states that the Sanger sequencing method was used for the analysis of HIV sequences.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that dried blood spots (DBSs) were obtained from 107 HIV-1-infected children aged less than 15 years old in two West African countries, Benin and Mali.

Rationale: The paper explicitly states that the study involved the collection and analysis of HIV sequences from dried blood spots (DBSs).

Answer: Dried blood spots (DBSs)
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that 51 ART-treated children with virological failure were included in the study.

Rationale: The paper explicitly states that the study involved the collection and analysis of HIV sequences from children with virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that 51 ART-treated children with virological failure were included in the study.

Rationale: The paper explicitly states that the study involved the collection and analysis of HIV sequences from children who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the children were receiving non-nucleoside-reverse-transcriptase-inhibitor (NNRTI)-based regimens.

Rationale: The paper explicitly states that the children were receiving NNRTI-based regimens.

Answer: NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information about the drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not mention the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",78
36920025,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any experiments or data related to in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific years for when the samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide information on the HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not provide information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not provide information on the treatment history of the individuals from whom the sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide information on the treatment history of the individuals from whom the sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the drug classes received by the individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the specific drugs received by the individuals in the study before sample sequencing.

Answer: Not reported
""""""",65
36931676,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-DNA sequences obtained from patient samples. Specifically, it mentions that HIV-DNA sequences were obtained from the peripheral blood of six participants over a period of 3 to ≥15 years of effective therapy.

Rationale: The paper focuses on the persistence of HIV in memory CD4+ T-cells and the genetic analysis of HIV-DNA sequences. It does not mention any experiments or data related to in vitro drug susceptibility testing.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper focuses on the persistence of HIV in memory CD4+ T-cells and the genetic analysis of HIV-DNA sequences. It does not mention any experiments or data related to in vitro drug susceptibility testing.

Rationale: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs. It focuses on the presence of drug resistance mutations rather than susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper provides specific GenBank accession numbers for the sequenced HIV isolates. It mentions that the generated HIV sequences were deposited in GenBank with accession numbers ranging from KR860607 to KR861345.

Rationale: The paper provides specific GenBank accession numbers for the sequenced HIV isolates. It mentions that the generated HIV sequences were deposited in GenBank with accession numbers ranging from KR860607 to KR861345.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper provides specific GenBank accession numbers for the sequenced HIV isolates. It mentions that the generated HIV sequences were deposited in GenBank with accession numbers ranging from KR860607 to KR861345.

Rationale: The paper provides specific GenBank accession numbers for the sequenced HIV isolates. It mentions that the generated HIV sequences were deposited in GenBank with accession numbers ranging from KR860607 to KR861345.

Answer: KR860607 to KR861345
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that six HIV-1 subtype-B positive individuals on prolonged ART were included in the study.

Rationale: The paper states that six HIV-1 subtype-B positive individuals on prolonged ART were included in the study.

Answer: 6
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was approved in Western Sydney Health Department for the Westmead Institute for Medical Research (Australia), and University of California San Francisco (United States), Vaccine Gene Therapy Institute-Florida (United States)

Rationale: The paper mentions that the study was approved in Western Sydney Health Department for the Westmead Institute for Medical Research (Australia), and University of California San Francisco (United States), Vaccine Gene Therapy Institute-Florida (United States)

Answer: United States, Australia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific years for when the samples were obtained. It only mentions the duration of therapy and the time points of sample collection relative to the initiation of ART.

Rationale: The paper does not provide specific years for when the samples were obtained. It only mentions the duration of therapy and the time points of sample collection relative to the initiation of ART.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any process of cloning the samples prior to sequencing. It describes single-proviral sequencing (SPS) which is a single genome sequencing method.

Rationale: The paper does not mention any cloning of samples prior to sequencing, focusing instead on the direct analysis of the plasma RNA.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that single-proviral sequencing (SPS) was used to amplify the gag-pol region of the HIV genome, specifically the p6-RT region.

Rationale: The paper mentions that single-proviral sequencing (SPS) was used to amplify the gag-pol region of the HIV genome, specifically the p6-RT region.

Answer: Gag, PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper describes the use of single-proviral sequencing (SPS) to obtain individual intracellular HIV-DNA sequences from the extracted DNA, but doesn't mention the sequencing method.

Rationale: The paper describes the use of single-proviral sequencing (SPS) to obtain individual intracellular HIV-DNA sequences from the extracted DNA, but doesn't mention the sequencing method.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper specifies that CD4+ T-cell subsets were sorted from frozen aliquots of peripheral blood mononuclear cells (PBMCs), and HIV-DNA was sequenced.

Rationale: The paper specifies that CD4+ T-cell subsets were sorted from frozen aliquots of peripheral blood mononuclear cells (PBMCs), and HIV-DNA was sequenced.

Answer: PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the participants had viral loads of <40-75 copies (HIV-RNA) per ml during the study period, indicating effective viral suppression and not virological failure.

Rationale: The paper mentions that the participants had viral loads of <40-75 copies (HIV-RNA) per ml during the study period, indicating effective viral suppression and not virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included individuals on prolonged ART, indicating that the participants had previously received antiretroviral drugs.

Rationale: The paper mentions that the study included individuals on prolonged ART, indicating that the participants had previously received antiretroviral drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific names of the drugs received by the individuals in the study. It only mentions that the participants were on prolonged ART.

Rationale: The paper does not provide specific names of the drugs received by the individuals in the study. It only mentions that the participants were on prolonged ART.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific names of the drugs received by the individuals in the study. It only mentions that the participants were on prolonged ART.

Rationale: The paper does not provide specific names of the drugs received by the individuals in the study. It only mentions that the participants were on prolonged ART.

Answer: Not reported
""""""",106
36961945,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""We investigated whether deep sequencing of archived HIV DNA of antiretroviral-naïve persons with acute/early HIV infection could identify transmitted drug resistance mutations (DRM), per the IAS drug resistance algorithm, that are not detected by routine bulk (consensus) sequencing.""

Rationale: The paper discusses the use of deep sequencing of archived HIV DNA from patient samples to identify transmitted drug resistance mutations.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not mention whether the sequences obtained were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Overall, 190 individuals were included, 72 (37.9%) with acute, 20 (10.5%) very early, and 98 (51.6%) with recent HIV infection.""

Rationale: The paper mentions that 190 individuals were included in the study.

Answer: 190
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not mention the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""Samples were collected from January 2005 to February 2020""

Rationale: The paper mentions that samples were collected from January 2005 to February 2020.

Answer: 2005-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""Genotypic resistance testing on PR, RT, and IN from proviral HIV-1 DNA was performed using a modified version of the ""deepTypeHIV"" assay""

Rationale: The paper mentions that genotypic resistance testing was performed on PR, RT, and IN genes.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""Genotypic resistance testing on PR, RT, and IN from proviral HIV-1 DNA was performed using a modified version of the ""deepTypeHIV"" assay""

Rationale: The paper mentions the use of a modified version of the ""deepTypeHIV"" assay for genotypic resistance testing, but does not specify the sequencing method.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Genomic DNA was isolated from patient PBMCs (10^6 cells) using QIAamp DNA blood mini kit""

Rationale: The paper specifies that genomic DNA was isolated from patient PBMCs.

Answer: PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Despite identifying both high frequency and low frequency DRMs in either archived proviral DNA or blood plasma, there was no evidence of viral rebound from any participants during the entire follow-up period""

Rationale: The paper mentions that there was no evidence of viral rebound from any participants during the entire follow-up period, indicating that sequences were not obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""No evidence""

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""No evidence""

Rationale: The paper focuses on antiretroviral-naïve individuals.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not provide specific names of the drugs received by the individuals in the study.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not provide specific names of the drugs received by the individuals in the study.

Answer: Not reported
""""""",73
36967989,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention obtaining HIV sequences from patient samples. It focuses on the development of a machine learning model for predicting HIV-1 protease resistance using genotypic, phenotypic, and molecular information.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention in vitro drug susceptibility data. It focuses on the development of a machine learning model for predicting HIV-1 protease resistance using genotypic, phenotypic, and molecular information.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention making sequences publicly available. It focuses on the development of a machine learning model for predicting HIV-1 protease resistance using genotypic, phenotypic, and molecular information.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not mention GenBank accession numbers for sequenced HIV isolates. It focuses on the development of a machine learning model for predicting HIV-1 protease resistance using genotypic, phenotypic, and molecular information.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing. It focuses on the development of a machine learning model for predicting HIV-1 protease resistance using genotypic, phenotypic, and molecular information.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention the countries from which the sequenced samples were obtained. It focuses on the development of a machine learning model for predicting HIV-1 protease resistance using genotypic, phenotypic, and molecular information.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention the years from which the sequenced samples were obtained. It focuses on the development of a machine learning model for predicting HIV-1 protease resistance using genotypic, phenotypic, and molecular information.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention cloning of samples prior to sequencing. It focuses on the development of a machine learning model for predicting HIV-1 protease resistance using genotypic, phenotypic, and molecular information.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not mention specific HIV genes that were sequenced. It focuses on the development of a machine learning model for predicting HIV-1 protease resistance using genotypic, phenotypic, and molecular information.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used. It focuses on the development of a machine learning model for predicting HIV-1 protease resistance using genotypic, phenotypic, and molecular information.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not mention the type of samples that were sequenced. It focuses on the development of a machine learning model for predicting HIV-1 protease resistance using genotypic, phenotypic, and molecular information.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention obtaining sequences from individuals with virological failure on a treatment regimen. It focuses on the development of a machine learning model for predicting HIV-1 protease resistance using genotypic, phenotypic, and molecular information.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial. It focuses on the development of a machine learning model for predicting HIV-1 protease resistance using genotypic, phenotypic, and molecular information.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention obtaining HIV sequences from individuals who had previously received ARV drugs. It focuses on the development of a machine learning model for predicting HIV-1 protease resistance using genotypic, phenotypic, and molecular information.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention the drug classes received by individuals in the study before sample sequencing. It focuses on the development of a machine learning model for predicting HIV-1 protease resistance using genotypic, phenotypic, and molecular information.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention the specific drugs received by individuals in the study before sample sequencing. It focuses on the development of a machine learning model for predicting HIV-1 protease resistance using genotypic, phenotypic, and molecular information.

Answer: Not reported
""""""",87
36982978,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the use of patient-derived viruses and clinical isolates, indicating that the sequences were obtained from patient samples.

Rationale: The paper mentions the use of patient-derived viruses and clinical isolates, which suggests that the sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper discusses the in vitro activity of various antiretroviral drugs against HIV-2 isolates, indicating that it reports in vitro drug susceptibility data.

Rationale: The paper mentions the in vitro activity of various antiretroviral drugs against HIV-2 isolates, which suggests that it reports in vitro drug susceptibility data.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any information about making the sequences publicly available.

Rationale: The paper does not mention making the sequences publicly available, and there is no evidence to suggest that the sequences were deposited in a public database.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide information on the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide information on the years from which the sequenced samples were obtained.

Rationale: The paper does not mention the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not provide information on whether samples were cloned prior to sequencing.

Rationale: The paper does not mention cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper discusses the sequencing of various HIV genes, including the reverse transcriptase, protease, and integrase genes.

Rationale: The paper mentions the sequencing of various HIV genes, including the reverse transcriptase, protease, and integrase genes.

Answer: RT, PR, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not provide information on the sequencing method used.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper discusses the use of patient-derived viruses and clinical isolates, indicating that the samples were obtained from patients.

Rationale: The paper mentions the use of patient-derived viruses and clinical isolates, which suggests that the samples were obtained from patients.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper discusses the use of patient-derived viruses and clinical isolates, indicating that some sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper mentions the use of patient-derived viruses and clinical isolates, which suggests that some sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide information on whether the patients were in a clinical trial.

Rationale: The paper does not mention whether the patients were in a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper discusses the use of patient-derived viruses and clinical isolates, indicating that some sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper mentions the use of patient-derived viruses and clinical isolates, which suggests that some sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper discusses the use of various antiretroviral drugs, including NRTIs, PIs, and INSTIs.

Rationale: The paper mentions the use of various antiretroviral drugs, including NRTIs, PIs, and INSTIs.

Answer: NRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper discusses the use of various antiretroviral drugs, including lamivudine, emtricitabine, abacavir, tenofovir, zidovudine, darunavir, and raltegravir.

Rationale: The paper mentions the use of various antiretroviral drugs, including lamivudine, emtricitabine, abacavir, tenofovir, zidovudine, darunavir, and raltegravir.

Answer: Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Tenofovir (TDF), Zidovudine (AZT), Darunavir (DRV), Raltegravir (RAL)
""""""",92
37017009,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses HIV drug resistance patterns and prevalence among paediatric patients failing ART in South Africa, and it mentions that resistance genotyping was performed using next-generation sequencing technologies.

Rationale: The paper focuses on HIV drug resistance testing and the identification of resistance mutations in patient samples, which indicates that HIV sequences from patient samples were analyzed.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on genotypic resistance testing and the identification of drug resistance mutations in patient samples, but it does not mention any in vitro susceptibility assays or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention that the sequences were made publicly available or provide any GenBank accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 899 participants were included in the study analysis.

Rationale: The paper states that 899 participants were included in the study analysis, indicating that samples were obtained from these individuals for HIV sequencing.

Answer: 899
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in South Africa.

Rationale: The paper states that the study was conducted in South Africa, indicating that the sequenced samples were obtained from this country.

Answer: South Africa
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from March 2017 to March 2019.

Rationale: The paper states that the study was conducted from March 2017 to March 2019, indicating that the sequenced samples were obtained during this period.

Answer: 2017-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, indicating that direct sequencing was performed.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the protease gene and the first 250 amino acids of the reverse transcriptase gene were sequenced.

Rationale: The paper states that the protease gene and the first 250 amino acids of the reverse transcriptase gene were sequenced, indicating that these genes were targeted for sequencing.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that next-generation sequencing technologies were used for sequencing.

Rationale: The paper states that next-generation sequencing technologies were used for sequencing, indicating that this method was employed.

Answer: NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that whole blood was collected using standard phlebotomy methods into a 6 mL EDTA tube.

Rationale: The paper states that whole blood was collected, indicating that this type of sample was used for sequencing.

Answer: Whole blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included children with virological failure.

Rationale: The paper states that the study included children with virological failure, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes the study as a cross-sectional study, not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included children who had been receiving ART.

Rationale: The paper states that the study included children who had been receiving ART, indicating that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included children who had been receiving ART, including PI-based regimens, NNRTI-based regimens, and NRTI-based regimens.

Rationale: The paper states that the study included children who had been receiving ART, including PI-based regimens, NNRTI-based regimens, and NRTI-based regimens, indicating that these drug classes were received by individuals in the study before sample sequencing.

Answer: PI, NNRTI, NRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included children who had been receiving ART, including ritonavir-boosted lopinavir, efavirenz, nevirapine, abacavir, lamivudine, and tenofovir disoproxil fumarate.

Rationale: The paper states that the study included children who had been receiving ART, including ritonavir-boosted lopinavir, efavirenz, nevirapine, abacavir, lamivudine, and tenofovir disoproxil fumarate, indicating that these drugs were received by individuals in the study before sample sequencing.

Answer: Ritonavir-boosted lopinavir, Efavirenz, Nevirapine, Abacavir, Lamivudine, Tenofovir disoproxil fumarate
""""""",95
37029656,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV sequences from patient samples, including their corresponding GenBank accession numbers.

Rationale: The paper explicitly mentions the analysis of HIV sequences from patient samples, indicating that it reports HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Rationale: The paper focuses on the presence of drug resistance mutations rather than susceptibility and does not mention any in vitro drug susceptibility assays being performed.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates, nor does it mention whether any sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not specify the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not specify the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not Found
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not specify the years during which the sequenced samples were obtained.

Rationale: The paper does not provide information on the years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information regarding whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not specify which HIV genes were sequenced.

Rationale: The paper does not provide information on which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the sequencing method used.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not specify the type of samples that were sequenced.

Rationale: The paper does not provide information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide information on whether any sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information indicating that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention any sequences obtained from individuals who had previously received ARV drugs.

Rationale: The paper does not provide information on whether any sequences were obtained from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any specific drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not provide information on the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any specific drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide information on the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",72
37039023,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that ""Forty-six PLWH from Rio de Janeiro (RJ) and 40 from Rio Grande (RS) had proviral HIV NFLG PCR-amplified and ultradeep sequenced.""

Rationale: The paper explicitly states that HIV sequences were obtained from patient samples, specifically mentioning that proviral HIV near full-length genomes (NFLG) were PCR-amplified and ultradeep sequenced from peripheral blood cells.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility data or phenotypic data.

Rationale: The paper focuses on sequencing and analyzing HIV genomes from archived proviruses, and there is no discussion of drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that ""The raw sequencing reads were deposited to the Sequence Read Archive under the BioProject PRJNA419915.""

Rationale: The paper explicitly states that the raw sequencing reads were deposited to the Sequence Read Archive, indicating that the sequences were made publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that ""Forty-six PLWH from Rio de Janeiro (RJ) and 40 from Rio Grande (RS) had proviral HIV NFLG PCR-amplified and ultradeep sequenced.""

Rationale: The paper explicitly states that 86 individuals (46 from RJ and 40 from RS) had samples obtained for HIV sequencing.

Answer: 86
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that ""Forty-six PLWH from Rio de Janeiro (RJ) and 40 from Rio Grande (RS) had proviral HIV NFLG PCR-amplified and ultradeep sequenced.""

Rationale: The paper explicitly states that the samples were obtained from Brazil, specifically from the cities of Rio de Janeiro (RJ) and Rio Grande (RS).

Answer: Brazil
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that ""All samples from RJ were collected between February 2016 and November 2018, whereas all samples from RS were collected between August and December 2017.""

Rationale: The paper explicitly states that the samples were collected between 2016 and 2018.

Answer: 2016-2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper describes the use of PCR amplification and ultradeep sequencing, but does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that ""Protease, reverse transcriptase, integrase and envelope regions are known to harbour antiretroviral resistance mutations, and all 86 study samples had at least one of these regions analysed.""

Rationale: The paper explicitly states that the protease, reverse transcriptase, integrase, and envelope regions were analyzed for antiretroviral resistance mutations.

Answer: PR, RT, IN, Env
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that ""Libraries were quantified in Qubit 3 (Life Technologies, Carlsbad, CA, USA) and sequenced using the Illumina MiSeq platform with a paired-end 2 × 251 protocol.""

Rationale: The paper explicitly states that the Illumina MiSeq platform was used for sequencing.

Answer: Illumina sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that ""Six millilitres of whole peripheral blood was collected from all patients who agreed to participate in the study and signed the informed consent.""

Rationale: The paper explicitly states that whole peripheral blood samples were collected from patients.

Answer: Whole Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that ""All patients maintained their successful treatment despite the high prevalence of DRMs at low (62.5%) or high (37.5%) frequency.""

Rationale: The paper explicitly states that all patients maintained successful treatment, indicating that sequences were not obtained from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes the study as a cohort study, but does not mention any clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that ""Most patients (RJ, 76.1%; RS, 95.0%) reported being infected through sexual transmission. The most prevalent therapeutic regimen combination used was tenofovir disoproxil fumarate (TDF), lamivudine (3TC) and efavirenz (EFV) (TDF + 3TC + EFV), accounting for 55.8% ( *n* = 48) of patients included.""

Rationale: The paper explicitly states that the patients had previously received ARV drugs, specifically mentioning the use of TDF, 3TC, and EFV.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that ""The most prevalent therapeutic regimen combination used was tenofovir disoproxil fumarate (TDF), lamivudine (3TC) and efavirenz (EFV) (TDF + 3TC + EFV), accounting for 55.8% ( *n* = 48) of patients included.""

Rationale: The paper explicitly states that the patients received NRTIs (TDF, 3TC) and NNRTIs (EFV) before sample sequencing.

Answer: NRTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that ""The most prevalent therapeutic regimen combination used was tenofovir disoproxil fumarate (TDF), lamivudine (3TC) and efavirenz (EFV) (TDF + 3TC + EFV), accounting for 55.8% ( *n* = 48) of patients included.""

Rationale: The paper explicitly states that the patients received TDF, 3TC, and EFV before sample sequencing.

Answer: Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)
""""""",107
37042390,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the amplification and sequencing of the HIV-1 integrase gene from plasma samples collected at baseline and at the time of virological failure.

Rationale: The paper focuses on the sequencing of HIV-1 integrase gene from patient samples, indicating that HIV sequences were obtained from these samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing. It focuses on genotyping and identifying drug resistance mutations from patient samples.

Rationale: The paper does not report any in vitro drug susceptibility data, as it focuses on genotypic resistance testing and the results of those tests without mentioning specific in vitro assays.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates, indicating that the sequences were not made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not specify the exact number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not specify the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not specify the years during which the sequenced samples were obtained.

Rationale: The paper does not provide information on the years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide information on whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the HIV-1 integrase gene was sequenced.

Rationale: The paper focuses on the sequencing of the HIV-1 integrase gene, indicating that this gene was sequenced.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the sequencing method used.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper specifies that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper discusses the sequencing of HIV-1 integrase gene from individuals with virological failure.

Rationale: The paper focuses on the sequencing of HIV-1 integrase gene from individuals with virological failure, indicating that sequences were obtained from individuals with virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide information on whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper discusses the sequencing of HIV-1 integrase gene from individuals who had previously received ARV drugs.

Rationale: The paper focuses on the sequencing of HIV-1 integrase gene from individuals who had previously received ARV drugs, indicating that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the individuals received various antiretroviral drugs from different classes, including NRTIs, NNRTIs, PIs, and INSTIs.

Rationale: The paper lists various antiretroviral drugs from different classes that were received by the individuals before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions specific antiretroviral drugs that were received by the individuals before sample sequencing, including TDF, 3TC, EFV, MVC, RAL, FTC.

Rationale: The paper lists specific antiretroviral drugs that were received by the individuals before sample sequencing.

Answer: Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)
""""""",83
37052343,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the reporting of HIV sequences from patient samples. The focus is on the clinical outcomes of the treatment in patients with HIV-1, but there is no specific mention of sequencing HIV from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility testing. It focuses on clinical outcomes and sequencing data from patient samples rather than laboratory-based drug susceptibility assays.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. It mentions sequencing and analysis but does not include specific accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. It mentions sequencing and analysis but does not include specific accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not specify which clinical specimens were sequenced. It focuses on the clinical outcomes of the treatment in patients with HIV-1.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention any specific countries from which sequenced samples were obtained. It focuses on the clinical outcomes of the treatment in patients with HIV-1.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific years for when the samples were obtained. It mentions the duration of the study but does not specify the exact years.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention that samples were cloned prior to sequencing. It focuses on the clinical outcomes of the treatment in patients with HIV-1.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not mention which HIV genes were sequenced. It focuses on the clinical outcomes of the treatment in patients with HIV-1.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention any specific sequencing method used. It focuses on the clinical outcomes of the treatment in patients with HIV-1.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify which clinical specimens were sequenced. It focuses on the clinical outcomes of the treatment in patients with HIV-1.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen. It focuses on the clinical outcomes of the treatment in patients with HIV-1.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial. It focuses on the clinical outcomes of the treatment in patients with HIV-1.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide specific names of the drugs received by the individuals in the study. It only mentions that the participants were on prolonged ART.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide specific names of the drugs received by the individuals in the study. It only mentions that the participants were on prolonged ART.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide specific names of the drugs received by the individuals in the study. It only mentions that the participants were on prolonged ART.

Answer: Not reported
""""""",76
37071019,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not mention the use of patient samples for obtaining HIV sequences. Instead, it focuses on laboratory-generated recombinant enzymes and mutations in integrase proteins from different HIV subtypes.

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-generated recombinant enzymes and mutations in integrase proteins from different HIV subtypes.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper includes data on HIV-1 susceptibility to DTG, RAL, and EVG in tissue culture, as well as the determination of the 50% inhibitory concentration (IC50) for these drugs.

Rationale: The paper includes data on HIV-1 susceptibility to DTG, RAL, and EVG in tissue culture, as well as the determination of the 50% inhibitory concentration (IC50) for these drugs.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: The paper does not mention the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the integrase (IN) gene of HIV-1.

Rationale: The paper focuses on the integrase (IN) gene of HIV-1.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not specify the type of clinical specimens that were sequenced.

Rationale: The paper does not specify the type of clinical specimens that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention that the patients had previously received ARV drugs.

Rationale: The paper does not mention that the patients had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not mention the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not mention the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",80
37085698,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that near full-length HIV-1 IN region, (263 codons) of the 49 study participants were successfully sequenced and analyzed.

Rationale: The paper describes the analysis of HIV-1 sequences from patient samples, indicating that the study involved sequencing HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Rationale: The absence of any mention of in vitro drug susceptibility testing or data indicates that the paper does not report such information.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states that all nucleotide sequences from this study have been deposited in the Genbank (ncbi) repository with accession numbers from MW560010 to MW560058.

Rationale: The paper explicitly states that the sequences have been deposited in a public database, indicating that they are publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper states that all nucleotide sequences from this study have been deposited in the Genbank (ncbi) repository with accession numbers from MW560010 to MW560058.

Rationale: The paper provides the specific GenBank accession numbers for the sequenced HIV isolates.

Answer: MW560010 to MW560058
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that near full-length HIV-1 IN region, (263 codons) of the 49 study participants were successfully sequenced and analyzed.

Rationale: The paper states that 49 study participants had their HIV-1 IN region sequenced.

Answer: 49
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not explicitly mention the country of origin for the sequenced samples, but it is implied to be Ethiopia based on the context.

Rationale: The paper does not provide explicit information about the country of origin for the sequenced samples.

Answer: Ethiopia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study participants were enrolled from June to December 2018.

Rationale: The paper provides the specific time frame during which the samples were collected.

Answer: 2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The absence of any mention of cloning in the methods or results sections indicates that samples were not cloned before sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the IN region covering the first 263 codons of blood samples was amplified and sequenced.

Rationale: The paper specifically mentions the sequencing of the IN region.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger DNA sequencing using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) was used.

Rationale: The paper describes the use of Sanger sequencing for the HIV-1 IN region.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper specifies that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention that the individuals had virological failure on a treatment regimen.

Rationale: The paper does not provide information about the treatment status or virological failure of the individuals.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide information about the patients being part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study participants were drug-naive.

Rationale: The paper explicitly states that the study participants were drug-naive, indicating that they had not previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drug classes received by the individuals in the study.

Rationale: The paper does not provide information about the treatment history or drug classes received by the individuals.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drugs received by the individuals in the study.

Rationale: The paper does not provide information about the treatment history or specific drugs received by the individuals.

Answer: Not reported
""""""",81
37104815,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 total DNA, ultra-sensitive plasma viral load (USpVL) and semen VL were measured in the first 121 participants.

Rationale: The paper involves the analysis of HIV-1 sequences from patient samples, including total DNA, USpVL, and semen VL measurements.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing.

Rationale: The paper focuses on clinical outcomes and genotypic resistance testing rather than in vitro susceptibility assays.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any publicly available sequences or accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any publicly available sequences or accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that HIV-1 total DNA, ultra-sensitive plasma viral load (USpVL) and semen VL were measured in the first 121 participants.

Rationale: The paper states that samples were obtained from 121 participants.

Answer: 121
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries of origin for the sequenced samples.

Rationale: The paper does not provide information on the countries where the samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that participants were screened from 7 September 2017 to 22 January 2018.

Rationale: The paper provides the enrollment period for the study, indicating the years from which the sequenced samples were obtained.

Answer: 2017-2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: There is no reference to cloning in the methods or results sections of the paper.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that Sanger and ultra-deep sequencing (UDS) were performed for the reverse transcriptase (RT), protease (PR) and integrase (INT) regions.

Rationale: The paper specifies that the sequencing involved the reverse transcriptase, protease, and integrase genes.

Answer: RT, PR, INT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger and ultra-deep sequencing (UDS) were performed using Illumina technology.

Rationale: The paper describes the use of Sanger sequencing and ultra-deep sequencing (UDS) using Illumina technology.

Answer: Sanger sequencing, Illumina sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that HIV-1 total DNA, ultra-sensitive plasma viral load (USpVL) and semen VL were measured in the first 121 participants.

Rationale: The paper specifies that plasma and semen samples were used for sequencing.

Answer: Plasma, Semen
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that resistance mutations related to current ART were detected more frequently by UDS.

Rationale: The paper describes the emergence of resistance mutations in individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was an open-label, randomized, multicentre, non-inferiority Phase III trial.

Rationale: The paper describes a clinical trial, confirming that the patients were part of it.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that participants had a long duration of ART (median 6.6 years) and a long duration of suppressed HIV viraemia (median 5.3 years).

Rationale: The paper indicates that the participants had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the cART regimens were based on INSTIs for 47.1%, NNRTIs for 47.1% and PIs for 5.8% of participants.

Rationale: The paper lists the specific drug classes that participants had received before sample sequencing.

Answer: INSTI, NNRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the baseline NRTI backbone consisted of tenofovir/emtricitabine or tenofovir alafenamide/emtricitabine for 76.0% of participants and abacavir/lamivudine for 24.0%.

Rationale: The paper lists specific antiretroviral drugs that were received by the individuals before sample sequencing.

Answer: Tenofovir, Emtricitabine, Tenofovir alafenamide, Abacavir, Lamivudine
""""""",89
37112971,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper analyzed sequences and linked demographic, clinical, and epidemiological data uploaded to the RuHIV database from 4481 treatment-naïve HIV-infected patients.

Rationale: The paper explicitly states that it analyzed sequences from treatment-naïve HIV-infected patients, indicating that the study involved sequencing HIV from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the analysis of HIV-1 genetic variants, drug resistance mutations, and surveillance drug resistance mutations, but it does not mention conducting in vitro drug susceptibility tests.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention making the sequences publicly available or providing GenBank accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper analyzed sequences and linked demographic, clinical, and epidemiological data uploaded to the RuHIV database from 4481 treatment-naïve HIV-infected patients.

Rationale: The paper explicitly states that it analyzed sequences from 4481 treatment-naïve HIV-infected patients.

Answer: 4481
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study patients were from Russia.

Rationale: The paper explicitly states that the study patients were from Russia.

Answer: Russia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the years of diagnosis based on first HIV-positive immune blotting ranged between 1997 and 2022, and blood sampling years ranged between 2006 and 2022.

Rationale: The paper explicitly states the years of diagnosis and blood sampling.

Answer: 2006-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the sequences covered the HIV-1 protease (PR), and part of the reverse transcriptase (RT) was available for all patients; additionally, sequences covering the HIV-1 integrase (INT) were available for 844 of them.

Rationale: The paper explicitly states that the sequences covered the PR, RT, and INT genes.

Answer: PR, RT, INT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that commercial genotyping kits and in-house methods were used for RNA extraction from the blood plasma samples and Sanger-based or NGS-based sequencing of the HIV pol gene regions.

Rationale: The paper explicitly states that Sanger-based or NGS-based sequencing was used.

Answer: Sanger sequencing or NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that RNA was extracted from blood plasma samples for sequencing.

Rationale: The paper explicitly states that RNA was extracted from blood plasma samples.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included treatment-naïve patients, meaning that the participants had not previously received antiretroviral drugs.

Rationale: The paper explicitly states that the study included treatment-naïve patients.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper describes the study as a cross-sectional, retrospective, surveillance study, not a clinical trial.

Rationale: The paper explicitly states that the study was not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included treatment-naïve patients, meaning that the participants had not previously received antiretroviral drugs.

Rationale: The paper explicitly states that the study included treatment-naïve patients.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information on the drug classes received by individuals before sample sequencing.

Rationale: The paper does not mention the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information on the drugs received by individuals before sample sequencing.

Rationale: The paper does not mention the drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",85
37147875,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper describes a case of a patient with HIV-1 primary infection and reports the results of Sanger-based sequencing (SBS) and next-generation sequencing (NGS) of the patient's HIV-1 reverse transcriptase (RT), protease, and integrase genes.

Rationale: The paper explicitly states that the patient's HIV-1 sequences were obtained through SBS and NGS, indicating that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not provide any in vitro drug susceptibility data.

Rationale: The paper focuses on the clinical case and the emergence of resistance mutations in the context of treatment, but does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention whether the sequences obtained were made publicly available.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates, which would indicate that the sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper describes a single case of a patient with HIV-1 primary infection.

Rationale: The focus of the paper is on one individual, indicating that only one person had samples obtained for sequencing.

Answer: 1
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention any specific countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the geographical origin of the samples.

Answer: Not Found
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific years for when the sequenced samples were obtained.

Rationale: The paper does not mention any specific years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the patient's HIV-1 reverse transcriptase (RT), protease, and integrase genes were sequenced.

Rationale: The paper explicitly states that the patient's HIV-1 RT, protease, and integrase genes were sequenced.

Answer: RT, PR, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger-based sequencing (SBS) and next-generation sequencing (NGS) were used.

Rationale: The paper explicitly states that SBS and NGS were used to sequence the patient's HIV-1 genes.

Answer: Sanger sequencing, NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not specify the type of samples sequenced.

Rationale: The paper does not mention the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper describes a case of a patient with HIV-1 primary infection and reports the results of Sanger-based sequencing (SBS) and next-generation sequencing (NGS) of the patient's HIV-1 reverse transcriptase (RT), protease, and integrase genes.

Rationale: The paper does not mention virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patient was part of a clinical trial.

Rationale: The paper describes a case report of a single patient and does not mention any clinical trial involvement.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention that the patient had previously received ARV drugs.

Rationale: The paper describes a case of a patient with HIV-1 primary infection and does not mention any previous ARV treatment.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any specific drug classes received by the patient before sample sequencing.

Rationale: The paper does not provide any information about the patient's treatment history before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any specific drugs received by the patient before sample sequencing.

Rationale: The paper does not provide any information about the patient's treatment history before sample sequencing.

Answer: Not reported
""""""",84
37272233,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-DNA sequences obtained from patient samples.

Rationale: The paper mentions that HIV-DNA sequences were obtained from the peripheral blood of six participants over a period of 3 to ≥15 years of effective therapy.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the clinical outcomes and resistance mutations in patients but does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that six HIV-1 subtype-B positive individuals on prolonged ART were included in the study.

Rationale: The paper mentions that six HIV-1 subtype-B positive individuals on prolonged ART were included in the study.

Answer: 6
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was approved in Western Sydney Health Department for the Westmead Institute for Medical Research (Australia), and University of California San Francisco (United States), Vaccine Gene Therapy Institute-Florida (United States)

Rationale: The paper mentions that the study was approved in Western Sydney Health Department for the Westmead Institute for Medical Research (Australia), and University of California San Francisco (United States), Vaccine Gene Therapy Institute-Florida (United States)

Answer: United States, Australia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the participants had viral loads of <40-75 copies (HIV-RNA) per ml during  the study period, indicating effective viral suppression and not virological failure.

Rationale: The paper does not provide specific years for when the samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions sequencing of the p6-protease-reverse transcriptase (p6PrRT) region and the integrase region to identify drug resistance mutations.

Rationale: The paper mentions sequencing of the p6-protease-reverse transcriptase (p6PrRT) region and the integrase region to identify drug resistance mutations.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the sequencing method used for the genotypic resistance tests.

Rationale: The paper does not specify the sequencing method used for the genotypic resistance tests.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that CD4+ T-cell subsets were sorted from frozen aliquots of peripheral blood mononuclear cells (PBMCs), and HIV-DNA was sequenced.

Rationale: The paper specifies that CD4+ T-cell subsets were sorted from frozen aliquots of peripheral blood mononuclear cells (PBMCs), and HIV-DNA was sequenced.

Answer: PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the participants had viral loads of <40-75 copies (HIV-RNA) per ml during  the study period, indicating effective viral suppression and not virological failure.

Rationale: The paper mentions that the participants had viral loads of <40-75 copies (HIV-RNA) per ml during  the study period, indicating effective viral suppression and not virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information about whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included individuals on prolonged ART, indicating that the participants had previously received antiretroviral drugs.

Rationale: The paper mentions that the study included individuals on prolonged ART, indicating that the participants had previously received antiretroviral drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that patients switched from combinations that included NRTIs, NNRTIs, PIs, and INSTIs.

Rationale: The paper mentions that patients switched from combinations that included NRTIs, NNRTIs, PIs, and INSTIs.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific names of the drugs received by the individuals in  the study.

Rationale: The paper does not provide specific names of the drugs received by the individuals in  the study.

Answer: Not reported
""""""",93
37279764,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that a total of 12,320 participants with demographic data and partial pol sequences were included in this study.

Rationale: The paper specifically focuses on the analysis of HIV-1 sequences from patient samples, indicating that it reports HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the analysis of HIV-1 sequences and the identification of drug resistance mutations, but it does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that the HIV-1 sequences generated from this study are available in the NCBI database with the GenBank accession numbers MW947591–MW957968, OP058117–OP058658.

Rationale: The paper states that the sequences are publicly available in the NCBI database, confirming that they can be accessed.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper mentions that the HIV-1 sequences generated from this study are available in the NCBI database with the GenBank accession numbers MW947591–MW957968, OP058117–OP058658.

Rationale: The paper provides the GenBank accession numbers for the sequences analyzed in the study.

Answer: MW947591–MW957968, OP058117–OP058658
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that a total of 12,320 participants with demographic data and partial pol sequences were included in this study.

Rationale: The paper states that 12,320 participants had samples obtained for HIV sequencing.

Answer: 12,320
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Shenzhen, China.

Rationale: The paper specifies that the study was conducted in Shenzhen, China, indicating that the samples were obtained from China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study included samples from newly diagnosed patients enrolled at Shenzhen from January 2011 to December 2019.

Rationale: The paper specifies that the samples were obtained from 2011 to 2019.

Answer: 2011-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, indicating that this information is not provided.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the HIV-1 partial pol gene region (HXB2: 2252–3255) was sequenced.

Rationale: The paper specifies that the partial pol gene region was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that nucleic acid extraction, PCR amplification work-up and sequencing were performed essentially as described previously.

Rationale: The paper does not explicitly mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that blood samples were collected from newly diagnosed patients enrolled at Shenzhen.

Rationale: The paper specifies that blood samples were used for sequencing.

Answer: Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on the analysis of HIV-1 sequences from newly diagnosed patients, indicating that the sequences were not obtained from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes the study as a retrospective analysis of HIV-1 sequences from newly diagnosed patients, indicating that it is not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the patients had not received antiretroviral treatment before sample collection.

Rationale: The paper specifies that the patients were treatment-naive, indicating that they had not previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any drug classes received by individuals in the study before sample sequencing.

Rationale: The paper specifies that the patients were treatment-naive, indicating that they had not previously received ARV drugs.

Answer: nan
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any drugs received by individuals in the study before sample sequencing.

Rationale: The paper specifies that the patients were treatment-naive, indicating that they had not previously received ARV drugs.

Answer: nan
""""""",84
37327289,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 RNA was extracted from plasma of 64 HIV-1 infected, drug-naïve subjects with CD4+ T-cell counts < 200/μl.

Rationale: The paper specifically mentions that the subjects were drug-naïve, meaning they had not received antiretroviral treatment before the samples were obtained.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility data.

Rationale: The paper focuses on sequencing and identifying drug resistance mutations in patient samples rather than conducting in vitro drug susceptibility tests.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that the *pol* sequences have been archived in the DDBJ Nucleotide Database [LC723952-LC724015].

Rationale: The paper explicitly states that the sequences were submitted to the DDBJ Nucleotide Database.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper mentions that the *pol* sequences have been archived in the DDBJ Nucleotide Database [LC723952-LC724015].

Rationale: The paper explicitly states that the sequences were submitted to the DDBJ Nucleotide Database.

Answer: LC723952-LC724015
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 64 HIV-seropositive plasma samples were collected from FSWs between November 2020 and April 2021.

Rationale: The paper specifically mentions that 64 plasma samples were collected from FSWs.

Answer: 64
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the participants were recruited from 7 sex worker outreach program (SWOP) clinics in Nairobi County, Kenya.

Rationale: The paper specifically mentions that the samples were obtained from Kenya.

Answer: Kenya
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the participants were recruited between November 2020 and April 2021.

Rationale: The paper specifically mentions the years during which the samples were obtained.

Answer: 2020-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper describes the use of Sanger sequencing and does not mention any cloning steps.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the *pol* gene was amplified and genotyped using Sanger sequencing.

Rationale: The paper specifically mentions that the *pol* gene was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing was used for the *pol* gene sequencing.

Rationale: The paper specifically mentions the use of Sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that HIV-1 RNA was extracted from plasma of 64 HIV-1 infected, drug-naïve subjects with CD4+ T-cell counts < 200/μl.

Rationale: The paper specifically mentions that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the subjects were treatment-naïve, meaning they had not received antiretroviral treatment before the samples were obtained.

Rationale: The paper specifically mentions that the subjects were treatment-naïve.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes a cross-sectional study and does not mention any clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the subjects were treatment-naïve, meaning they had not received antiretroviral treatment before the samples were obtained.

Rationale: The paper specifically mentions that the subjects were treatment-naïve.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information on the drug classes received by individuals before sample sequencing.

Rationale: The paper does not mention any previous treatment history.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information on the drugs received by individuals before sample sequencing.

Rationale: The paper does not mention any previous treatment history.

Answer: Not reported
""""""",79
37340869,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""The FLAIR study demonstrated noninferiority of monthly long-acting cabotegravir + rilpivirine versus daily oral dolutegravir/abacavir/lamivudine for maintaining virologic suppression.""

Rationale: The paper discusses the FLAIR study, which involved sequencing HIV-1 protease, reverse transcriptase, and integrase genes from patient samples to evaluate baseline and postbaseline resistance.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""The FLAIR study demonstrated noninferiority of monthly long-acting cabotegravir + rilpivirine versus daily oral dolutegravir/abacavir/lamivudine for maintaining virologic suppression.""

Rationale: The paper does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Across 3 studies, 1651 unique participants were included, 23/1651 (1.4%) of whom had CVF.""

Rationale: The paper mentions that 1651 unique participants were included in the study.

Answer: 1651
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""Overall, 11 participants with CVF were from Russia, all of whom had HIV-1 subtype A6/A1 (Supplementary Table 7 A).""

Rationale: The paper mentions that 11 participants with CVF were from Russia.

Answer: Russia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not provide specific years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""The presence of RPV RAMs, HIV-1 subtype A6/A1, and body mass index ≥30 kg/m^2 were associated with an increased risk of CVF (P <.05 adjusted incidence rate ratio), with participants with ≥2 of these baseline factors having a higher risk of CVF.""

Rationale: The paper mentions the sequencing of HIV-1 protease, reverse transcriptase, and integrase genes.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""No evidence""

Rationale: The paper does not specify the exact sequencing method used for the sequences.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Plasma HIV-1 RNA levels were evaluated at baseline and all study visits from week 12 onward.""

Rationale: The paper mentions that plasma HIV-1 RNA levels were evaluated, indicating plasma sample were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Across 3 studies, 1651 unique participants were included, 23/1651 (1.4%) of whom had CVF.""

Rationale: The paper discusses sequences obtained from individuals who experienced confirmed virologic failure (CVF) while on long-acting cabotegravir and rilpivirine therapy.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""FLAIR, ATLAS, and ATLAS-2M are randomized, multicenter, parallel-group, open-label, phase 3/3b studies.""

Rationale: The paper mentions that the study was a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""The presence of RPV RAMs, HIV-1 subtype A6/A1, and body mass index ≥30 kg/m^2 were associated with an increased risk of CVF (P <.05 adjusted incidence rate ratio), with participants with ≥2 of these baseline factors having a higher risk of CVF.""

Rationale: The paper mentions the presence of RPV RAMs, indicating that the individuals had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""The presence of RPV RAMs, HIV-1 subtype A6/A1, and body mass index ≥30 kg/m^2 were associated with an increased risk of CVF (P <.05 adjusted incidence rate ratio), with participants with ≥2 of these baseline factors having a higher risk of CVF.""

Rationale: The paper mentions the presence of RPV RAMs, indicating that the individuals had previously received NNRTI drugs.

Answer: NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""The FLAIR study demonstrated noninferiority of monthly long-acting cabotegravir + rilpivirine versus daily oral dolutegravir/abacavir/lamivudine for maintaining virologic suppression.""

Rationale: The paper mentions the study is about participants receive a regimen that included dolutegravir, abacavir, and lamivudine, comparing with receiving long-acting cabotegravir and rilpivirine.

Answer: Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC), Cabotegravir (CAB), Rilpivirine (RPV)
""""""",96
37358226,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide information on the HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not provide information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not provide information on whether sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not provide information on whether the patients were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide information on whether the individuals had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",58
37376649,"Here are the answers to the questions in the format you requested:


### Question 1: Does the paper report HIV sequences from patient samples?

Evidence: ""Retrospective baseline proviral DNA genotypes were performed for 734 participants (post-hoc analysis) to assess the impact of archived, pre-existing drug resistance on 144-week virologic outcomes by last on-treatment viral load (VL) and Snapshot.""

Rationale: The paper mentions that retrospective baseline proviral DNA genotypes were performed for 734 participants, indicating that HIV sequences were obtained from patient samples.

Answer: Yes


### Question 2: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility testing or data.

Answer: No


### Question 3: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No


### Question 4: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported


### Question 5: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Retrospective baseline proviral DNA genotypes were performed for 734 participants (post-hoc analysis) to assess the impact of archived, pre-existing drug resistance on 144-week virologic outcomes by last on-treatment viral load (VL) and Snapshot.""

Rationale: The paper mentions that retrospective baseline proviral DNA genotypes were performed for 734 participants.

Answer: 734


### Question 6: From which countries were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not mention the specific countries from which the sequenced samples were obtained.

Answer: Not reported


### Question 7: From what years were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported


### Question 8: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: Not reported


### Question 9: Which HIV genes were reported to have been sequenced?

Evidence: ""HIV-1 proviral DNA genotyping was conducted retrospectively with the GenoSure Archive assay (Monogram Biosciences, South San Francisco, CA, USA), which uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region;""

Rationale: The paper mentions that the GenoSure Archive assay uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region, which includes the protease, reverse transcriptase, and integrase genes.

Answer: PR, RT, IN


### Question 10: What method was used for sequencing?

Evidence: ""HIV-1 proviral DNA genotyping was conducted retrospectively with the GenoSure Archive assay (Monogram Biosciences, South San Francisco, CA, USA), which uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region;""

Rationale: The paper mentions that the GenoSure Archive assay uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region.

Answer: NGS


### Question 11: What type of samples were sequenced?

Evidence: ""Participants' baseline whole blood samples were used for the GenoSure Archive assay.""

Rationale: The paper mentions that participants' baseline whole blood samples were used for the GenoSure Archive assay.

Answer: Whole blood


### Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""No participants in the DTG/3TC group met protocol-defined CVW criteria through week 144, while three participants in the TBR group (all without any archived major RAMs) met CVW criteria with no resistance observed at virologic failure time""

Rationale: The paper mentions that three participants in the TBR group met protocol-defined CVW criteria, indicating virological failure.

Answer: Yes


### Question 13: Were the patients in the study in a clinical trial?

Evidence: ""The TANGO study (ClinicalTrials.gov, NCT03446573 ) demonstrated that switching to dolutegravir/lamivudine (DTG/3TC) was non-inferior to continuing tenofovir alafenamide-based regimens (TBR) through week 144.""

Rationale: The paper mentions that the TANGO study is a clinical trial.

Answer: Yes


### Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Among 120 subjects, 81% were on antiretroviral therapy and had been treated for a median time of 7 years.""

Rationale: The paper mentions that 81% of the subjects were on antiretroviral therapy and had been treated for a median time of 7 years.

Answer: Yes


### Question 15: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""The drugs most often used in the OBR were tenofovir (79%, either as TAF [53%] or as tenofovir disoproxil fumarate [26%]), FTC (68%), DRV (61%), DTG (50%), doravirine (26%), and IBA (24%).""

Rationale: The paper mentions that the drugs most often used in the optimized background regimen (OBR) for the study participants included NRTIs, NNRTIs, PIs, and INSTIs.

Answer: NRTI, NNRTI, PI, INSTI


### Question 16: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""The drugs most often used in the OBR were tenofovir (79%, either as TAF [53%] or as tenofovir disoproxil fumarate [26%]), FTC (68%), DRV (61%), DTG (50%), doravirine (26%), and IBA (24%).""

Rationale: The paper mentions the specific drugs that were most often used in the optimized background regimen (OBR) for the study participants.

Answer: Tenofovir (TFV), Emtricitabine (FTC), Darunavir (DRV), Dolutegravir (DTG), Doravirine (DOR), Ibalizumab (IBA)",103
37381002,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper describes the genetic characterization of HIV-1 viruses among cases with antiretroviral therapy failure in Suzhou City, China, and mentions that viral RNA was extracted from 200 µl plasma sample.

Rationale: The paper reports HIV sequences from patient samples, as it describes the extraction of viral RNA from plasma samples and the subsequent analysis of the pol gene.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Rationale: The paper focuses on the analysis of drug resistance mutations and their prevalence in patient samples, but it does not mention conducting in vitro drug susceptibility tests.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information regarding the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information regarding the GenBank accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that a total of 398 viral pol gene sequences were successfully sequenced from patients with failed antiviral treatment.

Rationale: The paper reports that 398 individuals had samples obtained for HIV sequencing.

Answer: 398
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Suzhou City, China.

Rationale: The paper reports that the sequenced samples were obtained from China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from 2017 to 2020.

Rationale: The paper reports that the sequenced samples were obtained from 2017 to 2020.

Answer: 2017-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information regarding the cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the partial pol gene fragment of HIV-1 virus was amplified, including the full length of the protease (PR) gene and the first 300 amino acids of the reverse transcriptase (RT) gene.

Rationale: The paper reports that the PR and RT genes were sequenced.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing method was used.

Rationale: The paper reports that Sanger sequencing was used for sequencing the pol gene.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that viral RNA was extracted from 200 µl plasma sample.

Rationale: The paper reports that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study aimed to characterize the distribution of HIV-1 genotypes and the prevalence of drug resistance mutations in people with antiretroviral treatment (ART) failure.

Rationale: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information regarding the patients being part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that among the 398 patients with failed antiviral treatment, 257 strains were resistant to at least one drug of NRTIs, NNRTIs, or PIs.

Rationale: The paper reports that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the regimen consisted of TDF/AZT, 3TC and EFV/NVP, which includes NRTIs and NNRTIs.

Rationale: The paper reports that NRTIs and NNRTIs were received by individuals in the study before sample sequencing.

Answer: NRTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the regimen consisted of TDF/AZT, 3TC and EFV/NVP.

Rationale: The paper reports that TDF, AZT, 3TC, EFV, and NVP were received by individuals in the study before sample sequencing.

Answer: TDF, AZT, 3TC, EFV, NVP
""""""",83
37439411,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 RNA protease/reverse transcriptase sequences, demographic and clinical data of adult PLWH from the Antiviral Response Cohort Analysis (ARCA) database.

Rationale: The paper explicitly states that it retrieved HIV-1 RNA protease/reverse transcriptase sequences from the ARCA database, which contains data from PLWH.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility data or phenotypic data.

Rationale: The paper focuses on the analysis of resistance mutations and virological data without mentioning specific accession numbers or in vitro drug susceptibility assays.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention whether any sequences were made publicly available, as it does not report on any sequencing data.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that it included 5982 naïves and 28 505 genotypes from 9387 treatment-experienced PLWH.

Rationale: The paper explicitly states the number of individuals included in the study.

Answer: 5982 naïves and 9387 treatment-experienced PLWH
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Italy.

Rationale: The paper explicitly states that the study was conducted in Italy.

Answer: Italy
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study analyzed data from 2000 to 2020.

Rationale: The paper explicitly states the time frame during which the data was analyzed.

Answer: 2000-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV-1 RNA protease/reverse transcriptase sequences were retrieved.

Rationale: The paper explicitly states that protease/reverse transcriptase sequences were analyzed.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the sequencing method used.

Rationale: The paper does not mention the specific sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that HIV-1 RNA protease/reverse transcriptase sequences were retrieved from the ARCA database.

Rationale: The paper explicitly states that RNA sequences were analyzed.

Answer: RNA
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that genotyping on RNA was performed exclusively in cases of virological failure with detectable viraemia.

Rationale: The paper explicitly states that genotyping was performed in cases of virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that previous exposure to any NNRTI was a predictor for resistance to the class.

Rationale: The paper explicitly states that previous exposure to NNRTIs was a predictor for resistance.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that previous exposure to any NNRTI was a predictor for resistance to the class.

Rationale: The paper explicitly states that previous exposure to NNRTIs was a predictor for resistance.

Answer: NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that previous exposure to any NNRTI was a predictor for resistance to the class.

Rationale: The paper explicitly states that previous exposure to NNRTIs was a predictor for resistance.

Answer: NNRTI
""""""",77
37495103,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 RNA was isolated from 250 µL of plasma using DeltaMag HBV/HCV/HIV (Vector-Best, Russia) according to the kit's manual. Reverse transcription and PCR were performed using RealBest Master Mix RT (Vector-Best, Russia) and BioMaster HS-Taq PCR-Color (BioLabMix, Russia), respectively, to amplify the HIV-1 PR-RT fragment (1302 bp).

Rationale: The paper describes the process of isolating HIV-1 RNA from patient plasma samples and amplifying the HIV-1 PR-RT fragment, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the analysis of HIV-1 drug resistance mutations and the genetic barrier to resistance in patient samples, but it does not mention conducting in vitro drug susceptibility tests.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention making the sequences publicly available through GenBank or any other database.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The study cohort included 271 patients who were on first-line ART and visited Novosibirsk Regional AIDS/HIV Clinical Hospital between March 2018 and August 2022.

Rationale: The paper states that 271 patients were included in the study, indicating the number of individuals from whom samples were obtained.

Answer: 271
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted in the Novosibirsk region, Russia.

Rationale: The paper mentions that the study was conducted in the Novosibirsk region, Russia, indicating the country of origin for the sequenced samples.

Answer: Russia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The study was conducted between March 2018 and August 2022.

Rationale: The paper mentions the years during which the study was conducted, indicating the years from which the sequenced samples were obtained.

Answer: 2018-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper describes the process of isolating HIV-1 RNA from patient plasma samples and amplifying the HIV-1 PR-RT fragment, but it does not mention cloning.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the HIV-1 PR-RT fragment (1302 bp) was amplified.

Rationale: The paper specifies that the HIV-1 PR-RT fragment was amplified, indicating that the protease and reverse transcriptase genes were sequenced.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that DNA sequencing was performed using an ABI PRISM 3130xl DNA Analyser (Applied Biosystems, USA).

Rationale: The paper describes the sequencing method used, indicating that Sanger sequencing was employed.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that HIV-1 RNA was isolated from 250 µL of plasma using DeltaMag HBV/HCV/HIV (Vector-Best, Russia) according to the kit's manual.

Rationale: The paper specifies that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that all patients had undetectable viral load (VL) levels for 3--6 months while taking ART with further virological failure.

Rationale: The paper describes cases of individuals who experienced virological failure on their treatment regimens, and sequences were obtained from these individuals.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes a study conducted in a clinical setting, but it does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that all patients received first-line ART prior to virological failure.

Rationale: The paper indicates that the patients had previously received ARV drugs, as they were on first-line ART prior to virological failure.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patients received first-line ART regimens, including TDF+3TC+EFV, ABC+3TC+EFV, TDF+3TC+DTG, and TDF+3TC+LPV/r.

Rationale: The paper lists the specific drug classes that were part of the treatment regimens, including NRTIs (TDF, 3TC, ABC), NNRTIs (EFV), INSTIs (DTG), and PIs (LPV/r).

Answer: NRTI, NNRTI, INSTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patients received first-line ART regimens, including TDF+3TC+EFV, ABC+3TC+EFV, TDF+3TC+DTG, and TDF+3TC+LPV/r.

Rationale: The paper lists the specific drugs that were part of the treatment regimens, including Tenofovir (TDF), Lamivudine (3TC), Abacavir (ABC), Efavirenz (EFV), Dolutegravir (DTG), and Lopinavir (LPV).

Answer: Tenofovir (TDF), Lamivudine (3TC), Abacavir (ABC), Efavirenz (EFV), Dolutegravir (DTG), Lopinavir (LPV)
""""""",104
37498738,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-1 proviral sequences from patient samples, specifically from peripheral blood mononuclear cells (PBMCs) of individuals with HIV-1 infection.

Rationale: The paper mentions the use of next-generation sequencing techniques to characterize the HIV-1 reservoir from PBMCs of individuals with HIV-1 infection, indicating that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the analysis and comparison of sequences but does not mention any experiments or results related to in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention depositing the sequences in GenBank or any other database.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention depositing the sequences in GenBank or any other database.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not specify the number of individuals from whom samples were obtained for HIV sequencing.

Rationale: The paper focuses on the methodology and results of the sequencing study but does not provide information on the number of individuals.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide specific information about the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention the geographical location of the samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific years during which the sequenced samples were obtained.

Rationale: The paper does not mention the exact years of sample collection.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper focuses on the methodology and results of the sequencing study but does not mention cloning.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions the sequencing of near full-length HIV-1 genomes.

Rationale: The paper discusses the sequencing of near full-length HIV-1 genomes, which implies that nearly the entire genome was sequenced.

Answer: Near full length genome
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions the use of next-generation sequencing (NGS) for the analysis of HIV-1 proviral sequences.

Rationale: The paper discusses the use of NGS for the analysis of HIV-1 proviral sequences.

Answer: Next-generation sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that peripheral blood mononuclear cells (PBMCs) were used for the characterization of the HIV-1 reservoir and subsequent sequencing.

Rationale: The paper specifies that PBMCs were used for the characterization of the HIV-1 reservoir and subsequent sequencing.

Answer: PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on the analysis of sequences from individuals with HIV-1 infection but does not mention virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide information on the study design or whether it was a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not provide information on whether the individuals had previously received ARV drugs.

Rationale: The paper focuses on the analysis of sequences from individuals with HIV-1 infection but does not mention previous ARV treatment.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information on the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not mention the specific drug classes or treatment regimens received by the individuals.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information on the drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not mention the specific drugs or treatment regimens received by the individuals.

Answer: Not reported
""""""",81
37515095,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper analyzed 968 partial HIV-1 *pol* sequences that were collected between 2017 and 2020 from PLHIV in Kazakhstan.

Rationale: The paper explicitly mentions that HIV-1 sequences were obtained from patient samples, specifically from people living with HIV (PLHIV) in Kazakhstan.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to drug resistance assays in a laboratory setting.

Rationale: The paper focuses on the analysis of HIV-1 sequences from patient samples and the prevalence of drug resistance mutations, but it does not mention any in vitro experiments measuring the effectiveness of drugs against HIV-1.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention that the sequences were made publicly available or provide any GenBank accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention that the sequences were made publicly available or provide any GenBank accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper analyzed 968 partial HIV-1 *pol* sequences that were collected between 2017 and 2020 from PLHIV in Kazakhstan.

Rationale: The paper explicitly mentions that 968 HIV-1 sequences were obtained from patient samples.

Answer: 968
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper analyzed 968 partial HIV-1 *pol* sequences that were collected between 2017 and 2020 from PLHIV in Kazakhstan.

Rationale: The paper explicitly mentions that the samples were obtained from Kazakhstan.

Answer: Kazakhstan
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper analyzed 968 partial HIV-1 *pol* sequences that were collected between 2017 and 2020 from PLHIV in Kazakhstan.

Rationale: The paper explicitly mentions that the samples were collected between 2017 and 2020.

Answer: 2017-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any process of cloning samples prior to sequencing.

Rationale: The paper does not provide any information regarding the cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper analyzed 968 partial HIV-1 *pol* sequences that were collected between 2017 and 2020 from PLHIV in Kazakhstan.

Rationale: The paper explicitly mentions that the sequence data consisted of partial HIV-1 *pol* gene sequences.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the sequencing method used.

Rationale: The paper does not provide any information regarding the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper analyzed 968 partial HIV-1 *pol* sequences that were collected between 2017 and 2020 from PLHIV in Kazakhstan.

Rationale: The paper explicitly mentions that the sequences were obtained from blood samples.

Answer: Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that 311 sequences exhibited high-level drug resistance.

Rationale: The paper does not explicitly mention that sequences were obtained from individuals with virological failure, but it does mention high-level drug resistance.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information regarding the patients being part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that 355 sequences exhibited low-to-high-level drug resistance to at least one of the 13 ARVs screened for.

Rationale: The paper does not explicitly mention that sequences were obtained from individuals who had previously received ARV drugs, but it does mention drug resistance.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that 464 participants were on second-generation ART regimens.

Rationale: The paper does not explicitly mention the drug classes received by individuals before sample sequencing, but it does mention the ART regimens.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the combination of FTC + TDF + EFV was the most common ART regimen administered.

Rationale: The paper does not explicitly mention the drugs received by individuals before sample sequencing, but it does mention the ART regimens.

Answer: Not reported
""""""",87
37515146,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper describes the collection of plasma samples from HIV-positive patients and the extraction of viral RNA, which indicates that HIV sequences were obtained from these patient samples.

Rationale: The paper mentions that viral RNA was extracted from plasma samples, which is a common method for obtaining HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper discusses the identification of drug resistance mutations and their correlation with treatment regimens, but it does not provide specific in vitro drug susceptibility data.

Rationale: The paper focuses on the analysis of HIV sequences and the identification of drug resistance mutations, but it does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper provides specific GenBank accession numbers for the sequenced HIV isolates, indicating that these sequences were made publicly available.

Rationale: The paper explicitly lists the GenBank accession numbers for the sequenced HIV isolates, which is a common practice for making sequence data publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper provides specific GenBank accession numbers for the sequenced HIV isolates, which are MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457.

Rationale: The paper explicitly lists the GenBank accession numbers for the sequenced HIV isolates, which is a common practice for making sequence data publicly available.

Answer: MK702015-MK702057, MK867695-MK867757, MK995397-MK995457
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 379 participants had successful sequencing data, giving a genotyping success rate of 96.9%.

Rationale: The paper mentions that 379 participants had successful sequencing data, which indicates the number of individuals from whom samples were obtained for sequencing.

Answer: 379
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Cameroon.

Rationale: The paper explicitly states that the study was conducted in Cameroon, which indicates the country from which the sequenced samples were obtained.

Answer: Cameroon
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from 2014 to 2019.

Rationale: The paper explicitly states that the study was conducted from 2014 to 2019, which indicates the years from which the sequenced samples were obtained.

Answer: 2014-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, which suggests that this step was not performed.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the protease and reverse transcriptase regions of the HIV-1 pol gene were genotyped.

Rationale: The paper specifically mentions that the protease and reverse transcriptase regions of the HIV-1 pol gene were genotyped, which indicates the HIV genes that were sequenced.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that sequencing was performed using a genetic analyzer (ABI 3500).

Rationale: The paper explicitly states that sequencing was performed using a genetic analyzer (ABI 3500), which is a common method for sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper specifically mentions that plasma samples were used for sequencing, which indicates the type of clinical specimens used.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included patients who were initiating ART, but it does not mention virological failure.

Rationale: The paper does not mention virological failure, which suggests that sequences were not obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention a clinical trial, which suggests that the patients were not part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included patients who were initiating ART, but it does not mention previous ARV drug use.

Rationale: The paper does not mention previous ARV drug use, which suggests that sequences were not obtained from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included patients who were initiating ART, but it does not mention specific drug classes.

Rationale: The paper does not mention specific drug classes, which suggests that this information is not reported.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included patients who were initiating ART, but it does not mention specific drugs.

Rationale: The paper does not mention specific drugs, which suggests that this information is not reported.

Answer: Not reported
""""""",92
37520425,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-DNA sequences obtained from patient samples.

Rationale: The paper mentions that HIV-DNA sequences were obtained from the peripheral blood of six participants over a period of 3 to ≥15 years of effective therapy.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility assays or data.

Rationale: The paper focuses on the analysis of HIV-DNA sequences and the persistence of HIV in memory CD4+ T-cells, but does not mention any experiments or data related to in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers, indicating that the sequences were not made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that six HIV-1 subtype-B positive individuals on prolonged ART were included in the study.

Rationale: The paper mentions that six individuals were included in the study.

Answer: 6
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was approved in Western Sydney Health Department for the Westmead Institute for Medical Research (Australia), and University of California San Francisco (United States), Vaccine Gene Therapy Institute-Florida (United States)

Rationale: The paper mentions that the study was approved in Australia and the United States.

Answer: United States, Australia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific years for when the sequenced samples were obtained.

Rationale: The paper does not mention specific years.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention cloning.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that single-proviral sequencing (SPS) was used to amplify the gag-pol region of the HIV genome, specifically the p6-RT region.

Rationale: The paper mentions that the gag-pol region was sequenced.

Answer: Gag, PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the sequencing method used for the viral sequences.

Rationale: The paper does not mention the sequencing method.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper specifies that CD4+ T-cell subsets were sorted from frozen aliquots of peripheral blood mononuclear cells (PBMCs), and HIV-DNA was sequenced.

Rationale: The paper mentions that PBMCs were used.

Answer: PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the participants had viral loads of <40-75 copies (HIV-RNA) per ml during the study period, indicating effective viral suppression and not virological failure.

Rationale: The paper does not mention virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included individuals on prolonged ART, indicating that the participants had previously received antiretroviral drugs.

Rationale: The paper mentions that the participants were on prolonged ART.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific names of the drugs received by the individuals in the study.

Rationale: The paper does not mention specific drug classes.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific names of the drugs received by the individuals in the study.

Rationale: The paper does not mention specific drugs.

Answer: Not reported
""""""",79
37537871,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-1 sequences obtained from patient samples, specifically from persistent controllers (PCs) and transient controllers (TCs). It mentions the use of next-generation sequencing techniques to characterize the HIV-1 reservoir from peripheral blood mononuclear cells (PBMCs) of these patients.

Rationale: The paper focuses on the analysis of HIV-1 sequences from patient samples, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any experiments or results related to in vitro drug susceptibility testing. The focus is on RNA-Seq of HIV-2 genomes from patient plasma samples and lab-adapted strains, and there is no discussion of drug susceptibility.

Rationale: The paper does not report in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper provides specific GenBank accession numbers for the sequenced HIV isolates. It mentions that the generated HIV sequences were deposited in GenBank with accession numbers ranging from KR860607 to KR861345.

Rationale: The paper provides GenBank accession numbers for the sequenced HIV isolates, indicating that the sequences were made publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper provides specific GenBank accession numbers for the sequenced HIV isolates. It mentions that the generated HIV sequences were deposited in GenBank with accession numbers ranging from KR860607 to KR861345.

Rationale: The paper provides GenBank accession numbers for the sequenced HIV isolates.

Answer: KR860607 to KR861345
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that amplicon 1 was amplified and sequenced in 649 HIV-infected subjects.

Rationale: The paper mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 649
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper specifies that the technique of long-range HIV genotyping was applied to specimens collected within three Botswana-Harvard AIDS Institute Partnership (BHP) studies. It lists several geographic localities in Botswana where the samples originated.

Rationale: The paper specifies the country from which the sequenced samples were obtained.

Answer: Botswana
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the long-range HIV genotyping from proviral DNA was applied to specimens collected from subjects participating in the BCPP baseline household survey from November 2013 until June 2014.

Rationale: The paper mentions the years during which the sequenced samples were obtained.

Answer: 2013-2014
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing. It describes the use of next-generation sequencing techniques and single proviral genome.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the full genome of the HIV-1 provirus was sequenced.

Rationale: The paper mentions the HIV genes that were sequenced.

Answer: Full length genome
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions the use of Illumina MiSeq sequencing for the analysis of full-length individual proviral sequences (FLIP-Seq) and integration site analysis (MIP-Seq).

Rationale: The paper mentions the sequencing method used.

Answer: Illumina sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper specifies that peripheral blood mononuclear cells (PBMCs) were used for the characterization of the HIV-1 reservoir and subsequent sequencing.

Rationale: The paper mentions the type of samples that were sequenced.

Answer: PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that sequences were obtained from individuals experiencing virological failure.

Rationale: The paper mentions sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial. It describes the collection of samples from elite controllers (ECs).

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that 142 samples were obtained from ART-experienced individuals, indicating that sequences were obtained from individuals who had previously received antiretroviral drugs.

Rationale: The paper mentions sequences obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions various antiretroviral drugs that belong to NRTI, NNRTI, INSTI, and CCR5 antagonist classes.

Rationale: The paper mentions the drug classes received by individuals in the study before sample sequencing.

Answer: NRTI, NNRTI, INSTI, CCR5 antagonist
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper specifically mentions drugs as part of the treatment regimens received by two cases, Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC).

Rationale: The paper mentions specific drugs received by individuals in the study before sample sequencing.

Answer: Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)
""""""",100
37540331,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention the reporting of HIV sequences from patient samples.

Rationale: The focus is on the clinical outcomes and genotypic resistance testing rather than the reporting of HIV sequences.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing.

Rationale: The paper focuses on clinical outcomes and genotypic resistance testing rather than in vitro susceptibility assays.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention whether the sequences were made publicly available, nor does it provide any relevant information to determine this.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any specific GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not specify the exact number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not specify the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not specify the years during which the sequenced samples were obtained.

Rationale: The paper does not provide information on the years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information that would imply cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not specify which HIV genes were sequenced.

Rationale: The paper does not provide information on the specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the sequencing method used.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not specify the type of samples that were sequenced.

Rationale: The paper does not provide information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not specify whether sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide information on whether sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not specify whether the patients were in a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not specify whether sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper does not provide information on whether sequences were obtained from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not specify which drug classes were received by individuals in the study before sample sequencing.

Rationale: The paper does not provide information on the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not specify which drugs were received by individuals in the study before sample sequencing.

Rationale: The paper does not provide information on the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",75
37541705,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that the study evaluated the pharmacokinetics, safety, and tolerability of once-daily dispersible and immediate-release FDC abacavir/dolutegravir/lamivudine in young children with HIV.

Rationale: The paper does not explicitly mention the reporting of HIV sequences from patient samples. However, it does mention the evaluation of pharmacokinetics, safety, and tolerability of the FDC abacavir/dolutegravir/lamivudine in young children with HIV, which implies that some form of genetic analysis may have been performed.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing.

Rationale: The paper focuses on the pharmacokinetics, safety, and tolerability of the FDC abacavir/dolutegravir/lamivudine in young children with HIV, but does not include any in vitro drug susceptibility testing results.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention any publicly available sequences or accession numbers.

Rationale: The paper does not provide any information about the public availability of sequences or accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 57 participants were enrolled in the study.

Rationale: The paper does not explicitly mention the number of individuals who had samples obtained for HIV sequencing, but it does mention the total number of participants enrolled in the study.

Answer: 57
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that participants were recruited from study sites in Botswana, South Africa, Thailand, and the U.S.

Rationale: The paper does not explicitly mention the countries from which the sequenced samples were obtained, but it does mention the countries where the study sites were located.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that participants were enrolled from September 9, 2020 through June 28, 2021.

Rationale: The paper does not explicitly mention the years from which the sequenced samples were obtained, but it does mention the enrollment period.

Answer: 2020-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention any specific HIV genes that were sequenced.

Rationale: The paper does not provide any information about the specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention any specific sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that pharmacokinetic samples were collected from participants.

Rationale: The paper does not explicitly mention the type of samples that were sequenced, but it does mention the collection of pharmacokinetic samples.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that one participant did not achieve virologic suppression at Week 24.

Rationale: The paper does not explicitly mention the sequencing of individuals with virological failure on a treatment regimen, but it does mention the virologic outcome of one participant.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was an international, phase I/II, multi-site, open-label, non-comparative dose confirmation study.

Rationale: The paper explicitly states that the study was a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that most participants were treatment-experienced at entry and switched from a regimen containing lopinavir/ritonavir, dolutegravir, or raltegravir as the anchor medication.

Rationale: The paper does not explicitly mention the sequencing of individuals who had previously received ARV drugs, but it does mention the treatment history of the participants.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants were treatment-experienced at entry and switched from a regimen containing lopinavir/ritonavir, dolutegravir, or raltegravir as the anchor medication.

Rationale: The paper does not explicitly mention the drug classes received by individuals before sample sequencing, but it does mention the treatment history of the participants.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants were treatment-experienced at entry and switched from a regimen containing lopinavir/ritonavir, dolutegravir, or raltegravir as the anchor medication.

Rationale: The paper does not explicitly mention the drugs received by individuals before sample sequencing, but it does mention the treatment history of the participants.

Answer: Not reported
""""""",94
37546367,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that ""Plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR with a pre-step of virus concentration by ultracentrifugation before extraction and the Sanger sequencing.""

Rationale: The paper explicitly states that plasma samples from patients were subjected to sequencing, indicating that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the analysis of drug resistance mutations and their prevalence in patient samples, but it does not mention conducting in vitro drug susceptibility tests.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that ""The partial pol nucleotide sequences were submitted to GenBank under the accession numbers: OQ886077 - OQ888150.""

Rationale: The paper provides specific GenBank accession numbers for the sequenced HIV isolates, indicating that these sequences were made publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper mentions that ""The partial pol nucleotide sequences were submitted to GenBank under the accession numbers: OQ886077 - OQ888150.""

Rationale: The paper provides specific GenBank accession numbers for the sequenced HIV isolates.

Answer: OQ886077 - OQ888150
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that ""A total of 3274 patients were enrolled and 2074 HIV-1 partial pol sequences were obtained and subsequently used to establish the dataset.""

Rationale: The paper states that 2074 HIV-1 partial pol sequences were obtained from patients.

Answer: 2074
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that ""Plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR...""

Rationale: The paper indicates that the samples were obtained from patients in Guangdong Province, China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that ""Plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR...""

Rationale: The paper specifies that the samples were obtained between 2011 and 2022.

Answer: 2011-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper describes the use of ultracentrifugation to concentrate HIV RNA from patients, but it does not mention any cloning steps.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that ""The partial HIV-1 pol gene (HXB2 nt 2253--3252) was amplified by one-step RT-PCR and nested PCR as previously described.""

Rationale: The paper specifies that the partial HIV-1 pol gene was sequenced.

Answer: pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that ""Then, the genotypic resistance test was performed and DR was analyzed by the Stanford HIVDB program.""

Rationale: The paper does not explicitly mention the sequencing method, but it mentions the use of the Stanford HIVDB program for genotypic resistance testing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that ""Plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR...""

Rationale: The paper specifies that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that ""HIV-1 infected individuals were eligible for inclusion in this study if they have received ART for at least 6 months with HIV-1 viral load between 200 to 1000 copies/mL.""

Rationale: The paper includes individuals who have received ART for at least 6 months, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes a retrospective study and does not mention any clinical trial involvement.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that ""HIV-1 infected individuals were eligible for inclusion in this study if they have received ART for at least 6 months with HIV-1 viral load between 200 to 1000 copies/mL.""

Rationale: The paper includes individuals who have received ART for at least 6 months, indicating that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that ""Patients whose initial treatment regimen was 2NRTI+PI were less likely to be resistant to drugs than those whose initial treatment regimen was 2NRTI+NNRTI.""

Rationale: The paper mentions that patients received NRTI and PI or NNRTI as part of their initial treatment regimen.

Answer: NRTI, PI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that ""Patients whose initial treatment regimen was 2NRTI+PI were less likely to be resistant to drugs than those whose initial treatment regimen was 2NRTI+NNRTI.""

Rationale: The paper does not specify the exact drugs received by individuals, but it mentions that patients received NRTI and PI or NNRTI as part of their initial treatment regimen.

Answer: Not reported
""""""",101
37554471,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not provide any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention whether the sequences obtained were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide information about the years when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not provide information about the HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not provide information about the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not provide information about virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not provide information about a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not provide information about HIV sequences from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information about the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information about the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",57
37573167,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-DNA sequences obtained from patient samples, specifically from virologically suppressed individuals.

Rationale: The paper mentions that HIV-DNA sequences were obtained from patient samples, and the analysis of these sequences is the main focus of the study.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any experiments or data related to in vitro drug susceptibility testing.

Rationale: The paper focuses on the analysis of HIV-DNA sequences and resistance mutations, but does not mention any in vitro drug susceptibility assays or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention making the sequences publicly available or provide any GenBank accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper includes 1126 HIV-1 drug-experienced virologically suppressed subjects with an available HIV-DNA GRT.

Rationale: The paper states that 1126 individuals were included in the study, and HIV-DNA GRT was performed on these individuals.

Answer: 1126
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not specify the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention the geographical origin of the samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study included HIV-DNA GRT performed over the period 2010-2021.

Rationale: The paper states that the study included data from 2010 to 2021.

Answer: 2010-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any process of cloning samples prior to sequencing.

Rationale: The paper does not mention cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that Sanger sequencing was performed on the protease/reverse transcriptase (PR/RT) and integrase genes.

Rationale: The paper specifies that the PR/RT and integrase genes were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing was performed.

Rationale: The paper states that Sanger sequencing was used for the analysis of HIV-DNA sequences.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that HIV-DNA was obtained from whole-blood or lymphomonocytic cells after separation from peripheral blood.

Rationale: The paper specifies that the samples were obtained from whole-blood or lymphomonocytic cells.

Answer: Whole Blood, PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included virologically suppressed individuals.

Rationale: The paper focuses on virologically suppressed individuals, indicating that the sequences were not obtained from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included HIV-1 drug-experienced virologically suppressed subjects.

Rationale: The paper states that the individuals were drug-experienced, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the individuals were under virological suppression for a median of 3.7 years, and were mainly under triple therapy based on PI, NNRTI or INSTI plus 2 NRTIs.

Rationale: The paper specifies that the individuals were receiving PI, NNRTI, INSTI, and NRTI drugs.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific names of the drugs received by the individuals in the study.

Rationale: The paper does not mention specific drug names.

Answer: Not reported
""""""",82
37574435,"Here are the answers to the questions in the format you requested:

### Question 1: Does the paper report HIV sequences from patient samples?

Question: Does the paper report HIV sequences from patient samples?

Evidence: ""We retrospectively reviewed the medical records of PWH who had viral rebound with plasma HIV RNA >1000 copies/mL and were switched to either dolutegravir combined with 2 NRTIs or BIC/FTC/TAF.""

Rationale: The paper does not explicitly state that HIV sequences were obtained from patient samples, but it mentions that the study included people with HIV who had viral rebound and were switched to different antiretroviral regimens.

Answer: No

### Question 2: Does the paper report in vitro drug susceptibility data?

Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility data.

Answer: No

### Question 3: Were sequences from the paper made publicly available?

Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not mention that the sequences were made publicly available.

Answer: No

### Question 4: What were the GenBank accession numbers for sequenced HIV isolates?

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

### Question 5: How many individuals had samples obtained for HIV sequencing?

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""We identified 79 PWH who met the criteria of viral rebound and switched to second-generation INSTI-containing regimens""

Rationale: The paper mentions that 79 people with HIV (PWH) were included in the study.

Answer: 79

### Question 6: From which countries were the sequenced samples obtained?

Question: From which countries were the sequenced samples obtained?

Evidence: ""This was a single-center, retrospective cohort study conducted in the National Taiwan University Hospital (NTUH).""

Rationale: The paper mentions that the study was conducted in Taiwan.

Answer: Taiwan

### Question 7: From what years were the sequenced samples obtained?

Question: From what years were the sequenced samples obtained?

Evidence: ""PWH who were aged ≥20 years and received HIV care with at least 3 months of ART prescription between 1 January 2016 and 30 March 2022 were eligible for the study.""

Rationale: The paper mentions that the study included people who received HIV care between 2016 and 2022.

Answer: 2016-2022

### Question 8: Were samples cloned prior to sequencing?

Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention whether samples were cloned prior to sequencing.

Answer: Not reported

### Question 9: Which HIV genes were reported to have been sequenced?

Question: Which HIV genes were reported to have been sequenced?

Evidence: ""No evidence""

Rationale: The paper does not mention which HIV genes were sequenced.

Answer: Not reported

### Question 10: What method was used for sequencing?

Question: What method was used for sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported

### Question 11: What type of samples were sequenced?

Question: What type of samples were sequenced?

Evidence: ""We retrospectively reviewed the medical records of PWH who had viral rebound with plasma HIV RNA >1000 copies/mL""

Rationale: The paper mentions that plasma HIV RNA was used for the study.

Answer: Plasma

### Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""We identified 79 PWH who met the criteria of viral rebound and switched to second-generation INSTI-containing regimens""

Rationale: The paper mentions that the study included people who had viral rebound, which indicates that they had virological failure on a treatment regimen.

Answer: Yes

### Question 13: Were the patients in the study in a clinical trial?

Question: Were the patients in the study in a clinical trial?

Evidence: ""This was a single-center, retrospective cohort study""

Rationale: The paper mentions that the study was a retrospective cohort study, not a clinical trial.

Answer: No

### Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""PWH who were aged ≥20 years and received HIV care with at least 3 months of ART prescription between 1 January 2016 and 30 March 2022 were eligible for the study.""

Rationale: The paper mentions that the study included people who had received HIV care, which implies that they had previously received ARV drugs.

Answer: Yes

### Question 15: Which drug classes were received by individuals in the study before sample sequencing?

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Most PWH (82.1%) in the DTG group switched from NNRTI-based ART to DTG-based regimens, while 75% of the PWH in the BIC group were receiving a first-generation INSTI-based ART before switch.""

Rationale: The paper mentions that the individuals in the study had received NNRTI-based ART, first-generation INSTI-based ART, and other antiretroviral regimens before switching to second-generation INSTI-containing regimens.

Answer: NNRTI, INSTI, NRTI

### Question 16: Which drugs were received by individuals in the study before sample sequencing?

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""Most PWH (82.1%) in the DTG group switched from NNRTI-based ART to DTG-based regimens, while 75% of the PWH in the BIC group were receiving a first-generation INSTI-based ART before switch.""

Rationale: The paper mentions that the individuals in the study had received NNRTI-based ART, first-generation INSTI-based ART, and other antiretroviral regimens before switching to second-generation INSTI-containing regimens.

Answer: DTG, BIC, FTC, TAF",104
37585352,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 proviral DNA sequences were generated using next-generation sequencing (NGS) from proviral DNA for the presence of RPV-RAMs.

Rationale: The paper specifically focuses on the analysis of HIV-1 proviral DNA sequences from patient samples, indicating that the sequences were derived from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the analysis of HIV-1 proviral DNA sequences and the prevalence of RPV-RAMs, but it does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that HIV-1 sequences are available on request through the PANGEA consortium (www.pangea-hiv.org).

Rationale: The paper provides information on how to access the HIV-1 sequences, indicating that they are available to the public.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that a total of 5805 proviral sequences from Botswana Combination Prevention Project (BCPP) participants were included in the analysis.

Rationale: The paper specifies the number of participants whose samples were used for HIV sequencing.

Answer: 5805
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Botswana.

Rationale: The paper specifies the country where the samples were obtained.

Answer: Botswana
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from 2013 to 2018.

Rationale: The paper specifies the years during which the samples were obtained.

Answer: 2013-2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper describes the use of next-generation sequencing (NGS) but does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that near full-length HIV-1 pol sequences were generated using next-generation sequencing (NGS) from proviral DNA.

Rationale: The paper specifies that the pol gene was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that next-generation sequencing (NGS) was used to generate HIV-1 proviral DNA sequences.

Rationale: The paper specifies the sequencing method used.

Answer: Next-generation sequencing (NGS)
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that HIV-1 proviral DNA sequences were generated from proviral DNA.

Rationale: The paper specifies the type of samples used for sequencing.

Answer: Proviral DNA
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included ART-suppressed individuals, but it does not specifically mention sequences from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on ART-suppressed individuals, but it does not provide information on virological failure.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes the study as an analysis of HIV-1 proviral DNA sequences from patient samples, but it does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included ART-suppressed individuals, indicating that they had previously received antiretroviral drugs.

Rationale: The paper specifies that the participants were on antiretroviral therapy (ART), indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the most common ART regimens used were efavirenz + emtricitabine + tenofovir (EFV/FTC/TDF), lamivudine + nevirapine + zidovudine (3TC/NVP/ZDV), and lamivudine + efavirenz + zidovudine (3TC/EFV/ZDV).

Rationale: The paper specifies the ART regimens used by the participants, which include NNRTIs (efavirenz, nevirapine), NRTIs (emtricitabine, lamivudine, tenofovir, zidovudine).

Answer: NNRTI, NRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the most common ART regimens used were efavirenz + emtricitabine + tenofovir (EFV/FTC/TDF), lamivudine + nevirapine + zidovudine (3TC/NVP/ZDV), and lamivudine + efavirenz + zidovudine (3TC/EFV/ZDV).

Rationale: The paper specifies the ART regimens used by the participants, which include efavirenz, emtricitabine, lamivudine, nevirapine, tenofovir, and zidovudine.

Answer: Efavirenz, emtricitabine, lamivudine, nevirapine, tenofovir, zidovudine
""""""",98
37593123,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper reports HIV-1 *pol* gene region sequences from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions between 2004 and 2022.

Rationale: The paper specifically focuses on ART-naïve individuals, meaning that the participants had not previously received antiretroviral drugs, and it reports HIV-1 *pol* gene region sequences from these individuals.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Rationale: The paper focuses on the presence of drug resistance mutations rather than susceptibility and does not provide any experimental results on how effective different drugs are against HIV-1 strains isolated from the studied individuals.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention that the sequences were deposited in a public database or provide any accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention that the sequences were deposited in a public database or provide any accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 57,902 ART-naïve HIV-infected individuals were included in the study.

Rationale: The paper mentions that the study population consisted of 57,902 ART-naïve HIV-infected individuals.

Answer: 57,902
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted in China.

Rationale: The paper specifically focuses on ART-naïve HIV-infected individuals in China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The samples were obtained between 2004 and 2022.

Rationale: The paper mentions that the study spanned from 2004 to 2022.

Answer: 2004-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about cloning samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper reports HIV-1 *pol* gene region sequences.

Rationale: The paper specifically mentions that the HIV-1 *pol* gene region was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not provide specific information about the sequencing method used.

Rationale: The paper does not mention the sequencing method used to generate the HIV-1 *pol* gene region sequences.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper reports HIV-1 *pol* gene region sequences from ART-naïve HIV-positive individuals.

Rationale: The paper specifically mentions that the samples were from ART-naïve HIV-positive individuals.

Answer: Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper specifically focuses on ART-naïve individuals, meaning that the participants had not previously received antiretroviral drugs.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information about the patients being part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention any sequences obtained from individuals who had previously received ARV drugs.

Rationale: The paper specifically focuses on ART-naïve individuals, meaning that the participants had not previously received antiretroviral drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information about the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not mention the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information about the drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not mention the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",80
37626789,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""HIV-1 genotyping and sequencing was performed for the pol gene region using in-house assay validated at the Chinese Center for Disease Control and Prevention, and the Stanford HIVDB v9.0 algorithm was used for identification of drug resistance mutations.""

Rationale: The paper mentions that HIV-1 genotyping and sequencing was performed for the pol gene region, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility data or phenotypic data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""A longitudinal study was conducted among 551 HIV-positive children (<15 years old) recruited between 2017 and 2019 at 40 antiretroviral treatment delivery sites in Ethiopia.""

Rationale: The paper states that 551 HIV-positive children had samples obtained for HIV sequencing.

Answer: 551
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""A longitudinal study was conducted among 551 HIV-positive children (<15 years old) recruited between 2017 and 2019 at 40 antiretroviral treatment delivery sites in Ethiopia.""

Rationale: The paper mentions that the study was conducted in Ethiopia.

Answer: Ethiopia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""A longitudinal study was conducted among 551 HIV-positive children (<15 years old) recruited between 2017 and 2019 at 40 antiretroviral treatment delivery sites in Ethiopia.""

Rationale: The paper states that the study was conducted between 2017 and 2019.

Answer: 2017-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""HIV-1 genotyping and sequencing was performed for the pol gene region using in-house assay validated at the Chinese Center for Disease Control and Prevention, and the Stanford HIVDB v9.0 algorithm was used for identification of drug resistance mutations.""

Rationale: The paper mentions that the pol gene region was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""HIV-1 genotyping and sequencing was performed for the pol gene region using in-house assay validated at the Chinese Center for Disease Control and Prevention, and the Stanford HIVDB v9.0 algorithm was used for identification of drug resistance mutations.""

Rationale: The paper mentions that an in-house assay validated at the Chinese Center for Disease Control and Prevention was used for sequencing.

Answer: In-house assay
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Whole blood was collected from children using two ethylenediaminetetraacetic acid (EDTA) coated test tubes of 3--5 mL each, and plasma was extracted using centrifugation at 2000 revolutions per minute (RPM).""

Rationale: The paper mentions that whole blood was collected and plasma was extracted for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Children with VF (i.e., viral load ≥ 1000 copies/mL) were included for HIV drug resistance investigation, given those with VL < 1000 copies/mL were considered as susceptible and excluded from HIVDR testing.""

Rationale: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""A longitudinal study was conducted among 551 HIV-positive children (<15 years old) recruited between 2017 and 2019 at 40 antiretroviral treatment delivery sites in Ethiopia.""

Rationale: The paper mentions that the study was conducted among HIV-positive children who were taking antiretroviral treatment.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""The first-line regimen for children of all ages was an association of two nucleoside reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI): zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.""

Rationale: The paper mentions that the first-line regimen included NRTIs and NNRTIs.

Answer: NRTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""The first-line regimen for children of all ages was an association of two nucleoside reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI): zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.""

Rationale: The paper mentions that the first-line regimen included zidovudine, stavudine, lamivudine, nevirapine, and efavirenz.

Answer: Zidovudine, Stavudine, Lamivudine, Nevirapine, Efavirenz
""""""",99
37632026,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper describes the sequencing of HIV-1 pol-gene (protease and reverse-transcriptase regions) from plasma samples of patients who had failed first- and second-line ART.

Rationale: The paper explicitly mentions that the study involved the sequencing of HIV-1 pol-gene from plasma samples of patients who had failed first- and second-line ART.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility assays or data.

Rationale: The paper focuses on the sequencing of HIV-1 pol-gene from plasma samples and the analysis of drug resistance mutations, but does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that sequences generated for the purpose of this study were submitted to Genbank under the following accession numbers: MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169, MK867721-MK867755; and OQ985493-OQ985958.

Rationale: The paper explicitly states that the sequences were submitted to Genbank, making them publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper mentions that sequences generated for the purpose of this study were submitted to Genbank under the following accession numbers: MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169, MK867721-MK867755; and OQ985493-OQ985958.

Rationale: The paper explicitly states that the sequences were submitted to Genbank under the specified accession numbers.

Answer: MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169, MK867721-MK867755; and OQ985493-OQ985958
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that a total of 759 participants were included in the study.

Rationale: The paper explicitly states that 759 participants were included in the study.

Answer: 759
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was carried out in Cameroon.

Rationale: The paper explicitly states that the study was carried out in Cameroon.

Answer: Cameroon
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was carried out from November 2011 to August 2019.

Rationale: The paper explicitly states that the study was carried out from November 2011 to August 2019.

Answer: 2011-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the HIV-1 pol-gene (protease and reverse-transcriptase regions) was sequenced.

Rationale: The paper explicitly states that the HIV-1 pol-gene (protease and reverse-transcriptase regions) was sequenced.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that sequencing was performed using an Applied Biosystems 3500 genetic analyzer.

Rationale: The paper explicitly states that sequencing was performed using an Applied Biosystems 3500 genetic analyzer.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper explicitly states that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included patients who had failed first- and second-line ART.

Rationale: The paper explicitly states that the study included patients who had failed first- and second-line ART.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included patients who had failed first- and second-line ART.

Rationale: The paper explicitly states that the study included patients who had failed first- and second-line ART, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patients had received NNRTI-based first-line ART and PI/r-based second-line ART.

Rationale: The paper explicitly states that the patients had received NNRTI-based first-line ART and PI/r-based second-line ART.

Answer: NRTI, NNRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patients had received AZT, TDF, 3TC, ABC, EFV, NVP, ATV/r, LPV/r, and DRV/r.

Rationale: The paper explicitly states that the patients had received these drugs.

Answer: AZT, TDF, 3TC, ABC, EFV, NVP, ATV/r, LPV/r, DRV/r
""""""",94
37632071,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""A total of 329 PLWH had plasma HIV RNA which was either undetectable or detectable at <50 copies/mL at T0, and 197 responded to all inclusion criteria: M/F 140/57; the median CD4+ cell count was 677 cells/mm^3^ ; and HIV RNA at T0 was undetectable in 108 patients.""

Rationale: The paper mentions that HIV RNA was analyzed from patient samples, indicating that HIV sequences were obtained from these samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility data or related experiments.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not mention whether any sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""A total of 329 PLWH had plasma HIV RNA which was either undetectable or detectable at <50 copies/mL at T0, and 197 responded to all inclusion criteria:""

Rationale: The paper mentions that 197 individuals had samples obtained for HIV sequencing.

Answer: 197
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""This retrospective cohort study was conducted at 4 (Rome, Treviso, Vicenza, and Venice) Italian Infectious Diseases Units""

Rationale: The paper mentions that the study was conducted in Italy.

Answer: Italy
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""Switching to bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) from other antiretroviral regimens is safe and effective for virologically suppressed people living with HIV (PLWH). The term virological suppression includes both low but detectable HIV viremia and undetectable HIV viremia, and the latter is possibly associated with a lower immune activation state. Herein, we describe a 24-month follow-up of experienced PLWH with plasma HIV RNA undetectable or detectable < 50 copies/ml switching to BIC/FTC/TAF. A previous 12-month monitoring was available, and the factors correlated with treatment efficacy. This retrospective multicenter study included PLWH who switched to BIC/FTC/TAF in the period of 2019--2022, and who were HBsAg and HCV RNA negative.""

Rationale: The paper mentions that the study included PLWH who switched to BIC/FTC/TAF in the period of 2019--2022.

Answer: 2019-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""No evidence""

Rationale: The paper does not mention which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""A total of 329 PLWH had plasma HIV RNA which was either undetectable or detectable at <50 copies/mL at T0, and 197 responded to all inclusion criteria:""

Rationale: The paper mentions that plasma samples were analyzed.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""The unique case of confirmed virological failure was observed at month 8 (HIV RNA rebound to 2610 copies/mL) in a patient who had been virologically suppressed for 48 months with the regimen tenofovir alafenamide/emtricitabine/darunavir/cobicistat.""

Rationale: The paper mentions one case of virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""The decision to start the new regimen was up to the treating physician according to the updated treatment guidelines [19, 20, 21, 22] and was performed as a routine clinical practice.""

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Most of the 197 patients (122, 61.9%) were on a previous INSTI-based regimen.""

Rationale: The paper mentions that most patients were on a previous INSTI-based regimen.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Most of the 197 patients (122, 61.9%) were on a previous INSTI-based regimen.""

Rationale: The paper mentions that most patients were on a previous INSTI-based regimen.

Answer: INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""Most of the 197 patients (122, 61.9%) were on a previous INSTI-based regimen.""

Rationale: The paper mentions that most patients were on a previous INSTI-based regimen.

Answer: INSTI-based regimen
""""""",95
37649807,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not provide any information regarding in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific years during which the samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not specify whether samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide information about the HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not provide information about virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide information about previous ARV drug use.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information about the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information about the specific drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",57
37662576,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-generated recombinant enzymes and mutations in integrase proteins from different HIV subtypes.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any experiments or data related to in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide information on the specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not provide information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not provide information on whether sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not provide information on whether the patients were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide information on whether the individuals had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",62
37674678,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 *pol* gene sequence was obtained by viral RNA extraction and nested PCR amplification from 1,393 ART-naïve individuals newly diagnosed with HIV-1.

Rationale: The paper describes the process of obtaining HIV-1 *pol* gene sequences from patient samples, indicating that it reports HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the analysis of HIV-1 sequences and the prevalence of transmitted drug resistance, but it does not mention any experiments or data related to in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any information about making the sequences publicly available.

Rationale: The paper does not mention depositing the sequences in a public database or providing access to the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention depositing the sequences in GenBank or providing accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 1,393 ART-naïve individuals newly diagnosed with HIV-1 were enrolled in the study.

Rationale: The paper states that 1,393 individuals were enrolled, and their samples were used for HIV sequencing.

Answer: 1,393
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples, but it mentions that the study was conducted in Nanjing, China.

Rationale: The paper focuses on the prevalence of transmitted drug resistance in Nanjing, China, indicating that the samples were obtained from China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from 1,393 ART-naïve individuals newly diagnosed with HIV-1 between January 2019 and December 2021.

Rationale: The paper states that the samples were obtained from individuals diagnosed between 2019 and 2021.

Answer: 2019-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any process of cloning the samples prior to sequencing.

Rationale: The paper describes the process of obtaining HIV-1 *pol* gene sequences from patient samples, but it does not mention cloning.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the HIV-1 *pol* gene sequence was obtained by viral RNA extraction and nested PCR amplification.

Rationale: The paper specifically mentions the *pol* gene, which includes the protease and reverse transcriptase regions.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that the PCR products were sent to Sangon Biotechnology Co., Ltd. for automatic DNA sequencing using ABI 3730XL.

Rationale: The paper describes the use of ABI 3730XL for DNA sequencing, which is a method associated with Sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were collected from 1,393 ART-naïve individuals newly diagnosed with HIV-1.

Rationale: The paper specifically mentions plasma samples as the type of clinical specimens sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included ART-naïve individuals, meaning that the participants had not previously received antiretroviral therapy.

Rationale: The paper focuses on ART-naïve individuals, indicating that no sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes the study as a cross-sectional study of ART-naïve individuals, but it does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included ART-naïve individuals, meaning that the participants had not previously received antiretroviral therapy.

Rationale: The paper focuses on ART-naïve individuals, indicating that no sequences were obtained from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information about the drug classes received by the individuals in the study.

Rationale: The paper does not mention the specific drugs or drug classes received by the participants.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information about the drugs received by the individuals in the study.

Rationale: The paper does not mention the specific drugs received by the participants.

Answer: Not reported
""""""",88
37701387,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples. It discusses the use of antiretroviral therapy (ART) and the characteristics of a specific ART regimen, but does not provide any information about HIV sequences.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention any in vitro drug susceptibility data. It focuses on the use of antiretroviral therapy (ART) and the characteristics of a specific ART regimen, but does not provide any information about in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any information about the public availability of sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide any information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide any information about the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information about cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not provide any information about the HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not provide any information about the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not provide any information about sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not provide any information about a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not provide any information about HIV sequences from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information about the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information about the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",64
37716367,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention if the sequences were made publicly available.

Answer: Not reported
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention if the samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not mention which HIV genes were reported to have been sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention if any sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention if the patients were in a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention if the sequences were from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention which drug classes were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention which drugs were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",56
37755428,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-1 sequences from patient samples, including the detection of drug resistance mutations and the use of genotypic resistance testing.

Rationale: The paper explicitly states that HIV-1 sequences were obtained from patient samples, indicating that the answer is yes.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Rationale: The paper focuses on the presence of drug resistance mutations rather than susceptibility, indicating that the answer is no.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention making the sequences publicly available, indicating that the answer is no.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, indicating that the answer is not reported.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 143 infants had remnant specimens available for HIVDR testing.

Rationale: The paper specifies the number of individuals from whom samples were obtained for sequencing, indicating that the answer is 143.

Answer: 143
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from Haiti.

Rationale: The paper specifies the country of origin for the sequenced samples, indicating that the answer is Haiti.

Answer: Haiti
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the samples were collected between April 2020 and March 2021.

Rationale: The paper specifies the years during which the samples were obtained, indicating that the answer is 2020-2021.

Answer: 2020-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information regarding the cloning of samples, indicating that the answer is no.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the protease/reverse transcriptase (PR/RT) and integrase regions were sequenced.

Rationale: The paper specifies the HIV genes that were sequenced, indicating that the answer is PR/RT and integrase.

Answer: PR/RT, integrase
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that a Sanger-based method was used for sequencing.

Rationale: The paper specifies the sequencing method used, indicating that the answer is Sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that dried blood spot specimens were used for sequencing.

Rationale: The paper specifies the type of clinical specimens sequenced, indicating that the answer is dried blood spots.

Answer: Dried blood spots
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that one infant had detectable DTG resistance, indicating virological failure.

Rationale: The paper discusses the presence of drug resistance mutations in the infant, indicating that the answer is yes.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not indicate that the patients were part of a clinical trial, indicating that the answer is no.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that most mothers had received DTG-based ART, indicating that the infants were exposed to ARV drugs.

Rationale: The paper discusses the exposure of infants to ARV drugs, indicating that the answer is yes.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that most mothers had received DTG-based ART, indicating that the infants were exposed to INSTIs.

Rationale: The paper discusses the exposure of infants to INSTIs, indicating that the answer is INSTI.

Answer: INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that most mothers had received DTG-based ART, indicating that the infants were exposed to DTG.

Rationale: The paper discusses the exposure of infants to DTG, indicating that the answer is DTG.

Answer: DTG
""""""",81
37775947,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that stored plasma from participants with entry HIV RNA \>1000 copies/mL were analysed using NGS (llumina MiSeq).

Rationale: The paper explicitly states that HIV sequences were obtained from patient samples using next-generation sequencing (NGS).

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the analysis of HIV sequences from patient samples and the impact of pre-existing drug resistance on treatment failure, but it does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention that the sequences were made publicly available or provide any GenBank accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that baseline NGS data were available for 1380 antiretroviral therapy (ART)-naïve participants enrolled over 2009--2013.

Rationale: The paper explicitly states that 1380 participants had samples obtained for HIV sequencing.

Answer: 1380
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that participants were enrolled in the START trial, which was conducted by the International Network for Strategic Initiatives in Global HIV Trials, and that the study population was from various regions, including South America, Africa, and the USA.

Rationale: The paper does not provide a comprehensive list of countries, but it mentions that the study population was from various regions.

Answer: Multiple countries
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that participants were enrolled in the START trial between April 2009 and December 2013.

Rationale: The paper explicitly states that the samples were obtained between 2009 and 2013.

Answer: 2009-2013
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that sequence reads (FASTQ files) were analyzed with VirVarSeq version 20140929, which calls variants at the codon level, and that the analysis focused on the *pol* gene from amino acid position 1--935.

Rationale: The paper explicitly states that the *pol* gene was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that stored plasma from participants with entry HIV RNA \>1000 copies/mL were analysed using NGS (llumina MiSeq).

Rationale: The paper explicitly states that next-generation sequencing (NGS) was used for sequencing.

Answer: NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that stored plasma from participants with entry HIV RNA \>1000 copies/mL were analysed using NGS (llumina MiSeq).

Rationale: The paper explicitly states that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the primary endpoint of this analysis was treatment failure (TF), a composite outcome defined at the time of two possible failure events.

Rationale: The paper does not explicitly state that sequences were obtained from individuals with virological failure, but it mentions that treatment failure was a primary endpoint.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was conducted by the International Network for Strategic Initiatives in Global HIV Trials and that participants were enrolled in the START trial.

Rationale: The paper explicitly states that the patients were part of a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study population consisted of ART-naïve participants, but it does not explicitly state that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper does not mention that sequences were obtained from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study population consisted of ART-naïve participants, but it does not explicitly state which drug classes were received by individuals before sample sequencing.

Rationale: The paper does not mention which drug classes were received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study population consisted of ART-naïve participants, but it does not explicitly state which drugs were received by individuals before sample sequencing.

Rationale: The paper does not mention which drugs were received by individuals before sample sequencing.

Answer: Not reported
""""""",89
37817087,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that viral RNA was isolated from plasma or serum samples, and that the sequences were obtained from 4559 new HIV diagnoses.

Rationale: The paper explicitly states that the sequences were obtained from patient samples, specifically from plasma or serum.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility data or phenotypic data.

Rationale: The paper focuses on the analysis of drug resistance mutations and their prevalence in patient samples, but it does not mention conducting in vitro drug susceptibility tests.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention making the sequences publicly available through GenBank or any other means.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that sequences were obtained from 4559 new HIV diagnoses.

Rationale: The paper explicitly mentions the number of individuals from whom samples were obtained.

Answer: 4559
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from Germany.

Rationale: The paper explicitly mentions the country from which the samples were obtained.

Answer: Germany
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from 2017 to 2020.

Rationale: The paper explicitly mentions the years during which the samples were obtained.

Answer: 2017-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the protease (PR), reverse transcriptase (RT), and integrase (IN) genes were sequenced.

Rationale: The paper explicitly mentions the genes that were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that an Illumina NGS method (MiSeq) was used for sequencing.

Rationale: The paper explicitly mentions the sequencing method used.

Answer: Illumina sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma or serum samples were sequenced.

Rationale: The paper explicitly mentions the type of samples that were sequenced.

Answer: Plasma; Serum
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention whether any sequences were obtained from individuals with virological failure.

Rationale: The paper does not mention virological failure in the context of the sequenced samples.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention a clinical trial in the context of the study.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that some individuals had previously received ARV drugs.

Rationale: The paper explicitly mentions that some individuals had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the individuals received NRTIs, NNRTIs, PIs, and INIs.

Rationale: The paper explicitly mentions the drug classes that were received by the individuals.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the individuals received various drugs, including TDF, FTC, EFV, and others.

Rationale: The paper explicitly mentions the drugs that were received by the individuals.

Answer: Tenofovir disoproxil fumarate (TDF), Emtricitabine (FTC), Efavirenz (EFV), and others
""""""",77
37823653,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-1 sequences from patient samples, including their corresponding GenBank accession numbers.

Rationale: The paper mentions the use of HIV-1 sequences from patient samples, indicating that the sequences were derived from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Rationale: The paper focuses on the presence of drug resistance mutations rather than susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 6,078 HIV-1 near full length sequences were generated for the BCPP study.

Rationale: The paper mentions that a total of 6,078 HIV-1 near full length sequences were generated for the BCPP study.

Answer: 6,078
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Botswana.

Rationale: The paper specifies that the study was conducted in Botswana.

Answer: Botswana
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study enrolled participants between 2013 and 2018.

Rationale: The paper specifies that the study enrolled participants between 2013 and 2018.

Answer: 2013-2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the gp120 fragment of the HIV envelope gene was sequenced.

Rationale: The paper specifies that the gp120 fragment of the HIV envelope gene was sequenced.

Answer: gp120
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that next-generation sequencing (NGS) was performed using the Illumina platform.

Rationale: The paper specifies that NGS was performed using the Illumina platform.

Answer: Illumina sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that proviral DNA templates were used for amplification.

Rationale: The paper specifies that proviral DNA templates were used for amplification.

Answer: Proviral DNA
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that sequences were obtained from individuals experiencing virological failure (VF) on ART.

Rationale: The paper specifies that sequences were obtained from individuals experiencing virological failure (VF) on ART.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper specifies that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the majority of ART-experienced participants were on efavirenz- or nevirapine-based ART.

Rationale: The paper specifies that the majority of ART-experienced participants were on efavirenz- or nevirapine-based ART.

Answer: NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the majority of ART-experienced participants were on efavirenz- or nevirapine-based ART.

Rationale: The paper specifies that the majority of ART-experienced participants were on efavirenz- or nevirapine-based ART.

Answer: Efavirenz, Nevirapine
""""""",78
37872202,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any experiments or data related to in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper  focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper  focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not specify the number of individuals from whom samples were obtained for HIV sequencing. It focuses on the methodology and results of the sequencing study.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify the exact type of clinical specimens sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention any experiments or data related to in vitro drug susceptibility testing.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not specify the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not specify the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",68
37878637,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 RNA was extracted from plasma and full-length cDNA synthesized as described previously. A total of 29 adult subjects recruited between 2006 and 2011 in Uganda and whose plasma was collected during the acute/early phase of HIV-1 infection were analyzed in this study.

Rationale: The paper discusses the analysis of HIV-1 sequences from patient samples, specifically from plasma samples collected during the acute/early phase of HIV-1 infection.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any experiments or data related to in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 29 adult subjects recruited between 2006 and 2011 in Uganda and whose plasma was collected during the acute/early phase of HIV-1 infection were analyzed in this study.

Rationale: The paper states that a total of 29 adult subjects were analyzed in the study.

Answer: 29
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Uganda.

Rationale: The paper clearly states that the study subjects were from Uganda.

Answer: Uganda
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study subjects were recruited between 2006 and 2011.

Rationale: Paper mentioned ""subjects recruited between 2006 and 2011"", hence 2006-2011

Answer: 2006-2011
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV-1 *pro-RT* (HXB2 corresponding numbers 2071 - 3870) and *envelope gp160* (5956 - 9089) were amplified from plasma RNA following our previously described single genome amplification strategy.

Rationale: The paper mentions sequencing of the *pro-RT* (protease and reverse transcriptase) and *envelope gp160* genes.

Answer: PR, RT, Env
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper doesn't mention the sequencing method.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were sequenced.

Rationale: The paper specifies that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention obtaining sequences from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide specific information on the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide specific information on the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide specific information on the drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",73
37880705,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 pol sequences from studies conducted between 2003 and 2018 among ART-naïve Ethiopian individuals were retrieved from GenBank and analyzed for the presence of PDR mutations.

Rationale: The paper reports analyzing HIV-1 pol sequences from patient samples, indicating that sequences were obtained from individuals.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the analysis of HIV-1 pol sequences and the prevalence of PDR mutations, but does not mention any experiments or data related to in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that sequences of the included studies were downloaded from GenBank if they were publicly available.

Rationale: The paper explicitly states that the sequences used in the study were publicly available in GenBank.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 1070 sequences were analyzed from ART-naïve Ethiopian individuals.

Rationale: The paper states that 1070 sequences were analyzed, indicating that samples were obtained from 1070 individuals.

Answer: 1070
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Ethiopia.

Rationale: The paper explicitly states that the study was conducted in Ethiopia, indicating that the sequenced samples were obtained from this country.

Answer: Ethiopia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted between 2003 and 2018.

Rationale: The paper explicitly states that the study was conducted between 2003 and 2018, indicating the range of years from which the sequenced samples were obtained.

Answer: 2003-2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV-1 pol sequences were analyzed.

Rationale: The paper specifically mentions that HIV-1 pol sequences were analyzed, indicating that the pol gene was the one sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the sequencing method used.

Rationale: The paper does not mention the sequencing method used for the viral sequences.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that sequences were obtained from ART-naïve Ethiopian individuals.

Rationale: The paper does not explicitly state the type of samples sequenced, but it mentions that sequences were obtained from individuals.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention obtaining sequences from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention obtaining sequences from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study was conducted among ART-naïve Ethiopian individuals.

Rationale: The paper explicitly states that the study was conducted among ART-naïve individuals, indicating that the sequences were not obtained from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information on the drug classes received by individuals before sample sequencing.

Rationale: The paper does not provide specific information on the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information on the drugs received by individuals before sample sequencing.

Rationale: The paper does not provide specific information on the drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",78
37896785,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 genotyping and mutation detection were performed based on analysis of the nucleotide sequences of the *pol* gene region.

Rationale: The paper explicitly states that HIV-1 genotyping and mutation detection were performed, which involves sequencing HIV-1 *pol* gene from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Rationale: The paper focuses on the presence of drug resistance mutations rather than susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that the nucleotide sequences of 61 HIV-1 samples were obtained and deposited in GenBank (numbers OQ215322-OQ215382).

Rationale: The paper explicitly states that the sequences were deposited in GenBank, making them publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper mentions that the nucleotide sequences of 61 HIV-1 samples were obtained and deposited in GenBank (numbers OQ215322-OQ215382).

Rationale: The paper explicitly states that the sequences were deposited in GenBank, providing the accession numbers.

Answer: OQ215322-OQ215382
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that the study material was blood plasma samples from HIV-infected pregnant women: 31 women showed virological failure of ART, and 30 women had not previously received therapy.

Rationale: The paper explicitly states that samples were obtained from 61 individuals.

Answer: 61
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study material was blood plasma samples from HIV-infected pregnant women in Ho Chi Minh City, South Vietnam.

Rationale: The paper explicitly states that the samples were obtained from Vietnam.

Answer: Vietnam
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the blood plasma after taking the material from women was sampled in 2021.

Rationale: The paper explicitly states that the samples were obtained in 2021.

Answer: 2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV-1 genotyping and mutation detection were performed based on analysis of the nucleotide sequences of the *pol* gene region.

Rationale: The paper explicitly states that the *pol* gene region was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper explicitly states that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that the study material was blood plasma samples from HIV-infected pregnant women.

Rationale: The paper explicitly states that plasma samples were used.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that 31 women showed virological failure of ART.

Rationale: The paper explicitly states that sequences were obtained from individuals with virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention any clinical trial involvement.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that 31 women showed virological failure of ART.

Rationale: The paper explicitly states that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the most common first-line regimen included zidovudine (ZDV), lamivudine (3TC), and lopinavir/ritonavir (LPV/RTV).

Rationale: The paper explicitly states that the most common first-line regimen included NRTIs and PIs.

Answer: NRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the most common first-line regimen included zidovudine (ZDV), lamivudine (3TC), and lopinavir/ritonavir (LPV/RTV).

Rationale: The paper explicitly states that the most common first-line regimen included zidovudine (ZDV), lamivudine (3TC), and lopinavir/ritonavir (LPV/RTV).

Answer: Zidovudine (ZDV), Lamivudine (3TC), Lopinavir/ritonavir (LPV/RTV)
""""""",85
37896860,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV drug resistance mutations in children with virological failure on antiretroviral treatment in Kenya.

Rationale: The paper mentions that HIV drug resistance testing was performed on plasma samples from children with virological failure, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Rationale: The paper focuses on the presence of drug resistance mutations rather than susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention that the sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 704 children were enrolled in the study.

Rationale: The paper mentions that 704 children were enrolled in the study, but it does not specify how many had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted in Kenya.

Rationale: The paper mentions that the study was conducted in Kenya, indicating that the sequenced samples were obtained from this country.

Answer: Kenya
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The study was conducted from March 2019 to December 2020.

Rationale: The paper mentions the study period, indicating the years when the sequenced samples were obtained.

Answer: 2019-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information regarding whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV drug resistance testing was performed on plasma samples from children with virological failure.

Rationale: The paper does not specify which HIV genes were sequenced, but it mentions that HIV drug resistance testing was performed.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing was used for the sequencing of the PCR products.

Rationale: The paper explicitly mentions that Sanger sequencing was used for the sequencing of the PCR products.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were used for HIV drug resistance testing.

Rationale: The paper specifies that plasma samples were used for HIV drug resistance testing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper discusses the analysis of HIV drug resistance mutations in children with virological failure on antiretroviral treatment in Kenya.

Rationale: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper describes a randomized controlled trial.

Rationale: The paper explicitly mentions that the study was a randomized controlled trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the children were on antiretroviral treatment.

Rationale: The paper mentions that the children were on antiretroviral treatment, indicating that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the children were on antiretroviral treatment, including NNRTI and PI-containing regimens.

Rationale: The paper mentions that the children were on antiretroviral treatment, including NNRTI and PI-containing regimens.

Answer: NNRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the children were on antiretroviral treatment, including lamivudine, abacavir, lopinavir/ritonavir, and efavirenz.

Rationale: The paper mentions that the children were on antiretroviral treatment, including lamivudine, abacavir, lopinavir/ritonavir, and efavirenz.

Answer: Lamivudine, Abacavir, Lopinavir/ritonavir, Efavirenz
""""""",82
37910452,"Here are the answers to the questions in the format you requested:

### Question 1: Does the paper report HIV sequences from patient samples?

Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No

### Question 2: Does the paper report in vitro drug susceptibility data?

Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention in vitro drug susceptibility data.

Answer: No

### Question 3: Were sequences from the paper made publicly available?

Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention making sequences publicly available.

Answer: No

### Question 4: What were the GenBank accession numbers for sequenced HIV isolates?

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not mention GenBank accession numbers.

Answer: Not reported

### Question 5: How many individuals had samples obtained for HIV sequencing?

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

### Question 6: From which countries were the sequenced samples obtained?

Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained.

Answer: Not reported

### Question 7: From what years were the sequenced samples obtained?

Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the years from which the sequenced samples were obtained.

Answer: Not reported

### Question 8: Were samples cloned prior to sequencing?

Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention cloning of samples prior to sequencing.

Answer: Not reported

### Question 9: Which HIV genes were reported to have been sequenced?

Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not mention specific HIV genes that were sequenced.

Answer: Not reported

### Question 10: What method was used for sequencing?

Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported

### Question 11: What type of samples were sequenced?

Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention the type of samples that were sequenced.

Answer: Not reported

### Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention virological failure on a treatment regimen.

Answer: Not reported

### Question 13: Were the patients in the study in a clinical trial?

Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention a clinical trial.

Answer: Not reported

### Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Answer: Not reported

### Question 15: Which drug classes were received by individuals in the study before sample sequencing?

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention specific drug classes received by individuals in the study before sample sequencing.

Answer: Not reported

### Question 16: Which drugs were received by individuals in the study before sample sequencing?

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported",72
37914679,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the detection of pre-existing low-frequency resistance mutations in HIV-1-infected patients using the MiSeq second-generation sequencing platform.

Rationale: The paper focuses on the sequencing of HIV-1 from patient samples to detect pre-existing low-frequency resistance mutations.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the detection of pre-existing low-frequency resistance mutations in HIV-1-infected patients and their impact on virological response, but does not report any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any information about making the sequences publicly available.

Rationale: The paper does not mention whether the sequences obtained were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any specific GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 76 HIV-1-infected patients were enrolled in the study.

Rationale: The paper states that 76 patients were included in the study, confirming the number of individuals from whom samples were obtained for sequencing.

Answer: 76
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention any specific countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information about the countries from which the samples were obtained.

Answer: Not Found
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the patients were enrolled in the study during January 1, 2018 to December 31, 2020.

Rationale: The paper provides specific years during which the patients were enrolled in the study.

Answer: 2018-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any process of cloning samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the MiSeq second-generation sequencing platform was used to detect pre-existing low-frequency resistance mutations in HIV-1-infected patients.

Rationale: The paper does not specifically mention which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that the MiSeq second-generation sequencing platform was used to detect pre-existing low-frequency resistance mutations in HIV-1-infected patients.

Rationale: The paper specifies that the MiSeq second-generation sequencing platform was used for sequencing.

Answer: MiSeq second-generation sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were used for the study.

Rationale: The paper does not specifically mention the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included patients who failed antiviral therapy.

Rationale: The paper discusses the analysis of samples from patients who failed antiviral therapy, confirming that sequences were obtained from these individuals.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes the study as a retrospective study and does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the patients received ART and were followed up for 12 months.

Rationale: The paper discusses the analysis of samples from patients who received ART, indicating that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patients received 2NRTI + NNRTI in 77.6% of the cases.

Rationale: The paper lists specific drug classes that were received by the individuals before sample sequencing.

Answer: NRTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patients received 2NRTI + NNRTI in 77.6% of the cases.

Rationale: The paper does not specifically mention which drugs were received by the individuals before sample sequencing.

Answer: Not reported
""""""",80
37920909,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-1 integrase genes from 601 ART-naïve individuals, indicating that HIV sequences from patient samples were reported.

Rationale: The paper explicitly mentions the sequencing of HIV-1 integrase genes from patient samples, which is a clear indication that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or results.

Rationale: The paper focuses on the analysis of HIV-1 integrase genes and the prevalence of INSTI resistance mutations in patient samples, but it does not provide any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention whether the sequences obtained were made publicly available or provide any GenBank accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any specific GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that the HIV-1 integrase genes of 601 cases were sequenced successfully.

Rationale: The paper explicitly mentions the number of individuals who had their HIV-1 integrase genes sequenced.

Answer: 601
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention any specific countries from which the sequenced samples were obtained, but it does mention that the study was conducted in Tianjin, China.

Rationale: The paper does not provide information on the countries of origin for the sequenced samples, but it does indicate that the study was conducted in China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study recruited 629 ART-naïve individuals from Tianjin Second People's Hospital between January 1, 2020, and April 1, 2023.

Rationale: The paper explicitly mentions the years during which the samples were collected.

Answer: 2020-2023
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information on cloning procedures.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the HIV-1 integrase genes of 601 cases were sequenced successfully.

Rationale: The paper explicitly mentions the sequencing of HIV-1 integrase genes.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that an in-house genotyping method and standard Sanger sequencing were used to amplify and sequence HIV-1 integrase genes.

Rationale: The paper explicitly mentions the sequencing method used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that 5 mL of blood was collected from the participants.

Rationale: The paper explicitly mentions the type of sample used for sequencing.

Answer: Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention any virological failure on a treatment regimen.

Rationale: The paper focuses on ART-naïve individuals and does not discuss virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention any clinical trial involvement.

Rationale: The paper does not provide any information on clinical trial participation.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper focuses on ART-naïve individuals and does not discuss previous ARV drug use.

Rationale: The paper explicitly mentions that the study participants were ART-naïve.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any specific drug classes received by the individuals before sample sequencing.

Rationale: The paper focuses on ART-naïve individuals and does not discuss previous ARV drug use.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any specific drugs received by the individuals before sample sequencing.

Rationale: The paper focuses on ART-naïve individuals and does not discuss previous ARV drug use.

Answer: Not reported
""""""",79
37938856,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: 820

Rationale: The paper mentions that 820 women were enrolled in the study.

Answer: 820
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: Kenya

Rationale: The paper mentions that the study was conducted in Kenya.

Answer: Kenya
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: 2019-2022

Rationale: The paper mentions that the study was conducted from 2019 to 2022.

Answer: 2019-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not mention which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Plasma

Rationale: The paper mentions that plasma samples were used for VL testing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: Yes

Rationale: The paper mentions that some participants experienced viraemia during pregnancy and postpartum periods.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No

Rationale: The paper describes the study as a prospective cohort study, not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: Yes

Rationale: The paper mentions that some participants had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: NRTI, NNRTI, PI, INSTI

Rationale: The paper mentions that participants were on various ART regimens, including NRTIs, NNRTIs, PIs, and INSTIs.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: Various ART drugs

Rationale: The paper mentions that participants were on various ART regimens, including dolutegravir, emtricitabine, tenofovir alafenamide, efavirenz, lamivudine, and others.

Answer: Dolutegravir, Emtricitabine, Tenofovir alafenamide, Efavirenz, Lamivudine, and others
""""""",61
37941373,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that plasma samples were obtained from HIV-1 patients at Chongqing Public Health Medical Center from July 2019 to August 2022, and the HIV-1 IN gene was amplified by a validated In-house method.

Rationale: The paper explicitly states that plasma samples were obtained from HIV-1 patients and the HIV-1 IN gene was amplified, indicating that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the analysis of HIV-1 sequences and drug resistance mutations in patient samples, but it does not provide any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention that the sequences were made publicly available or provide any GenBank accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that samples were harvested from 1080 patients, and successful amplification of the IN gene was achieved in 1032 samples.

Rationale: The paper explicitly states that 1032 samples were successfully amplified and sequenced.

Answer: 1032
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Chongqing, China.

Rationale: The paper explicitly states that the study was conducted in Chongqing, China, indicating that the sequenced samples were obtained from China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that plasma samples were obtained from HIV-1 patients at Chongqing Public Health Medical Center from July 2019 to August 2022.

Rationale: The paper explicitly states that the samples were obtained from 2019 to 2022.

Answer: 2019-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper describes the amplification of the HIV-1 IN gene by a validated In-house method, but it does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the HIV-1 IN gene was amplified by a validated In-house method.

Rationale: The paper explicitly states that the HIV-1 IN gene was sequenced.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger dideoxy sequencing was employed for the identification of the clinically significant known drug resistance mutations.

Rationale: The paper explicitly states that Sanger sequencing was used for sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were obtained from HIV-1 patients at Chongqing Public Health Medical Center from July 2019 to August 2022.

Rationale: The paper explicitly states that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that some patients had resistance to INSTIs, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper discusses the presence of drug resistance mutations in patients with treatment, indicating that sequences were obtained from such individuals.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that some patients had resistance to INSTIs, indicating that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper discusses the presence of drug resistance mutations in patients with treatment, indicating that sequences were obtained from such individuals.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that patients received INSTIs, NNRTIs, and NRTIs before sample sequencing.

Rationale: The paper discusses the presence of drug resistance mutations in patients with treatment, indicating that sequences were obtained from such individuals.

Answer: INSTI, NNRTI, NRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that patients received dolutegravir, rilpivirine, lamivudine, tenofovir, crizaline, and efavirenz before sample sequencing.

Rationale: The paper explicitly states that these drugs were received by patients before sample sequencing.

Answer: Dolutegravir, Rilpivirine, Lamivudine, Tenofovir, Crizaline, Efavirenz
""""""",89
37946329,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that the partial pol gene sequence was successfully amplified in 921 patients, and the integrase (INT) gene sequence in 751 patients.

Rationale: The paper explicitly states that the partial pol gene sequence was successfully amplified in 921 patients, and the integrase (INT) gene sequence in 751 patients, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Rationale: The paper focuses on the analysis of drug resistance mutations and their prevalence in patient samples, but it does not mention conducting in vitro drug susceptibility tests.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates, indicating that the sequences were not made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that a total of 921 HIV-1 patients were included in the study.

Rationale: The paper explicitly states that a total of 921 HIV-1 patients were included in the study, indicating the number of individuals from whom samples were obtained for sequencing.

Answer: 921
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Henan Province, China.

Rationale: The paper explicitly states that the study was conducted in Henan Province, China, indicating the country of origin for the sequenced samples.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from June 2018 to April 2022.

Rationale: The paper explicitly states that the study was conducted from June 2018 to April 2022, indicating the years from which the sequenced samples were obtained.

Answer: 2018-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information regarding the cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the partial pol gene sequence was successfully amplified in 921 patients, and the integrase (INT) gene sequence in 751 patients.

Rationale: The paper explicitly states that the partial pol gene sequence and the integrase (INT) gene sequence were successfully amplified, indicating the specific genes sequenced.

Answer: Pol, Integrase
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the sequencing method used.

Rationale: The paper does not provide any information regarding the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were used for the study.

Rationale: The paper explicitly states that plasma samples were used for the study, indicating the type of clinical specimens sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included patients who failed in ART treatment.

Rationale: The paper explicitly states that the study included patients who failed in ART treatment, indicating that sequences were obtained from individuals with virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information regarding whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included patients who failed in ART treatment.

Rationale: The paper explicitly states that the study included patients who failed in ART treatment, indicating that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included patients who failed in ART treatment, and the most common regimens were NNRTI-based.

Rationale: The paper explicitly states that the study included patients who failed in ART treatment, and the most common regimens were NNRTI-based, indicating that NNRTIs were the drug class received before sample sequencing.

Answer: NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included patients who failed in ART treatment, and the most common regimens were NNRTI-based.

Rationale: The paper explicitly states that the study included patients who failed in ART treatment, and the most common regimens were NNRTI-based, but it does not provide specific drug names.

Answer: Not reported
""""""",87
37957382,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-1 sequences obtained from patient samples, specifically from CD4+ T cells in peripheral blood and lymph nodes of five HIV-1-infected individuals.

Rationale: The paper mentions the sequencing of HIV-1 from patient samples, specifically from CD4+ T cells in peripheral blood and lymph nodes of five HIV-1-infected individuals.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility data. It focuses on the analysis and comparison of sequences but does not mention depositing the sequences in GenBank or any other database.

Rationale: The paper does not mention any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. It mentions the use of sequences but does not specify the accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. It mentions the use of sequences but does not specify the accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that samples were obtained from 5 HIV-1-infected individuals who had been virally suppressed on ART for a median of 7.3 years (range, 1.8 to 13.4 years).

Rationale: The paper states that samples were obtained from 5 HIV-1-infected individuals.

Answer: 5
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the samples.

Rationale: The paper does not mention the country of origin for the samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the specific years during which the sequenced samples were obtained.

Rationale: The paper does not mention the specific years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing. It describes the use of single-genome amplification (SGA) and direct sequencing of PCR products.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions the sequencing of the *env* gene from PBMCs of the two elite controllers.

Rationale: The paper mentions the sequencing of the *env* gene from PBMCs of the two elite controllers.

Answer: Env
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not mention the sequencing method.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper describes the sequencing of mononuclear cells from lymph nodes (LNMCs), PBMCs, and plasma.

Rationale: The paper describes the sequencing of mononuclear cells from lymph nodes (LNMCs), PBMCs, and plasma.

Answer: Plasma, PBMC, LNMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that one participant had a viral rebound at the time of sampling, indicating virological failure.

Rationale: The paper mentions that one participant had a viral rebound at the time of sampling, indicating virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the blood samples were collected in a cohort who had suppressed viral loads, which means the individuals had received ARV drugs.

Rationale: The paper mentions that the blood samples were collected in a cohort who had suppressed viral loads, which means the individuals had received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the blood samples were collected in a cohort who had suppressed viral loads, which means the individuals had received ARV drugs, but the drug classes and treatment history were not reported.

Rationale: The paper mentions that the blood samples were collected in a cohort who had suppressed viral loads, which means the individuals had received ARV drugs, but the drug classes and treatment history were not reported.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the blood samples were collected in a cohort who had suppressed viral loads, which means the individuals had received ARV drugs, but the drugs and treatment history were not reported.

Rationale: The paper mentions that the blood samples were collected in a cohort who had suppressed viral loads, which means the individuals had received ARV drugs, but the drugs and treatment history were not reported.

Answer: Not reported
""""""",96
37966701,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not provide any information regarding in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information about the countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not specify whether samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide information about the specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not provide information about virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide information about the patients' previous treatment history.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information about the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information about the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",57
37973713,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-1 sequences from patient samples, including their corresponding GenBank accession numbers.

Rationale: The paper mentions the analysis of HIV-1 sequences from patient samples, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Rationale: The paper focuses on the presence of drug resistance mutations rather than susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not provide specific information about the number of individuals from whom samples were obtained for sequencing.

Rationale: The paper does not provide specific information about the number of individuals from whom samples were obtained for sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study included patients from Ukraine and Poland.

Rationale: The paper specifies that the study included patients from Ukraine and Poland.

Answer: Ukraine, Poland
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted during 2 years period (2020--2022).

Rationale: The paper specifies that the study was conducted during 2 years period (2020--2022).

Answer: 2020-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the drug resistance genotyping of HIV-1 protease (PR) and reverse transcriptase (RT) coding region was performed.

Rationale: The paper specifies that the drug resistance genotyping of HIV-1 protease (PR) and reverse transcriptase (RT) coding region was performed.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that the drug resistance genotyping of HIV-1 protease (PR) and reverse transcriptase (RT) coding region was performed based on a Sanger sequencing method.

Rationale: The paper specifies that the drug resistance genotyping of HIV-1 protease (PR) and reverse transcriptase (RT) coding region was performed based on a Sanger sequencing method.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not specify the exact type of clinical specimens sequenced.

Rationale: The paper does not specify the exact type of clinical specimens sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention that the patients were experiencing virological failure on a treatment regimen.

Rationale: The paper does not mention that the patients were experiencing virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the clinical trial received a positive opinion from the Bioethics Committee at the Medical University of Warsaw and was registered on clinicaltrials.gov.

Rationale: The paper specifies that the clinical trial received a positive opinion from the Bioethics Committee at the Medical University of Warsaw and was registered on clinicaltrials.gov.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that among the analyzed cohorts, 44% of patients had DRMs, indicating that some sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper mentions that among the analyzed cohorts, 44% of patients had DRMs, indicating that some sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patients were receiving ART with thymidine analogue treatment, and were receiving zidovudine, lamivudine, or didanosine.

Rationale: The paper mentions that the patients were receiving ART with thymidine analogue treatment, and were receiving zidovudine, lamivudine, or didanosine.

Answer: NRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patients were receiving zidovudine, lamivudine, or didanosine.

Rationale: The paper mentions that the patients were receiving zidovudine, lamivudine, or didanosine.

Answer: Zidovudine (AZT), Lamivudine (3TC), Didanosine (DDI)
""""""",89
37976080,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: A total of 2869 HIV-positive individuals were initially recruited into the study. After removal of 16 HIV-positive individuals who were younger than 18 years and 9 individuals who had not started ART, the penultimate sample size was 2844. PDR test results were available for 90.3% (n=2568) of participants in RT/PR regions, thus yielding a final sample size of 2568.

Rationale: The paper mentions that a total of 2568 HIV-positive individuals were included in the study, and PDR test results were available for them, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention that the sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not mention the GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 2869 HIV-positive individuals were initially recruited into the study. After removal of 16 HIV-positive individuals who were younger than 18 years and 9 individuals who had not started ART, the penultimate sample size was 2844. PDR test results were available for 90.3% (n=2568) of participants in RT/PR regions, thus yielding a final sample size of 2568.

Rationale: The paper states that a total of 2568 HIV-positive individuals were included in the study, and PDR test results were available for them, indicating the number of individuals from whom samples were obtained for sequencing.

Answer: 2568
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: We selected 8 provincial-level administrative divisions (PLADs) in China as the study area to conduct a large multicenter observational cross-sectional study.

Rationale: The paper mentions that the study was conducted in 8 provincial-level administrative divisions in China, indicating the country from which the sequenced samples were obtained.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: Recruitment and specimen collection of HIV-positive individuals occurred in 2022 as individuals initiated ART.

Rationale: The paper mentions that the recruitment and specimen collection occurred in 2022, indicating the year from which the sequenced samples were obtained.

Answer: 2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The HIV pol gene region (HXB2: 2253-3553 nt) was amplified, which covered the PR region (4-99 amino acids) and the partial RT region (1-251 amino acids).

Rationale: The paper mentions that the HIV pol gene region was amplified, which includes the PR and RT regions.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: Sanger sequencing

Rationale: The paper mentions that Sanger sequencing was used for the sequencing of the PCR products.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Viral RNA was extracted from 200 µL plasma samples using the QIAamp viral RNA mini kit (Qiagen, Hilton, Germany) according to the operational instructions.

Rationale: The paper mentions that viral RNA was extracted from plasma samples, indicating the type of clinical specimens used.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: 3.2% (n=81) of participants had prior ARV drug exposure.

Rationale: The paper mentions that 3.2% of participants had prior ARV drug exposure, indicating that some sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention the specific drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",83
37976185,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-DNA sequences obtained from patient samples.

Rationale: The paper mentions the analysis of HIV-DNA sequences, which indicates that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Rationale: The paper focuses on the presence of drug resistance mutations rather than susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not provide specific information on the number of individuals whose samples were obtained for HIV sequencing.

Rationale: The paper does not provide specific information on the number of individuals whose samples were obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide specific information on the countries where the samples were obtained.

Rationale: The paper does not provide specific information on the countries where the samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific information on the years during which the samples were obtained.

Rationale: The paper does not provide specific information on the years during which the samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not provide specific information on the HIV genes that were sequenced.

Rationale: The paper does not provide specific information on the HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not provide specific information on the sequencing method used.

Rationale: The paper does not provide specific information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not provide specific information on the type of samples that were sequenced.

Rationale: The paper does not provide specific information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not provide specific information on whether sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide specific information on whether sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide specific information on whether the patients were part of a clinical trial.

Rationale: The paper does not provide specific information on whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not provide specific information on whether sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper does not provide specific information on whether sequences were obtained from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information on the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not provide specific information on the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information on the drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide specific information on the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",75
37993493,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Viral load testing was performed using Roche cobas 6800/8800 systems with a lower limit of detection of 15 copies/mL. Given that we followed the current Tanzania national HIV treatment guidelines, only samples with viral load count ≥ 1000 copies/mL were subjected to analysis of HIVDR mutations.""

Rationale: The paper mentions that viral load testing was performed on patient samples, and HIVDR mutations were analyzed in samples with a viral load count ≥ 1000 copies/mL.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""The detection of high-level resistance against NRTs and NNRTIs was consistent with patients' treatment history. Furthermore, patients with INSTI mutations and high level INSTI resistance (MC-243, MC-367 and CR-048) had a history of using DTG-based regimen.""

Rationale: The paper does not report in vitro drug susceptibility data. Instead, it discusses the detection of high-level resistance against NRTs and NNRTIs based on patients' treatment history and INSTI mutations.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""The datasets used and/or analysed during the current study are available in the National Centre for Biotechnology Information GenBank.""

Rationale: The paper does not explicitly state that the sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""The datasets used and/or analysed during the current study are available in the National Centre for Biotechnology Information GenBank.""

Rationale: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""In total 600 individuals participated in this survey, the majority were female (76.83%), mean age ( ± standard deviation) was 44.0 ( ± 11.6) years.""

Rationale: The paper states that 600 individuals participated in the survey, but it does not specify how many had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""This study aimed at determining the prevalence of viral suppression and HIV drug resistance (HIVDR) among a random sample of 600 HIV treatment-experienced adults (18 years and above) living in Ukonga and Gongolamboto, Dar es Salaam, three years after the introduction of dolutegravir (DTG)-based antiretroviral therapy (ART).""

Rationale: The paper mentions that the study was conducted in Dar es Salaam, Tanzania.

Answer: Tanzania
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""This study aimed at determining the prevalence of viral suppression and HIV drug resistance (HIVDR) among a random sample of 600 HIV treatment-experienced adults (18 years and above) living in Ukonga and Gongolamboto, Dar es Salaam, three years after the introduction of dolutegravir (DTG)-based antiretroviral therapy (ART).""

Rationale: The paper does not specify the exact years when the samples were obtained, but it mentions that the study was conducted three years after the introduction of DTG-based ART.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""We used Management and Development for Health (MDH) WHO adapted protocol (Unpublished) to perform HIVDR testing using the 3500xL genetic analyser (Applied Biosystems), a capillary sequencer using Sanger-style sequencing.""

Rationale: The paper does not mention cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""The sequenced codons were 6--99, 1--251, and 1--288, for protease, reverse transcriptase and integrase proteins, respectively.""

Rationale: The paper mentions that the protease, reverse transcriptase, and integrase genes were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""We used Management and Development for Health (MDH) WHO adapted protocol (Unpublished) to perform HIVDR testing using the 3500xL genetic analyser (Applied Biosystems), a capillary sequencer using Sanger-style sequencing.""

Rationale: The paper mentions that Sanger-style sequencing was used for HIVDR testing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Viral load testing was performed using Roche cobas 6800/8800 systems with a lower limit of detection of 15 copies/mL. Given that we followed the current Tanzania national HIV treatment guidelines, only samples with viral load count ≥ 1000 copies/mL were subjected to analysis of HIVDR mutations.""

Rationale: The paper mentions that plasma samples were used for viral load testing and HIVDR mutation analysis.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Out of 33 patients with high viral load (≥ 1000 copies/mL) despite taking ART, 30 (90.91%) were using a DTG-based regimen, mostly TDF + 3TC + DTG, two patients were using ABC + 3TC + LPV/r, and one was taking ABC + 3TC + ATV/r.""

Rationale: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""A cross-sectional survey was conducted between February and May 2023 in the Dar es Salaam Urban Cohort Study (DUCS) platform of the Ilala district in Dar es Salaam.""

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Out of 33 patients with high viral load (≥ 1000 copies/mL) despite taking ART, 30 (90.91%) were using a DTG-based regimen, mostly TDF + 3TC + DTG, two patients were using ABC + 3TC + LPV/r, and one was taking ABC + 3TC + ATV/r.""

Rationale: The paper mentions that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Out of 33 patients with high viral load (≥ 1000 copies/mL) despite taking ART, 30 (90.91%) were using a DTG-based regimen, mostly TDF + 3TC + DTG, two patients were using ABC + 3TC + LPV/r, and one was taking ABC + 3TC + ATV/r.""

Rationale: The paper mentions that individuals received NRTIs (TDF, 3TC, ABC), PIs (LPV, ATV), and INSTIs (DTG) before sample sequencing.

Answer: NRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""Out of 33 patients with high viral load (≥ 1000 copies/mL) despite taking ART, 30 (90.91%) were using a DTG-based regimen, mostly TDF + 3TC + DTG, two patients were using ABC + 3TC + LPV/r, and one was taking ABC + 3TC + ATV/r.""

Rationale: The paper mentions that individuals received TDF, 3TC, ABC, LPV, ATV, and DTG before sample sequencing.

Answer: TDF, 3TC, ABC, LPV, ATV, DTG
""""""",126
38005921,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. Instead, it focuses on laboratory-generated recombinant enzymes and mutations in integrase proteins from different HIV subtypes.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates. It mentions the use of sequences from GenBank but does not list the accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates. It mentions the use of sequences from GenBank but does not list the accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not specify the number of individuals from whom samples were obtained for HIV sequencing. It focuses on the methodology and results of the sequencing study.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific years during which the sequenced samples were obtained. It focuses on the methodology and results of the sequencing study.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: IN

Rationale: The paper focuses on the integrase (IN) gene of HIV-1.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper doesn't mention the sequencing method.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention that the patients were experiencing virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not provide any information indicating that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not specify the drug classes received by individuals in the study before sample sequencing. It only mentions that the participants were on suppressive ART.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not specify the drug classes received by individuals in the study before sample sequencing. It only mentions that the participants were on suppressive ART.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not specify the drug classes received by individuals in the study before sample sequencing. It only mentions that the participants were on suppressive ART.

Answer: Not reported
""""""",65
38020274,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses genotypic resistance testing performed on patient samples to determine resistance mutations.

Rationale: The paper mentions that genotypic resistance testing was performed on patient samples, which indicates that HIV sequences were obtained from these samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on genotypic resistance testing and the identification of drug resistance mutations in patient samples, but it does not mention any in vitro drug susceptibility assays or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates, indicating that the sequences were not made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 311 APHI were included at the enrolment phase (T1) with 272 followed-up at 6-months (T2), and 243 at 12-months (T3).

Rationale: The paper states that 311 APHI were included at the enrolment phase, indicating the number of individuals from whom samples were obtained for sequencing.

Answer: 311
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Cameroon.

Rationale: The paper states that the study was conducted in Cameroon, indicating the country from which the sequenced samples were obtained.

Answer: Cameroon
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from 2018-2020.

Rationale: The paper states that the study was conducted from 2018-2020, indicating the years from which the sequenced samples were obtained.

Answer: 2018-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, indicating that this step was not performed.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that genotypic resistance testing was carried out at each time point among participants with plasma viral load (PVL) ≥1,000 RNA copies/ml using an in-house protocol as previously described by our working group (10) using blood samples stored at -80˚C.

Rationale: The paper does not specify which HIV genes were sequenced, but it mentions that genotypic resistance testing was performed.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the sequencing method used.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that blood samples were stored at -80˚C for genotypic resistance testing.

Rationale: The paper states that blood samples were used for genotypic resistance testing, indicating the type of clinical specimens used.

Answer: Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that genotypic resistance testing was carried out at each time point among participants with plasma viral load (PVL) ≥1,000 RNA copies/ml.

Rationale: The paper specifically focuses on individuals with virological failure, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information indicating that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the participants were on prolonged ART.

Rationale: The paper mentions that the participants were on prolonged ART, indicating that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the participants were on RTI-based first-line ART and PI/r-based second-line ART.

Rationale: The paper specifies that the participants were on RTI-based first-line ART and PI/r-based second-line ART, indicating the drug classes received by individuals in the study before sample sequencing.

Answer: RTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the participants were on RTI-based first-line ART and PI/r-based second-line ART.

Rationale: The paper specifies that the participants were on RTI-based first-line ART and PI/r-based second-line ART, but it does not provide specific names of the drugs received by the individuals in the study.

Answer: Not reported
""""""",89
38022124,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention any HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 116 patients, 66 (56.9%) treatment-experienced and 50 (43.1%) naive, were evaluated within the scope of the study.

Rationale: The paper mentions the number of patients included in the study.

Answer: 116
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted in Turkey.

Rationale: The paper mentions the country where the study was conducted.

Answer: Turkey
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The study was conducted between June 2020 and June 2022.

Rationale: The paper mentions the years during which the study was conducted.

Answer: 2020-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not mention any specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention any sequencing methods.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not mention any type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not report any sequences obtained from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not report any HIV sequences from individuals, regardless of their previous ARV drug history.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide specific names of the drugs received by the individuals in the study.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide specific names of the drugs received by the individuals in the study.

Answer: Not reported
""""""",59
38031075,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide specific information about the number of individuals from whom samples were obtained for sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific information about the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide specific information about the HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not provide specific information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not provide specific information about the type of clinical specimens sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not provide specific information about the virological status of the individuals from whom sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not provide specific information about whether the patients were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide specific information about the treatment history of the individuals from whom sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide specific information about the drug classes received by the individuals in the study.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide specific information about the drugs received by the individuals in the study.

Answer: Not reported
""""""",59
38033131,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""A total of 492 children and adolescent HIV patients were followed for different periods for a total of 20,169 Person Months (PM) observations.""

Rationale: The paper does not explicitly mention HIV sequences from patient samples. However, it does mention that the study followed HIV patients and collected data on their treatment outcomes, which suggests that some form of biological sample may have been collected.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""The study participants were followed for a minimum of 10 months and a maximum of 60 months The incidence rate of first-line ART virological failure was 4.2 per1000 follow-up months (95% CI: 3.41, 5.22).""

Rationale: The paper does not report in vitro drug susceptibility data. It focuses on the incidence rate of virological failure in HIV patients on first-line ART.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not mention making sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""A total of 492 children and adolescent HIV patients were followed for different periods for a total of 20,169 Person Months (PM) observations.""

Rationale: The paper does not explicitly mention the number of individuals who had samples obtained for HIV sequencing. However, it does mention that 492 children and adolescent HIV patients were followed in the study.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""The study was conducted in five Oromia regional public hospitals namely Adama college referral hospital, Bishoftu general hospital, Olenchity hospital, Batu hospital and Mojo hospital.""

Rationale: The paper does not explicitly mention the country of origin for the sequenced samples. However, it does mention that the study was conducted in Oromia regional public hospitals in Ethiopia.

Answer: Ethiopia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""The study was conducted from January 2015 to December 2019.""

Rationale: The paper mentions the study period, which suggests that the samples were obtained during this time frame.

Answer: 2015-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""No evidence""

Rationale: The paper does not mention which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""No evidence""

Rationale: The paper does not mention the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""The incidence rate of first-line ART virological failure was 4.2 per1000 follow-up months (95% CI: 3.41, 5.22).""

Rationale: The paper mentions virological failure in HIV patients on first-line ART, which suggests that sequences may have been obtained from individuals with virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""The study was a retrospective follow-up study.""

Rationale: The paper does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""The study participants were on first-line ART.""

Rationale: The paper mentions that the study participants were on first-line ART, which suggests that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""The majority of study participants were initiated on NVP-based NNRTI regimen.""

Rationale: The paper mentions that the majority of study participants were initiated on NVP-based NNRTI regimen, which suggests that they received NNRTI drugs before sample sequencing.

Answer: NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""The majority of study participants were initiated on NVP-based NNRTI regimen.""

Rationale: The paper mentions that the majority of study participants were initiated on NVP-based NNRTI regimen, which suggests that they received NVP drugs before sample sequencing.

Answer: NVP
""""""",83
38058846,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper describes three cases of treatment-emergent resistance to nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) in patients with suboptimal treatment adherence and assess whether the resistance-associated mutations were present before BIC/TAF/FTC initiation or emerged during therapy.

Rationale: The paper discusses the sequencing of HIV from patient samples to identify resistance mutations.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility testing or results.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention whether the sequences obtained were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper describes three cases of patients from whom HIV sequencing was performed.

Rationale: The paper presents three cases of patients from whom HIV sequencing was performed.

Answer: 3
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not specify the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information regarding the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific years for when the sequenced samples were obtained.

Rationale: The paper does not provide information regarding the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that genotypic HIV drug resistance testing for NRTI  and INSTI was performed, which typically involves sequencing the reverse transcriptase, and integrase genes.

Rationale: The paper mentions that genotypic HIV drug resistance testing for NRTI  and INSTI was performed.

Answer: RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the exact sequencing method used for genotypic resistance testing.

Rationale: The paper does not provide information regarding the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper specifies that plasma viral load specimens were used for sequencing.

Rationale: The paper mentions that plasma viral load specimens were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper describes cases of individuals who developed treatment-emergent resistance mutations, which means sequences were from individuals who had virological failure.

Rationale: The paper discusses cases of virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The study is a case report.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper describes cases of individuals who had treatment-emergent resistance, which means sequences were from individuals who had previously received ARV drugs.

Rationale: The paper discusses cases of treatment-emergent resistance.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper lists various antiretroviral drugs from different classes that were received by the individuals before sample sequencing.

Rationale: The paper lists various antiretroviral drugs from different classes.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper lists specific antiretroviral drugs that were received by the individuals before sample sequencing.

Rationale: The paper lists specific antiretroviral drugs.

Answer: DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c.
""""""",76
38072961,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses a case report involving a patient with HIV infection and mentions the use of genotypic drug resistance testing by Sanger sequencing to identify emergent resistance mutations in plasma viral load specimens collected after combination antiretroviral therapy initiation.

Rationale: The paper describes the use of genotypic drug resistance testing by Sanger sequencing on plasma viral load specimens collected from a patient with HIV infection, indicating that HIV sequences from patient samples were analyzed.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or results.

Rationale: The paper focuses on the clinical case and the genotypic resistance findings without mentioning specific in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention whether the sequences obtained were made publicly available.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper describes a single case report involving a patient with HIV infection.

Rationale: The paper focuses on one individual, indicating that only one person had samples obtained for sequencing.

Answer: 1
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention any specific countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the countries from which the sequenced samples were obtained.

Answer: Not Found
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific years for when the sequenced samples were obtained.

Rationale: The paper does not mention any specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions genotypic resistance tests for reverse transcriptase, protease, and integrase genes.

Rationale: The paper describes the sequencing of the protease, reverse transcriptase, and integrase genes for resistance genotyping.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions the use of Sanger sequencing for genotypic drug resistance testing.

Rationale: The paper describes the use of Sanger sequencing for genotypic drug resistance testing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper specifies that plasma samples were analyzed.

Rationale: The paper mentions that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper describes a patient with virological failure on multiple treatment regimens, and sequences were obtained from this individual.

Rationale: The paper discusses a patient with virological failure on multiple treatment regimens, indicating that sequences were obtained from such individuals.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information about the patients being part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper describes a patient who has been on multiple antiretroviral treatment regimens and had virologic failure.

Rationale: The paper discusses a patient who has been on multiple antiretroviral treatment regimens, indicating that sequences were from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper lists various antiretroviral drugs from different classes that the patients received before the genotypic resistance tests.

Rationale: The paper describes the use of different antiretroviral drugs from various classes, including NRTI, NNRTI, PI, and INSTI.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper lists specific antiretroviral drugs that were received by the individuals before sample sequencing.

Rationale: The paper describes the use of specific antiretroviral drugs, including Lamivudine (3TC), Zidovudine (AZT), Emtricitabine (FTC), Tenofovir (TFV), Efavirenz (EFV), Lopinavir (LPV), Dolutegravir (DTG).

Answer: Lamivudine (3TC), Zidovudine (AZT), Emtricitabine (FTC), Tenofovir (TFV), Efavirenz (EFV), Lopinavir (LPV), Dolutegravir (DTG)
""""""",89
38090027,"Here are the answers to the questions in the format you requested:

### Question 1: Does the paper report HIV sequences from patient samples?

Evidence: ""A validated in-house method was used to identify resistance-associated mutations (RAMs), as previously described by our group. 11 GRT on plasma HIV-RNA and PBMC HIV-DNA was interpreted according to the Stanford University HIV Drug Resistance Database version 9.0 (hivdb.stanford.edu/hivdb/by-sequences/, last updated on 22 June 2023).""

Rationale: The paper mentions the use of a validated in-house method to identify resistance-associated mutations (RAMs) from plasma HIV-RNA and PBMC HIV-DNA, indicating that HIV sequences were obtained from patient samples.

Answer: Yes

### Question 2: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Answer: No

### Question 3: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No

### Question 4: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

### Question 5: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Overall, 1040 patients who met the above-mentioned inclusion criteria were considered in the analysis""

Rationale: The paper mentions that 1040 patients were included in the analysis, indicating the number of individuals from whom samples were obtained for sequencing.

Answer: 1040

### Question 6: From which countries were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not specify the country from which the sequenced samples were obtained.

Answer: Not reported

### Question 7: From what years were the sequenced samples obtained?

Evidence: ""The retrospective cohort study, which included adult treatment-experienced and virologically suppressed PLWH, switched to BFTAF from June 2019 to June 2021.""

Rationale: The paper mentions the years during which the samples were obtained, specifically from June 2019 to June 2021.

Answer: 2019-2021

### Question 8: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No

### Question 9: Which HIV genes were reported to have been sequenced?

Evidence: ""GRT on plasma HIV-RNA and PBMC HIV-DNA was interpreted according to the Stanford University HIV Drug Resistance Database version 9.0""

Rationale: The paper mentions the use of the Stanford University HIV Drug Resistance Database, which typically involves sequencing of the protease, reverse transcriptase, and integrase genes.

Answer: PR, RT, IN

### Question 10: What method was used for sequencing?

Evidence: ""A validated in-house method was used to identify resistance-associated mutations (RAMs), as previously described by our group.""

Rationale: The paper mentions the use of a validated in-house method for sequencing, but does not specify the exact method used.

Answer: Not reported

### Question 11: What type of samples were sequenced?

Evidence: ""GRT on plasma HIV-RNA and PBMC HIV-DNA was interpreted according to the Stanford University HIV Drug Resistance Database version 9.0""

Rationale: The paper mentions that plasma HIV-RNA and PBMC HIV-DNA were sequenced.

Answer: Plasma, PBMC

### Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""VF occurred in 44 (4.2%) patients, with an incidence rate of 1.63 (95% CI 1.16--2.11) per 1000 PMFU; this event occurred after a median of 12.8 (5.8--22.8) months of observation.""

Rationale: The paper mentions that sequences were obtained from individuals who experienced virological failure on the BFTAF treatment regimen.

Answer: Yes

### Question 13: Were the patients in the study in a clinical trial?

Evidence: ""The retrospective cohort study, which included adult treatment-experienced and virologically suppressed PLWH, switched to BFTAF from June 2019 to June 2021.""

Rationale: The paper describes the study as a retrospective cohort study, not a clinical trial.

Answer: No

### Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""The median duration of prior ARV treatment for the 43 virologically suppressed participants was 2.8 (range, 0.3–14.9) years.""

Rationale: The paper mentions that the participants had previously received ARV drugs, indicating that sequences were obtained from individuals with a history of ARV drug treatment.

Answer: Yes

### Question 15: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Most patients (52.4%) were NNRTI-experienced in the DTG plus RPV group, and (42.2%) had INSTI in the DTG plus 3TC group.""

Rationale: The paper mentions that individuals in the study had experience with NNRTI and INSTI drug classes prior to sample sequencing.

Answer: NRTI, NNRTI, INSTI

### Question 16: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""The median duration of prior ARV treatment for the 43 virologically suppressed participants was 2.8 (range, 0.3–14.9) years. Of the 43 virologically suppressed participants, most were on NNRTI-based regimens (32/43; 74.4%) prior to study entry, while 10 (23.3%) were on PI-based and 1 (2.3%) was on an INSTI-based regimen.""

Rationale: The paper lists specific antiretroviral drugs that were received by the individuals before sample sequencing, including NNRTIs, PIs, and INSTIs.

Answer: DOR, 3TC, TDF",101
38140553,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that the study analyzed 3178 HIV-1 pol sequences obtained from HIV-infected patients from seven Russian federal districts.

Rationale: The paper explicitly states that the study analyzed HIV-1 sequences from patient samples, indicating that the study involved sequencing HIV from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to drug resistance assays in a laboratory setting.

Rationale: The paper focuses on the analysis of HIV-1 sequences and the identification of recombinant forms and drug resistance mutations, but it does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states that all nucleotide sequences obtained in the study were deposited in the international database of the Los Alamos laboratory.

Rationale: The paper explicitly mentions that the sequences were made publicly available in the Los Alamos laboratory database.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that the study analyzed 3178 HIV-1 pol sequences obtained from HIV-infected patients from seven Russian federal districts.

Rationale: The paper explicitly states that the study analyzed sequences from 3178 individuals.

Answer: 3178
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study analyzed sequences from HIV-infected patients from seven Russian federal districts.

Rationale: The paper explicitly states that the samples were obtained from Russia.

Answer: Russia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study analyzed sequences from HIV-infected patients from 2011 to 2020.

Rationale: The paper explicitly states that the samples were obtained from 2011 to 2020.

Answer: 2011-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the study analyzed HIV-1 pol sequences, which include the protease (PR) and part of the reverse transcriptase (RT) genes.

Rationale: The paper explicitly states that the study analyzed the pol region of the HIV-1 genome, which includes the PR and RT genes.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger-based sequencing was used for the HIV-1 pol region.

Rationale: The paper explicitly states that Sanger-based sequencing was used for the HIV-1 pol region.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that blood plasma, peripheral blood mononuclear cells (lymphocytes), and frozen whole blood samples were used for sequencing.

Rationale: The paper explicitly states that different types of samples were used for sequencing, including plasma, lymphocytes, and whole blood.

Answer: Plasma; Lymphocytes; Whole blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention obtaining sequences from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention any information about virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention any information about a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that some patients had previously received ARV drugs, but it does not provide specific information on the treatment history and drugs being received.

Rationale: The paper mentions that some patients had previously received ARV drugs, but it does not provide specific information on the treatment history and drugs being received.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information on the drug classes received by individuals before sample sequencing.

Rationale: The paper does not provide specific information on the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information on the drugs received by individuals before sample sequencing.

Rationale: The paper does not provide specific information on the drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",85
38140649,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 RNA plasma samples were collected from newly diagnosed HIV patients over a four-year period during the diagnostic process and clinical follow-up at UHID.

Rationale: The paper specifically focuses on the analysis of HIV-1 sequences from patient samples, indicating that the study involved sequencing HIV from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Rationale: The paper focuses on the presence of drug resistance mutations rather than susceptibility, and does not mention performing in vitro drug susceptibility assays.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states that all sequences obtained in this study by SS were submitted to the GeneBank nucleotide sequence database under accession numbers OR605755-OR606279 and OR613869-OR613875.

Rationale: The paper explicitly states that the sequences were submitted to GeneBank, confirming that the sequences can be accessed.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper states that all sequences obtained in this study by SS were submitted to the GeneBank nucleotide sequence database under accession numbers OR605755-OR606279 and OR613869-OR613875.

Rationale: The paper explicitly lists the GenBank accession numbers for the sequenced HIV isolates.

Answer: OR605755-OR606279, OR613869-OR613875
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that a total of 280 newly diagnosed treatment-naïve persons entered the Croatian Reference Centre for HIV-AIDS, but 10 people did not meet the inclusion criteria, so the final data set consisted of 270 persons.

Rationale: The paper states that 270 persons met the inclusion criteria.

Answer: 270
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted at the Department for Immunological and Molecular Diagnostics at UHID, and the majority of the patients originated from and reported Croatia as the country of infection.

Rationale: The paper specifies that the study was conducted in Croatia, and the majority of the patients were from Croatia.

Answer: Croatia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from January 2019 to December 2022.

Rationale: The paper specifies the time frame during which the samples were collected.

Answer: 2019-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any process of cloning samples prior to sequencing.

Rationale: The paper focuses on the direct analysis of the plasma RNA.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that amplification of the HIV-1 *pol* gene was performed for two regions in two separate reactions: (1) sequencing of the HIV-1 protease and partial sequencing of the reverse transcriptase gene; and (2) sequencing of the HIV-1 integrase gene.

Rationale: The paper specifies the genes that were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that nested PCR amplicons were purified and sequenced with a BigDye Terminator v3.1 Cycle Sequencing Kit.

Rationale: The paper describes the use of Sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper specifies the type of clinical specimens sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included treatment-naïve individuals, but it does not mention virological failure on a treatment regimen.

Rationale: The paper focuses on treatment-naïve individuals, meaning that the participants had not previously received antiretroviral drugs.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes the collection of samples from HIV-1-infected patients, but it does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included treatment-naïve individuals, meaning that the participants had not previously received antiretroviral drugs.

Rationale: The paper specifically focuses on treatment-naïve individuals.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper focuses on treatment-naïve individuals, meaning that the participants had not previously received antiretroviral drugs.

Answer: nan
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the drugs received by individuals in the study before sample sequencing.

Rationale: The paper focuses on treatment-naïve individuals, meaning that the participants had not previously received antiretroviral drugs.

Answer: nan
""""""",93
38140667,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses various studies and cases involving HIV sequences from patient samples, including genotypic resistance tests and integrase sequencing.

Rationale: The paper focuses on treatment-emergent resistance to integrase strand transfer inhibitors (INSTIs) in HIV patients, which involves analyzing HIV sequences from patient samples to identify resistance mutations.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data. Instead, it focuses on clinical cases of treatment-emergent resistance to nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) in HIV patients treated with bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC).

Rationale: The paper does not report in vitro drug susceptibility data because it primarily focuses on clinical outcomes and resistance analyses from the CAPELLA study.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates, indicating that the sequences were not made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 358 people living with HIV who switched to DTG + 3TC before August 2019 were included in the analysis.

Rationale: The paper population comprised 358 people with HIV (PWH) who were included in the analysis.

Answer: 358
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Spain.

Rationale: The study was conducted at Hospital Universitario La Paz in Madrid, Spain, and the patient cohort was from this center.

Answer: Spain
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study included data from patients who were prescribed DTG-2DR from January 1, 2015, to October 31, 2021.

Rationale: The study includes data from patients who were prescribed DTG-2DR from January 1, 2015, to October 31, 2021.

Answer: 2015-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that historical protease, transcriptase, and integrase resistance mutations were collected.

Rationale: The paper mentions that historical protease, transcriptase, and integrase resistance mutations were collected, indicating that these genes were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing was performed for the protease, reverse transcriptase (RT), and integrase genes during the standard follow-up of patients.

Rationale: The paper states that Sanger sequencing was performed for the protease, reverse transcriptase (RT), and integrase genes during the standard follow-up of patients.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples from three time points and cells (buffy coat/peripheral blood mononuclear cells [PBMCs]) from two time points were collected (S1, S2 & S3) for further investigation.

Rationale: The paper mentions that plasma samples and PBMCs were collected and sequenced.

Answer: Plasma, PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that resistance tests were performed on individuals who experienced virological failure.

Rationale: The paper mentions that resistance tests were performed on individuals who experienced virological failure, and specific mutations were identified in one person with a high viral load.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper explicitly states that patients in clinical trials were excluded from the study.

Rationale: The paper explicitly states that patients in clinical trials were excluded from the study.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included treatment-experienced patients who started DTG + 3TC in a cohort of PWH, and the study population had a median number of previous antiretroviral combinations of three.

Rationale: The paper mentions that the study included treatment-experienced patients who started DTG + 3TC in a cohort of PWH, and the study population had a median number of previous antiretroviral combinations of three.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that patients switched from combinations that included NRTIs, NNRTIs, PIs, and INSTIs.

Rationale: The paper mentions that patients switched from combinations that included NRTIs, NNRTIs, PIs, and INSTIs.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper lists specific antiretroviral drugs that were received by the individuals before sample sequencing, including Lamivudine (3TC), Zidovudine (AZT), Emtricitabine (FTC), Tenofovir (TFV), Efavirenz (EFV), Lopinavir (LPV), Dolutegravir (DTG).

Rationale: The paper lists specific antiretroviral drugs that were received by the individuals before sample sequencing.

Answer: Lamivudine (3TC), Zidovudine (AZT), Emtricitabine (FTC), Tenofovir (TFV), Efavirenz (EFV), Lopinavir (LPV), Dolutegravir (DTG)
""""""",106
38142692,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the use of genotypic drug resistance testing by Sanger sequencing and ultra-deep sequencing by Illumina MiSeq on plasma viral load specimens collected from patients.

Rationale: The paper describes the use of genotypic drug resistance testing by Sanger sequencing and ultra-deep sequencing by Illumina MiSeq on plasma viral load specimens collected from patients, which indicates that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing.

Rationale: The paper does not mention any in vitro drug susceptibility testing. It focuses on clinical cases of treatment-emergent resistance to nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) in HIV patients treated with bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC).

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that samples from 74 participants with a viral load ≥ 1000 copies/mL had successful PRRT and INT sequencing completed.

Rationale: The paper states that samples from 74 participants with a viral load ≥ 1000 copies/mL had successful PRRT and INT sequencing completed.

Answer: 74
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in the Southern Highland zone of Tanzania.

Rationale: The paper states that the study was conducted in the Southern Highland zone of Tanzania, and the samples were obtained from participants in this region.

Answer: Tanzania
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that participants were enrolled between 2019 and 2021.

Rationale: The study mentions that participants were enrolled between 2019 and 2021, indicating that the samples were obtained during this period.

Answer: 2019 to 2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV genes (reverse transcriptase, protease and integrase) were amplified by PCR and directly sequenced.

Rationale: Genes were directly mentioned "" genes (reverse transcriptase, protease and integrase)"" were amplified and sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing using sets of routine forward and reverse primers was performed on Applied Biosystems 3730XL DNA Analyser.

Rationale: The paper mentions that Sanger sequencing was performed using sets of routine forward and reverse primers on an Applied Biosystems 3730XL DNA Analyser.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples from all participants with VL ≥ 1000 copies/mL underwent sequencing of the Pol region.

Rationale: The paper specifies that plasma samples from participants with a viral load ≥ 1000 copies/mL were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that participants with a viral load ≥ 1000 copies/mL were underwent sequencing for drug resistance mutations.

Rationale: The paper mentions that participants with a viral load ≥ 1000 copies/mL were underwent sequencing for drug resistance mutations, it also mentions 117 CALHIV were unsuppressed, which indicates virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper describes a cross-sectional study design and does not mention that the patients were part of a clinical trial.

Rationale: The paper describes a cross-sectional study design and does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that participants had been on ART for more than 6 months, and had been on first- or second-line ART for at least 6 months.

Rationale: The paper includes participants who had been on ART for more than 6 months, and had been on first- or second-line ART for at least 6 months.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants were on ART regimens that included NRTIs, NNRTIs, and INSTIs.

Rationale: The paper mentions that participants were on ART regimens that included NRTIs, NNRTIs, and INSTIs.

Answer: NRTI, NNRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper specifies the ART regimens that participants were on, which included abacavir (ABC), zidovudine (AZT), lamivudine (3TC), tenofovir (TDF), and dolutegravir (DTG).

Rationale: The paper specifies the ART regimens that participants were on, which included abacavir (ABC), zidovudine (AZT), lamivudine (3TC), tenofovir (TDF), and dolutegravir (DTG).

Answer: Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Tenofovir (TDF), Dolutegravir (DTG)
""""""",102
38152686,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper describes a case report of an HIV/Tuberculosis coinfected patient who developed Human Immunodeficiency Virus (HIV) treatment failure during dolutegravir therapy.

Rationale: The paper discusses the sequencing of HIV from a patient sample, as evidenced by the detailed description of the patient's treatment history, the sequencing methods used, and the results obtained.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility assays or data.

Rationale: The paper focuses on a clinical case report and discusses the patient's treatment history, resistance mutations, and clinical outcomes without mentioning any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention whether the sequences obtained were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper describes a single case report of an HIV/Tuberculosis coinfected patient.

Rationale: The paper focuses on one individual, indicating that only one person had samples obtained for sequencing.

Answer: 1
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not specify the country from which the sequenced samples were obtained.

Rationale: The paper does not mention any specific countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific years for when the sequenced samples were obtained.

Rationale: The paper does not mention any specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions sequencing of the integrase gene and reverse transcriptase genes.

Rationale: The paper discusses the sequencing of the integrase gene and mentions the reverse transcriptase mutation M184V in association with integrase mutations.

Answer: RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the sequencing method used.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were obtained for HIV-1 population-based sequencing testing.

Rationale: The paper mentions that plasma samples were obtained for HIV-1 population-based sequencing testing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper describes a case of virological failure during initial treatment with tenofovir disoproxil fumarate/emtricitabine/dolutegravir twice daily.

Rationale: The paper discusses a patient who experienced virological failure while on treatment, confirming that sequences were obtained from such individuals.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patient was part of a clinical trial.

Rationale: The paper describes a case report of a single patient and does not mention any clinical trial involvement.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper discusses a patient who had been on multiple antiretroviral treatment regimens and had virologic failure.

Rationale: The paper describes a patient who had been on various ART, and had not suppressing for two years on DTG-based regimen, which means sequences were from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper lists various antiretroviral drugs from different classes that the patient received before the samples were obtained for sequencing.

Rationale: The paper lists the specific antiretroviral drugs that the patient was on before the samples were obtained for sequencing, including Lamivudine (3TC, NRTI), Zidovudine (AZT, NRTI), Emtricitabine (FTC, NRTI), Tenofovir (TFV, NRTI), Efavirenz (EFV, NNRTi), Lopinavir (LPV, PI), Dolutegravir (DTG, INSTI).

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper lists specific antiretroviral drugs that the patient received before the samples were obtained for sequencing.

Rationale: The paper lists the specific antiretroviral drugs that the patient was on before the samples were obtained for sequencing, including Lamivudine (3TC), Zidovudine (AZT), Emtricitabine (FTC), Tenofovir (TFV), Efavirenz (EFV), Lopinavir (LPV), Dolutegravir (DTG).

Answer: Lamivudine (3TC), Zidovudine (AZT), Emtricitabine (FTC), Tenofovir (TFV), Efavirenz (EFV), Lopinavir (LPV), Dolutegravir (DTG)
""""""",95
38314093,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that serum samples from HIV-infected individuals were analyzed for HIV-1 sequences.

Rationale: The paper focuses on the analysis of HIV-1 sequences from patient samples, indicating that it reports HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the analysis of HIV-1 sequences and drug resistance mutations, but it does not mention conducting in vitro drug susceptibility tests.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates, indicating that the sequences were not made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 195 HIV-infected individuals had samples obtained for HIV sequencing.

Rationale: The paper specifically mentions that 195 HIV-infected individuals had samples obtained for HIV sequencing.

Answer: 195
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from Meizhou, China.

Rationale: The paper specifically mentions that the samples were obtained from Meizhou, China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from May 2008 to December 2019.

Rationale: The paper specifically mentions that the samples were obtained from May 2008 to December 2019.

Answer: 2008-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide any information regarding the cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the protease-reverse transcriptase (PR-RT) sequence of HIV-1 was amplified and subjected to high-throughput sequencing.

Rationale: The paper specifically mentions that the PR-RT sequence of HIV-1 was amplified and subjected to high-throughput sequencing.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that high-throughput sequencing was used to analyze the PR-RT sequence of HIV-1.

Rationale: The paper specifically mentions that high-throughput sequencing was used to analyze the PR-RT sequence of HIV-1.

Answer: High-throughput sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that serum samples from HIV-infected individuals were analyzed for HIV-1 sequences.

Rationale: The paper specifically mentions that serum samples from HIV-infected individuals were analyzed for HIV-1 sequences.

Answer: Serum
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that some patients developed cross-resistance to NRTIs and NNRTIs simultaneously and the first-line treatment regimen ceased to be efficacious.

Rationale: The paper specifically mentions that some patients developed cross-resistance to NRTIs and NNRTIs simultaneously and the first-line treatment regimen ceased to be efficacious, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information indicating that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that some patients developed cross-resistance to NRTIs and NNRTIs simultaneously and the first-line treatment regimen ceased to be efficacious.

Rationale: The paper specifically mentions that some patients developed cross-resistance to NRTIs and NNRTIs simultaneously and the first-line treatment regimen ceased to be efficacious, indicating that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the first-line treatment regimen consisted of two nucleoside reverse transcriptase inhibitors (NRTIs) plus efavirenz (EFV)/nevirapine (NVP) in 31 cases or zidovudine (AZT)/lamivudine (3TC) plus EFV in 6 cases.

Rationale: The paper specifically mentions that the first-line treatment regimen consisted of two nucleoside reverse transcriptase inhibitors (NRTIs) plus efavirenz (EFV)/nevirapine (NVP) in 31 cases or zidovudine (AZT)/lamivudine (3TC) plus EFV in 6 cases.

Answer: NRTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the first-line treatment regimen consisted of two nucleoside reverse transcriptase inhibitors (NRTIs) plus efavirenz (EFV)/nevirapine (NVP) in 31 cases or zidovudine (AZT)/lamivudine (3TC) plus EFV in 6 cases.

Rationale: The paper specifically mentions that the first-line treatment regimen consisted of two nucleoside reverse transcriptase inhibitors (NRTIs) plus efavirenz (EFV)/nevirapine (NVP) in 31 cases or zidovudine (AZT)/lamivudine (3TC) plus EFV in 6 cases.

Answer: Efavirenz (EFV), Nevirapine (NVP), Zidovudine (AZT), Lamivudine (3TC)
""""""",102
38427738,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not include in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the number of individuals.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide information on the HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not provide information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not provide information on the treatment history of the individuals.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not provide information on whether the patients were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide information on the treatment history of the individuals.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the drug classes received by the individuals.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the specific drugs received by the individuals.

Answer: Not reported
""""""",67
38864613,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention any patient samples or sequences derived from patients. It primarily discusses in vitro studies and resistance mechanisms.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""The combination of ISL with LEN demonstrated additive inhibition of HIV-1 replication with no evidence of antagonism across the range of concentrations tested.""

Rationale: The paper includes in vitro drug susceptibility data, specifically examining the susceptibility of HIV-1 to ISL and LEN using a multiple-cycle antiviral assay.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""Sequences from resistance selection experiments have been deposited in GenBank under accession numbers PP827803 -- PP828572.""

Rationale: The paper provides GenBank accession numbers for the sequences from resistance selection experiments.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""Sequences from resistance selection experiments have been deposited in GenBank under accession numbers PP827803 -- PP828572.""

Rationale: The paper provides a range of GenBank accession numbers for the sequences from resistance selection experiments.

Answer: PP827803 -- PP828572
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not mention any patient samples or sequences derived from patients. It primarily discusses in vitro studies and resistance mechanisms.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the geographical origin of the samples, as it primarily focuses on in vitro studies.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""The CA or RT-encoding region was amplified by the one-step RT-PCR method.""

Rationale: The paper mentions that the CA or RT-encoding region was amplified and sequenced.

Answer: CA, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify the method used for sequencing.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify the type of clinical specimens sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention any patient samples or sequences related to virological failure, focusing instead on laboratory studies.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not provide any information regarding clinical trials involving patients, as it focuses on laboratory studies.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention any sequences from individuals who had received antiretroviral drugs, focusing instead on laboratory studies.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding drug classes received by individuals, as it does not discuss patient samples.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention any specific drugs received by individuals, as it focuses on in vitro studies and resistance mechanisms.

Answer: Not reported
""""""",70
